Antibodies targeting OX40 and antibody-drug conjugates and their uses
By developing antibodies and ADCs that specifically bind to human OX40, the limited efficacy of OX40-targeted therapy in cancer has been addressed, resulting in enhanced anti-tumor immune responses and reduced immunosuppression, thus improving the therapeutic effects on various cancers and inflammatory diseases.
Patent Information
- Application Number
- CN202611145795.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-05-30
- Filing Date
- 2025-01-29
- Publication Date
- 2026-11-17
AI Technical Summary
Existing OX40-targeted therapies have limited effectiveness in cancer treatment and have not yet been able to effectively enhance the immune system's ability to recognize and eliminate cancer cells, posing clinical challenges.
We offer novel antibodies and antibody-drug conjugates (ADCs) that specifically bind to human OX40. These antibodies do not block the binding of OX40L to OX40, can be endocytosed by OX40-positive cells, deplete OX40-positive cells, enhance anti-tumor immune responses, and contain therapeutic components such as monomethylolpropionate (MMAE) or topoisomerase I inhibitors to enhance immunological activity.
It significantly enhances the anti-tumor immune response, reduces immunosuppression in the tumor microenvironment, and improves the therapeutic effect on OX40-positive cancers such as T-cell leukemia, lymphoma, and solid tumors. It also has therapeutic potential for inflammatory diseases such as rheumatoid arthritis.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Priority requirements
[0001] This application claims priority to PCT International Application No. PCT / CN2024 / 074689, filed on January 30, 2024, and PCT International Application No. PCT / CN2024 / 096494, filed on May 30, 2024, the entire contents of which are incorporated herein by reference. Divisional Application Instructions
[0002] This application is a divisional application of Chinese invention patent application filed on January 29, 2025, with application number 202580006542.6 and invention title "Antibody targeting OX40 and antibody-drug conjugate and its use". Reference to the electronically submitted sequence list
[0003] This application incorporates a sequence list as an XML file, titled "720A002CN04-260766", created on July 30, 2026, and having a size of 74,407 bytes. Technical Field
[0004] This invention relates to molecular biology and immunology. This document provides novel antibodies and antibody-drug conjugates targeting OX40, and their use in the treatment of cancer. Background Technology
[0005] OX40, a member of the tumor necrosis factor receptor superfamily 4, is an immune co-stimulatory receptor. OX40 is primarily expressed on activated T cells and plays a crucial role in the regulation and response of the immune system. Studies have shown that targeting OX40 can enhance anti-tumor immune responses by directly or indirectly promoting T cell activation and proliferation (e.g., through exhaustion of regulatory T cells (Tregs)) or through other additional mechanisms of action (MOAs) within the tumor microenvironment or TME, thereby enhancing the immune system's ability to recognize and eliminate cancer cells. Identifying OX40 as a tumor-associated antigen also opens new avenues for developing targeted therapies aimed at leveraging the body's immune system to combat cancer.
[0006] Despite the promising potential of OX40 as a therapeutic target, developing effective immunotherapies for tumors has faced significant challenges and setbacks in clinical practice. Numerous attempts to utilize OX40 for cancer treatment have yielded only limited success. Therefore, there remains an urgent unmet need to develop effective cancer therapies targeting OX40. The compositions and methods presented in this article address these needs and offer relative advantages. Summary of the Invention
[0007] This article provides antibodies or antigen-binding fragments thereof that specifically bind to human OX40, comprising: (a) a light chain variable region (VL) containing VL CDR1, VL CDR2, and VL CDR3 of the amino acid sequence of SEQ ID NO:15; or a variant thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and / or (b) a heavy chain variable region (VH) containing VH CDR1, VH CDR2, and VH CDR3 of the amino acid sequence of SEQ ID NO:16; or a variant thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions.
[0008] In some embodiments of the antibody or antigen-binding fragments disclosed herein: (a) the VL CDR1, VLCDR2, and VL CDR3 have amino acid sequences of SEQ ID NOs:4, 5, and 6, respectively; or variations thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and / or (b) the VH CDR1, VH CDR2, and VH CDR3 have amino acid sequences of SEQ ID NOs:10, 11, and 12, respectively; or variations thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the antibody or antigen-binding fragment comprises VL CDR1, VLCDR2, VL CDR3, VH CDR1, VH CDR2, and VH CDR3, which have amino acid sequences of SEQ ID NOs:4, 5, 6, 10, 11, and 12, respectively.
[0009] In some embodiments, the antibody or antigen-binding fragments disclosed herein are humanized. In some embodiments, the humanized antibody or antigen-binding fragment comprises: (a) a VL having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 15; and / or (b) a VH having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO: 16. In some embodiments, the antibody or antigen-binding fragment comprises VL and VH, which have the amino acid sequences of SEQ ID NOs: 15 and 16, respectively.
[0010] In some embodiments, the antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment. In some embodiments, the antibody or antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab')2, Fv, scFv, (scFv)2, single-domain antibodies (sdAb), and heavy chain antibodies (HCAb). In some embodiments, the antibody or antigen-binding fragment is an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody.
[0011] In some embodiments, the antibody or antigen-binding fragments disclosed herein further include a light chain constant region (CL) and a heavy chain constant region (CH). In some embodiments, the CL region is kappa CL (Cκ; SEQ ID NO:19) or lambda CL (Cλ; SEQ ID NO:20), or a variant thereof, wherein it has up to ten amino acid substitutions. In some embodiments, the CH region is IgG1 CH (SEQ ID NO:21), IgG2 CH (SEQ ID NO:22), IgG3 CH (SEQ ID NO:23), or IgG4 CH (SEQ ID NO:24), or a variant thereof, wherein it has up to ten amino acid substitutions.
[0012] In some embodiments, the antibody or antigen-binding fragment disclosed herein is an IgG1 antibody. In some embodiments, the antibody or antigen-binding fragment disclosed herein comprises: a light chain whose amino acid sequence is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:27; and a heavy chain whose amino acid sequence is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SEQ ID NO:28 or SEQ ID NO:29.
[0013] In some implementations, the antibody or antigen-binding fragment disclosed herein (1) does not block the binding of OX40L to OX40; (2) is effectively internalized by OX40-positive cells; (3) depletes OX40-positive cells; (4) depletes OX40-positive regulatory T cells in the TME; (5) exhibits significant ADCC; (6) enhances antitumor immune responses; (7) reduces immunosuppression in the TME; or (8) enhances immunological activity in the TME; or any combination of (1) to (8).
[0014] This article also provides polynucleotides encoding polypeptides that encode the antibody or antigen-binding fragments disclosed herein.
[0015] This article also provides vectors containing the polynucleotides disclosed herein.
[0016] This article also provides host cells containing the polynucleotides or vectors disclosed herein.
[0017] This document also provides a method for producing an antibody that specifically binds to human OX40 or an antigen-binding fragment thereof, comprising culturing cells disclosed herein under conditions suitable for expressing said antibody or antigen-binding fragment. In some embodiments, the method further includes isolating said antibody or antigen-binding fragment from the culture.
[0018] This article also provides pharmaceutical compositions comprising a therapeutically effective amount of the antibody or antigen-binding fragment disclosed herein and a pharmaceutically acceptable carrier.
[0019] This document also provides antibody-drug conjugates (“ADCs”) comprising an antibody or antigen-binding fragment thereof conjugated to a therapeutic portion, wherein the antibody or antigen-binding fragment specifically binds to human OX40 and comprises: (a) a VL comprising VL CDR1, VL CDR2, and VL CDR3 of a VL having the amino acid sequence of SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:50, or SEQ ID NO:52; or variants thereof, wherein there are up to about 5 amino acid substitutions, additions, and / or deletions in the VLCDRs; and / or (b) a VH comprising VH CDR1, VH CDR2, and VH CDR3 of a VH having the amino acid sequence of SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:56. CDR3; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments of the ADC disclosed herein, the amino acid sequences of the VL and VH are independently identical to (1) SEQ ID NOs:38 and 39, respectively; (2) SEQ ID NOs:40 and 41, respectively; (3) SEQ ID NOs:42 and 43, respectively; (4) SEQ ID NOs:44 and 45, respectively; (5) SEQ ID NOs:46 and 47, respectively; (6) SEQ ID NOs:50 and 51, respectively; (7) SEQ ID NOs:52 and 53, respectively; or (8) SEQ ID NOs:38 and 56, respectively, having at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity. In some embodiments, the antibody comprises a light chain and a heavy chain whose amino acid sequences are independently identical to (1) SEQ ID NOs: 59 and 60, respectively; (2) SEQ ID NOs: 59 and 61, respectively; (3) SEQ ID NOs: 62 and 63, respectively; (4) SEQ ID NOs: 62 and 64, respectively; (5) SEQ ID NOs: 65 and 66, respectively; and (6) SEQ ID NOs: 65 and 67, respectively, having at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity.
[0020] In some embodiments, this document provides an ADC comprising an antibody or antigen-binding fragment disclosed herein conjugated to a therapeutic portion, wherein the antibody or antigen-binding fragment specifically binds to human OX40 and does not block the binding of OX40L to OX40. In some embodiments of the ADCs disclosed herein, the antibody or antigen-binding fragment is conjugated to the therapeutic portion via a linker. In some embodiments of the ADCs disclosed herein, the linker is... , , , ,or In some implementations of the ADC disclosed herein, the connector is , , , or .
[0021] In some embodiments of the ADC disclosed herein, the therapeutic portion is monomethyloprestatin. In some embodiments of the ADC disclosed herein, the monomethyloprestatin is monomethyloprestatin E (MMAE).
[0022] In some implementations, the ADC disclosed herein has the following structure: Where Ab is the antibody or antigen-binding fragment, and p represents a number ranging from 1 to 16.
[0023] In some implementations, the ADC disclosed herein has the following structure: .
[0024] In some embodiments of the ADC disclosed herein, the monomethyloprestatin is monomethyloprestatin F (MMAF).
[0025] In some implementations, the ADC disclosed herein has the following structure: Where Ab is the antibody or antigen-binding fragment, and p represents a number ranging from 1 to 16. In some embodiments, the ADC disclosed herein has the following structure: .
[0026] In some embodiments of the ADC disclosed herein, the therapeutic component is a topoisomerase I inhibitor. In some embodiments, the topoisomerase I inhibitor is camptothecin, Dxd, SN-38, or eczemacon (DX-8951). In some embodiments, the topoisomerase I inhibitor is Dxd. In some embodiments, the topoisomerase I inhibitor is SN-38. In some embodiments, the topoisomerase I inhibitor is eczemacon.
[0027] In some implementations, the ADC disclosed herein has the following structure: Where Ab is the antibody or antigen-binding fragment, and p represents a number ranging from 1 to 16.
[0028] In some implementations, the ADC disclosed herein has the following structure: .
[0029] In some implementations, the ADC disclosed herein has the following structure: Where Ab is the antibody or antigen-binding fragment, and p represents a number ranging from 1 to 16.
[0030] In some implementations, the ADC disclosed herein has the following structure: .
[0031] In some implementations, the ADC disclosed herein has the following structure: Where Ab is the antibody or antigen-binding fragment, and p represents a number ranging from 1 to 16.
[0032] In some implementations, the ADC disclosed herein has the following structure: .
[0033] In some embodiments of the ADC disclosed herein, the therapeutic portion is a derivative of spongin B. In some embodiments, the therapeutic portion is eribulin.
[0034] In some implementations, the ADC disclosed herein has the following structure: Where Ab is the antibody or antigen-binding fragment, and p represents a number ranging from 1 to 16.
[0035] In some implementations, the ADC disclosed herein has the following structure: .
[0036] In some embodiments of the ADCs disclosed herein, p represents a number ranging from 1 to 10. In some embodiments, p is approximately 4. In some embodiments, p is approximately 5. In some embodiments, p is approximately 8. In some embodiments, the average value of p in the population of said ADCs is approximately 2.8, approximately 3.5, approximately 3.6, approximately 4, approximately 4.2, approximately 4.3, approximately 4.5, approximately 4.6, approximately 5, approximately 5.3, or approximately 8. In some embodiments, the average value of p in the population of said ADCs is approximately 5.3 or approximately 8.
[0037] In some embodiments, this document provides an ADC comprising an antibody or antigen-binding fragment thereof conjugated to a therapeutic portion; wherein the antibody or antigen-binding fragment specifically binds to human OX40 and has: (1) VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:15; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:16; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; (2) VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:38; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of VH having SEQ ID NO:39. (2) VH CDR1, VH CDR2, and VH CDR3; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; (3) VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:40; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and VH CDR1, VH CDR2, and VHCDR3 of VH having the amino acid sequence of SEQ ID NO:41; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; (4) VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:42; or variants thereof, wherein the VLCDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and VH CDR1, VH CDR2, and VHCDR3 of VH having the amino acid sequence of VH having SEQ ID NO:43. CDR1, VH CDR2 and VH CDR3; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions and / or deletions; (5) VL CDR1, VLCDR2 and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:38; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions and / or deletions; and VH CDR1, VH CDR2 and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:56; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions and / or deletions;The therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczemab, or eribulin. In some embodiments, this document provides an ADC comprising an antibody or antigen-binding fragment thereof conjugated to the therapeutic portion; wherein the antibody or antigen-binding fragment specifically binds to human OX40 and has amino acid sequences VL and VH of SEQ ID NOs:15 and 16, respectively; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczemab, or eribulin.
[0038] In some implementations, the ADCs disclosed herein: (1) do not block the binding of OX40L to OX40; (2) are effectively internalized by OX40-positive cells; (3) deplete OX40-positive cells; (4) deplete OX40-positive regulatory T cells within the TME; (5) exhibit significant ADCC; (6) maintain the basic ADCC of the anti-OX40 antibody or antigen-binding fragment; (7) enhance anti-tumor immune responses; (8) reduce immunosuppression in the TME; or (9) enhance immunological activity in the TME; or any combination of (1) to (9).
[0039] This document also provides a method for preparing the ADC disclosed herein, which includes conjugating the antibody or antigen-binding fragment to the therapeutic portion.
[0040] This article also provides pharmaceutical compositions comprising the ADC disclosed herein and a pharmaceutically acceptable carrier.
[0041] This document also provides methods for treating cancer in subjects of need, comprising administering to the subject a therapeutically effective amount of the disclosed antibody or antigen-binding fragment. In some embodiments, this document provides the use of the disclosed antibody or antigen-binding fragment in the treatment of cancer. In some embodiments, this document provides the use of the disclosed antibody or antigen-binding fragment in the preparation of a cancer therapeutic agent. In some embodiments, this document provides methods for treating autoimmune diseases or inflammatory diseases in subjects of need, comprising administering to the subject a therapeutically effective amount of the disclosed antibody or antigen-binding fragment. In some embodiments, this document provides the use of the disclosed antibody or antigen-binding fragment in the treatment of autoimmune diseases or inflammatory diseases. In some embodiments, this document provides the use of the disclosed antibody or antigen-binding fragment in the preparation of an inflammatory disease or a therapeutic agent for an inflammatory disease.
[0042] In some embodiments, this document provides a method of treating cancer in a subject of need, comprising administering a therapeutically effective amount of the disclosed ADC to the subject. In some embodiments, this document provides the use of the disclosed ADC in treating cancer. In some embodiments, this document provides the use of the disclosed ADC in preparing a cancer therapeutic agent. In some embodiments, this document provides a method of treating an autoimmune disease or inflammatory disease in a subject of need, comprising administering a therapeutically effective amount of the disclosed ADC to the subject. In some embodiments, this document provides the use of the disclosed ADC in treating an inflammatory disease or inflammatory inflammatory condition. In some embodiments, this document provides the use of the disclosed ADC in preparing an inflammatory disease or inflammatory inflammatory medicament.
[0043] In some implementations, the methods disclosed herein also include administering additional therapy to the subject.
[0044] In some implementations, the subject is a human being.
[0045] In some embodiments, the cancer to be treated by the methods disclosed herein may have OX40+ tumor-infiltrating lymphocytes (TILs). In some embodiments, the cancer may be OX40+ cancer. In some embodiments, the cancer may be liquid cancer. In some embodiments, the cancer is T-cell leukemia or lymphoma. In some embodiments, the cancer is peripheral T-cell lymphoma (PTCL, such as adult T-cell leukemia (ATL), angioimmunoblastic T-cell lymphoma (AITL)) or T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the cancer may be a solid tumor. In some embodiments, the cancer is sarcoma, breast cancer, non-small cell lung cancer (NSCLC), melanoma, or ovarian cancer. In some embodiments, the cancer may be HPV+ cancer or EBV+ cancer. In some implementations, the cancer is EBV+ B-cell lymphoma, extranodal NK / T-cell lymphoma (ENKTL; e.g., nasal type), HPV16+ head and neck squamous cell carcinoma (HNSCC), EBV+ esophageal cancer, or HPV18+ cervical cancer.
[0046] In some embodiments, the inflammatory disease or inflammatory condition may be characterized as excessive T cell activation. In some embodiments, the autoimmune disease or inflammatory condition is rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease (CD), graft-versus-host disease (GvHD), multiple sclerosis (MS), type 1 diabetes mellitus, atopic dermatitis, asthma, psoriasis, Sjögren's syndrome (SS), or idiopathic thrombocytopenic purpura (ITP).
[0047] This article also provides kits containing the antibodies or antigen-binding fragments disclosed herein. Kits containing the ADCs disclosed herein are also provided herein. Attached Figure Description
[0048] Figure 1A-1D Representative results are provided for characterizing the biochemical and biological properties of the humanized monoclonal antibody HX011. Figure 1A The results of luciferase assays of the reporter gene driven by the IL-2 promoter are shown, demonstrating the activation of T cells by HX011 and the chimeric anti-OX40 antibody 9C12H11. Figure 1B The flow cytometry results of HX011 binding to OX40-expressing 293T cells are shown. Figure 1C The results of the IL-2 release assay show that HX011 reactivated SEB-depleted PBMC-derived T cells in a dose-dependent manner. Figure 1D The ELISA results are shown, indicating that HX011 does not compete with OX40L for binding to human OX40.
[0049] Figure 2A-2C A schematic diagram is provided to illustrate the strong antitumor activity of HX011 in vitro and in vivo. Figure 2A The FACS results show that HX011 triggered antibody-dependent cell-mediated cytotoxicity (ADCC) activity of human PBMCs on OX40-positive cells. Figure 2B The results of the luciferase assay are shown, indicating that HX011 activates Jurkat cells expressing FcγRIIIa (reporter gene: luciferase) when incubated with OX40-positive target cell lines. 50 (Approximately 0.61 nM). Figure 2C The changes in MC38 tumor volume over time are shown, indicating that different doses of HX011 (IV twice weekly) inhibited tumor growth.
[0050] Figures 3A-3E A schematic diagram is provided illustrating the amount of cytokine release induced by HX011. The cytokines measured include IL-2 (…). Figure 3A ), IL-6 ( Figure 3B ), IL-4 ( Figure 3C ), TNF-α ( Figure 3D ) and IFN-γ ( Figure 3E Human PBMCs were incubated in vitro with different doses of HX011 for 24 or 48 hours in solid phase (coated plate) or aqueous phase (soluble). SEB was used as a positive control.
[0051] Figures 4A-4C Provided monoclonal antibody HX011 ( Figure 4A ), ADC HX111 ( Figure 4B ) and HX111 coupling ( Figure 4C Schematic diagram of HPLC analysis.
[0052] Figures 5A-5C Flow cytometry results were provided for measuring OX40 expression in various hematologic malignancies. Figure 5A The study showed increased OX40 expression in two HTLV-1 infected ATL cell lines, HuT-102 and HuT-78. Figure 5B The study showed that HuT-102 cells exhibited significant OX40 expression on their surface, while HPB-ALL cells showed almost no expression. Figure 5C The study showed that the mRNA level of OX40 in EBV-positive lymphoma PDX was significantly upregulated compared to the EBV-negative counterpart.
[0053] Figures 6A-6B A schematic diagram is provided to illustrate the endocytosis of OX40 monoclonal antibody HX011 or ADC HX111 into OX40-positive lymphoma / leukemia cells. Figure 6A This study showed that HX111 and HX011 had the same endocytosis rate in the OX40-positive T leukemia cell line HuT-102. Figure 6B The endocytosis of the monoclonal antibody HX011 in Jurkat cells overexpressing HuT-102 and OX40 is shown.
[0054] Figures 7A-7D Results of in vitro cytotoxicity assays in OX40-positive leukemia / lymphoma cells are provided. Figure 7A HX111 demonstrated significant cytotoxicity against HuT-102 cells (OX40++ cytokine leukemia) in the sub-nanomolar range. Figure 7B The HX111 and HX011 are shown in relation to the HuT-78 (OX40). + The effect of T-cell leukemia at relatively high concentrations (100 nM and above). Figure 7C HX111 and HX011 showed almost no cytotoxicity against NAMALWA cells (B-cell lymphoma). Figure 7D HX111 (DAR2.8 and DAR4) demonstrated potent cytotoxicity against OX40-overexpressing Jurkat cell lines in the sub-nanomolar range, with cytotoxicity increasing with increasing DAR.
[0055] Figures 8A-8BA schematic diagram is provided to illustrate the bystander cytotoxicity of HX111. In the presence of HX111, OX40-negative cells (Raji cells or Jurkat cells) were co-cultured with OX40-positive cells (Hut-102 cells or Jurkat-OX40-5E9 cells) at different ratios, and their viability was measured. Figure 8A This study demonstrates that HX111 induces cytotoxicity in OX40-negative Raji cells in the presence of Hut-102 cells. Figure 8B This study demonstrates that HX111 induces cytotoxicity in OX40-negative Jurkat cells in the presence of Jurkat-OX40-5E9 cells.
[0056] Figures 9A-9B Schematic diagrams are provided to illustrate in vivo tumor growth inhibition in HuT-102 and HuT-78 small tumor xenograft models. Figure 9A The results showed that in the HuT-102 xenograft model, HX111 induced potent tumor growth inhibition in a dose-dependent manner without causing weight loss. Figure 9B The results show that in the HuT-78 xenograft model, HX111 caused tumor growth inhibition in a dose-dependent manner, without causing weight loss.
[0057] Figure 10 A schematic diagram is provided to illustrate in vivo tumor growth inhibition in the HuT-102 large tumor xenograft model. As shown in the figure, HX111 administered with different dosing regimens exhibited strong activity in inducing tumor regression without causing weight loss.
[0058] Figure 11 A schematic diagram is provided to illustrate the cytotoxicity of HX011-based ADCs against HuT-102 cells (OX40++ T-cell leukemia). As shown in the figure, ADCs conjugated with various therapeutic groups to the anti-OX40 antibody HX011 exhibit effective killing effects on HuT-102 cells.
[0059] Figure 12 A-12C provides data indicating that HX111 attenuates GvHD disease activity in a dose-dependent manner. Figure 12 A shows that HX111 prevents weight loss. Figure 12 B showed that HX111 inhibited the occurrence of GvHD disease. Figure 12 C showed that HX111 significantly improved the survival rate of PBMC allogeneic mice.
[0060] Figures 13A-13H HX011-Exd is provided ( Figure 13A and 13B HX011-SN-38 Figure 13C HX011-Eriblin ( Figure 13D HX518-MMAE ( Figure 13E HX523-1-MMAE ( Figure 13F HX534-MMAE ( Figure 13G ) and HX543-MMAE ( Figure 13H Schematic diagram of HPLC analysis.
[0061] Figure 14 A schematic diagram is provided to illustrate that HX011, HX518, HX518-MMAE, HX523-1, HX523-1-MMAE, HX534, HX534-MMAE, HX543, and HX543-MMAE have comparable target binding affinity.
[0062] Figure 15 A schematic diagram is provided to illustrate that HX011, HX111, HX518, HX518-MMAE, HX523-1, HX523-1-MMAE, HX534, HX534-MMAE, HX543, and HX543-MMAE are all significantly internalized by HuT-102 cells.
[0063] Figure 16 A schematic diagram is provided to illustrate that the anti-OX40 ADCs (HX111, HX518-MMAE, HX523-1-MMAE, HX534-MMAE and HX543-MMAE) have significant killing activity against OX40+ HuT-102 cells.
[0064] Figures 17A-17C Data provided indicate that HX011 attenuates GvHD disease activity. Figure 17A The HX011 was shown to prevent weight loss. Figure 17B The results showed that HX011 inhibited the occurrence of GvHD disease. Figure 17C The results showed that HX011 significantly improved the survival rate of PBMC allogeneic mice.
[0065] Figures 18A-18B Flow cytometry results are provided for measuring the number of human CD45+ white blood cells and human CD4+ T cells in living cells. Figure 18A The results showed that HX011 significantly reduced the number of human CD45+ white blood cells. Figure 18B HX011 was shown to significantly reduce the number of pathogenic human CD4+ T cells. Detailed Implementation
[0066] OX40, or tumor necrosis factor receptor superfamily member 4 (TNFRSF4), is an immune co-stimulatory receptor. Together with its ligand OX40L, it forms an OX40-OX40L trimer-trimer complex on the surfaces of activated T cells (OX40) and APCs / NK cells (OX40L), and is considered a co-stimulatory receptor for T cell activation. Human OX40 is a type I transmembrane glycoprotein with a molecular weight of 47–51 kDa, composed of 249 amino acids, with 188, 24, and 37 amino acids in the extramembrane, transmembrane, and intramembrane regions, respectively. The corresponding gene is located on human chromosome 1p36. OX40 is mainly expressed on the surface of activated CD4+ / CD8+ T cells. In addition, OX40 is also expressed on regulatory T cells (T cells). reg OX40 is overexpressed in cells, especially within the TME. The interaction between OX40 and its ligand OX40L initiates a signaling cascade that activates T cells via the NF-κB1 pathway and inhibits bcl-x and survivin to prevent apoptosis. It also downregulates FoxP3 / CTLA4, thereby regulating T cells. reg Function.
[0067] OX40L, also known as gp34, CD252, or TNFSF4, is a type II glycoprotein with a 23-amino acid cytoplasmic tail and a 133-amino acid extracellular domain. It is expressed as a trimer and possesses a TNF homologous domain. Structurally, it is similar to other molecules in the TNF superfamily and exhibits some sequence homology. OX40L is primarily expressed on professional antigen-presenting cells (APCs), but can also be expressed on activated B cells, mature conventional dendritic cells (cDCs), Langerhans cells, plasmacytoid DCs (pDCs), and macrophages.
[0068] T reg The function of these cells is to provide immunosuppression, and within the TME, this immunosuppressive function promotes tumor growth. Compared to normal blood compartments, and compared to activated CD8+ T cells within the TME... eff Compared to other cells, OX40 is more effective in tumor-infiltrating (TIL) T cells. reg It is constitutively expressed at high levels in cells. This increased rate directly contributes to enhanced antitumor immunity, thereby generating antitumor activity. Therefore, agonist anti-OX40 monoclonal antibodies (mAbs) have been proposed to activate T cells and enhance antitumor immunity; alternatively, anti-OX40 monoclonal antibodies with intact Fc function can act as depletion antibodies and have also been proposed to deplete regulatory T cells overexpressing OX40 in the tumor microenvironment, thereby enhancing antitumor immunity, although clinical benefit has not yet been confirmed.
[0069] The following section describes in detail a novel anti-human OX40 agonist antibody that binds to OX40 with high affinity. Unlike other anti-OX40 agonist antibodies, the antibody presented herein does not block the binding of OX40L to OX40, thus allowing for maximal activation of the OX40 / OX40L pathway. As an IgG1 antibody, it also functions as a depletion antibody on OX40-expressing cells. The strong antitumor activity of the disclosed antibody in preclinical models is also presented in this article.
[0070] OX40 has also been identified as a tumor-associated antigen (TAA) in certain lymphomas and leukemias, such as adult T-cell leukemia (ATL). HTLV-1 was the first human retrovirus identified to infect T cells. Approximately 5% of infected individuals eventually develop ATL. Currently, there are few effective treatment options available for ATL, creating an urgent need. HTLV-1 encodes the oncogene Tax, which upregulates the expression of OX40L and OX40. Due to its high expression on the surface of ATL cells, drugs targeting OX40 and causing a reduction in ATL cells have the potential to become a new treatment for ATL. In addition, AITL (angioimmunoblastic lymphoma), a peripheral T-cell lymphoma (PTCL) derived from follicular helper T (Tfh) cells, has a high frequency of OX40 positive expression. Similarly, some EBV-infected lymphomas, such as B-cell lymphoma and extranodal NK / T-cell lymphoma (ENKTL), also overexpress OX40. These tumors may also potentially be treated with OX40-targeting therapies.
[0071] Furthermore, OX40 overexpression associated with T cell activation has been implicated in a variety of inflammatory and autoimmune diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), graft-versus-host disease (GvHD), MS, type 1 diabetes, and dermatitis. When T cells are overactivated, they release pro-inflammatory molecules, such as cytokines, leading to inflammation and tissue damage. This excessive immune response can target various organs or tissues in the body, resulting in widespread autoimmune or inflammatory diseases. Therefore, without being bound by theory, these autoimmune or inflammatory diseases characterized by unintended or excessive T cell activation can be treated by depleting such pathological T cells, which are typically characterized by OX40 expression.
[0072] The following text also describes anti-OX40 antibodies and antibody-drug conjugates (ADCs) that effectively target and kill OX40-positive cancer cells, such as ATL, AITL, and ENKTL cells, without being constrained by theoretical limitations. This article also provides data demonstrating the strong anti-tumor activity of these anti-OX40 ADCs.
[0073] As used herein and in accordance with the understanding in the art, "hot tumor" and "cold tumor" refer to different tumor microenvironments (TMEs) that influence the effectiveness of the immune system in recognizing and attacking cancer cells. "Hot tumors" are also known as "immunologically active" or "inflammatory" tumors. These tumors are characterized by significant infiltration of immune cells, particularly cytotoxic T cells (CD8+ T cells), within the TME. This immune infiltration indicates that the immune system has recognized the tumor as a threat and is attempting to initiate a response. Hot tumors typically exhibit a higher number of somatic mutations that produce neoantigens that are recognized by T cells. Hot tumors are often associated with pro-inflammatory cytokines such as interferon-γ (IFN-γ), which help recruit immune cells to the tumor site.
[0074] On the other hand, "cold tumors," also known as "immunologically inactive" or "non-inflammatory" tumors, lack significant immune cell infiltration. The absence of T cells or other immune components within the tumor microenvironment (TME) indicates that the immune system either fails to recognize the tumor or has been effectively excluded or suppressed by tumor mechanisms. Cold tumors typically have fewer mutations, meaning fewer new antigens available to trigger an immune response. These tumors may actively exclude immune cells from the TME (immune rejection) or exhibit a complete lack of immune activity (immune desert). Cold tumors are often surrounded by an immunosuppressive microenvironment, including the presence of myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), or other factors that inhibit T cell activation and infiltration. Cold tumors generally respond poorly to immunotherapy because the immune system does not interact with the tumor.
[0075] Before further describing this disclosure, it should be understood that this disclosure is not limited to the specific embodiments set forth herein, and it should also be understood that the terminology used herein is intended to describe specific embodiments and is not intended to constitute a limitation. 1.1 Definition
[0076] Unless otherwise defined herein, scientific and technical terms used in this disclosure should be understood in the same sense as commonly understood by one of ordinary skill in the art. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd edition, 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd edition, 1999, Academic Press; and the Oxford Dictionary of Biochemistry and Molecular Biology, revised edition, 2000, Oxford University Press, provide one of the general dictionaries for those skilled in the art of the many terms used in this disclosure.
[0077] Unless the context otherwise requires, singular terms should include the plural form, and plural terms should include the singular form. Generally, the nomenclature and techniques described herein relating to cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization should be those well-known and commonly used in the field.
[0078] The term “a” or “an” refers to one or more of the entity; for example, “an antibody” should be understood to mean one or more antibodies.
[0079] As used herein, the term “and / or” should be considered as a specific disclosure of each of the two specified features or components, with or without the other. Therefore, the term “and / or” as used in phrases such as “A and / or B” is intended to include “A and B”, “A or B”, “A alone”, and “B alone”. Similarly, the term “and / or” as used in phrases such as “A, B, and / or C” is intended to cover each of the following: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A alone; B alone; and C alone.
[0080] As used herein, the term "about" is used to indicate a value that includes inherent error variation of the device, error variation of the method used to determine the value, or variation among study subjects. The term "about" encompasses the precise value. In some embodiments, "about" means within ±10% of a given value or range. In some embodiments, "about" means the variation is ±5%, ±4%, ±3%, ±2%, ±1%, ±0.5%, ±0.2%, or ±0.1% of the value indicated by "about". In some embodiments, "about" means the variation is ±1%, ±0.5%, ±0.2%, or ±0.1% of the value indicated by "about".
[0081] The terms “peptide,” “peptide chain,” “polypeptide,” and “protein,” which are used interchangeably in this document, and their grammatical equivalents, refer to an amino acid polymer of any length, which may be linear or branched. It may include non-natural or modified amino acids, or be interrupted by non-amino acid molecules. Polypeptides, peptides, polypeptide chains, peptide chains, or proteins may also be modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other treatment or modification.
[0082] The terms “polynucleotide,” “nucleic acid,” and their grammatical equivalents, used interchangeably herein, refer to nucleotide polymers of any length, including DNA and RNA. The nucleotides may be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogues, or any substrate that can be incorporated into a polymer by DNA or RNA polymerases.
[0083] The term "variant," as used herein in relation to a protein or polypeptide with a specific sequence characteristic ("reference protein" or "reference polypeptide"), refers to a different protein or polypeptide compared to the reference protein or reference polypeptide with one or more (e.g., about 1 to about 25, about 1 to about 20, about 1 to about 15, about 1 to about 10, or about 1 to about 5) amino acid substitutions, deletions, and / or additions. Changes to the amino acid sequence can be amino acid substitutions. Changes to the amino acid sequence can be conserved amino acid substitutions. Functional fragments or functional variants of the protein or polypeptide should maintain the basic structural and functional properties of the reference protein or reference polypeptide.
[0084] As used herein and as understood in the art, an "antibody" refers to an immunoglobulin molecule that recognizes and specifically binds to a target (e.g., a protein) through at least one antigen-binding fragment (typically located within a variable region of the immunoglobulin molecule). Antibodies can have a variety of different types and structures. For example, an antibody can be a polyclonal antibody, monoclonal antibody, multispecific antibody, bispecific antibody, monospecific antibody, monovalent antibody, or any other modified immunoglobulin molecule containing an antigen-binding site. Antibodies also include, but are not limited to, mouse antibodies, camel antibodies, chimeric antibodies, humanized antibodies, and human antibodies. An antibody can be any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or a subclass (isotype) (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) based on the identity of its heavy chain constant domain, referred to as alpha, delta, epsilon, gamma, and mu, respectively. Unless otherwise expressly indicated, the term "antibody" as used herein includes the "antigen-binding fragment" of the complete antibody. As used herein, the term "antigen-binding fragment" refers to a portion or fragment of a complete antibody, which is the antigen-determining variable region of the complete antibody. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv, linear antibodies, single-chain antibody molecules (e.g., scFv), heavy chain antibodies (HCAbs), light chain antibodies (LCAbs), disulfide-linked scFv (dsscFv), dibodies, tribodies, tetrabodies, minibodies, bivariate domain antibodies (DVD), single variable domain antibodies (sdAbs; e.g., camelid antibodies, alpaca antibodies), and the single variable domain (VHH) of heavy chain antibodies.
[0085] The structure of immunoglobulins has been well characterized (see, for example, Chapter 7 of Fundamental Immunology (Paul, W., ed., 2nd ed., Raven Press, New York (1989))). Typically, immunoglobulins consist of two pairs of polypeptide chains, one pair of light (L; low molecular weight) chains and one pair of heavy (H; high molecular weight) chains, all four chains being interconnected by disulfide bonds.
[0086] Each light chain of an immunoglobulin typically comprises a variable region (“VL region”) and a constant region (“CL region”). There are two distinct types of light chains, designated kappa (κ) or lambda (λ) based on the amino acid sequence of the CL region. The amino acid sequence of the constant region is well-known in the art.
[0087] Each heavy chain typically comprises a heavy chain variable region (“VH region”) and a heavy chain constant region (“CH region”). The heavy chain variable region can be one of five different types, designated alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ) based on their amino acid sequences. When bound to a light chain, these different types of heavy chains produce five known classes of antibodies: IgA, IgD, IgE, IgG, and IgM. IgG has four subclasses: IgG1, IgG2, IgG3, and IgG4. The amino acid sequences of the CH regions of different antibody classes are well known in the art.
[0088] The CH region of an immunoglobulin comprises more than one domain. For example, the CH region of an IgG antibody consists of three domains: heavy chain constant domain 1 (CH1), heavy chain constant domain 2 (CH2), and heavy chain constant domain 3 (CH3). The highly flexible region between the CH1 and CH2 domains is called the "hinge region." The disulfide bonds in the hinge region are part of the interaction between the two heavy chains in an immunoglobulin. The "Fc region" refers to the C-terminal region of the immunoglobulin heavy chain, which contains at least a portion of the constant region. In the IgG, IgA, and IgD isotypes, the Fc region consists of the CH2 and CH3 domains; the Fc regions of IgM and IgE contain three heavy chain constant domains (CH domains 2–4). The amino acid sequences of the Fc regions of human IgG, IgA, IgD, IgM, and IgE, as well as the subtypes IgG1, IgG2, IgG3, and IgG4, are known to those skilled in the art. The native Fc region can be modified.
[0089] Unless otherwise stated or the context contradicts, references to amino acid positions in constant regions are made to EU numbers (Edelman et al., PNAS. 1969; 63:78-85, Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition. 1991 NIH Publication No. 91-3242). An exemplary list of amino acid sequences for the constant domains / regions of human IgG antibodies is provided below. Several exemplary variants are also included, and further variants are disclosed in the following sections.
[0090] Table 1. Amino acid sequence of the constant region of the light chain of human IgG antibody
[0091] Table 2. Amino acid sequence of the constant region of the heavy chain of human IgG antibody
[0092] As used in this article, the term "variable region" refers to a portion of the immunoglobulin light or heavy chain, typically located at the amino terminus of the light or heavy chain, and is responsible for the binding and specificity of each particular antibody to its specific antigen. The variable region of the light chain is called the "light chain variable region" or "VL region," and it includes at least one, usually a "light chain variable domain" or "VL." The variable region of the heavy chain is called the "heavy chain variable region" or "VH region," and it includes at least one, usually a "heavy chain variable domain" or "VH." Variable domains vary widely in sequence between different antibodies. A "VL / VH pair" can associate with each other to form a binding site that specifically binds to a target antigen or epitope.
[0093] The VL and VH regions can be further subdivided into hypervariable regions (or hypervariable areas, which may exhibit structurally defined loops in sequence and / or structure), also known as complementarity-determining regions (CDRs), interspersed with more conserved regions called frame regions (FRs). Sequence variability is concentrated in the CDRs, while the less variable portions of the variable domains are called frame regions (FRs). The CDRs of the light and heavy chains are primarily responsible for antibody-antigen interactions. Each VH and VL typically consists of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk, J Mol Biol 1987;196:901-17).
[0094] CDR refers to one of the three hypervariable regions (H1, H2, or H3) within the non-framework region of the VH β-sheet framework of an immunoglobulin (Ig or antibody), or one of the three hypervariable regions (L1, L2, or L3) within the non-framework region of the VL β-sheet framework of an antibody. CDR regions are well known to those skilled in the art and have been defined using various methods / systems. These systems and / or definitions have been developed and refined over many years, including Kabat, Chothia, IMGT, AbM, and Contact. For example, Kabat defines the region with the highest variability within the variable (V) domain of an antibody (Kabat et al., J. Biol. Chem. 252:6609-6616 (1977); Kabat, Adv. Prot. Chem. 32: 1-75 (1978)). Software programs (e.g., abYsis) for analyzing antibody sequences and determining CDRs are known and available to those skilled in the art.
[0095] As used herein, the term "humanized antibody" refers to a non-human (e.g., mouse) antibody containing a minimum amount of non-human sequence, consisting of a specific immunoglobulin chain, chimeric immunoglobulin, or fragment thereof. Typically, humanized antibodies are human immunoglobulins. In some cases, the variable region residues of a human immunoglobulin are replaced with corresponding residues from a non-human species antibody. In other cases, CDR residues are replaced with CDR residues from a non-human species (e.g., mouse, rat, hamster, camel, rabbit, goat, shark, alpaca) having the desired specificity, affinity, and / or binding capacity. Humanized antibodies can also be further modified by replacing additional residues within the variable region and / or within the replaced non-human residues to refine and optimize the antibody's specificity, affinity, and / or binding capacity. As used herein, the term "human antibody" refers to an antibody produced by a human, or an antibody having an amino acid sequence corresponding to that of a human-produced antibody and prepared using any technique known in the art.
[0096] As used herein, the term "specific binding" refers to a more frequent, faster, longer-lasting, or more affinity interaction between a polypeptide or molecule and an epitope, protein, or target molecule, compared to interactions with surrogate substances, including related and unrelated proteins. The binding moiety (e.g., antibody) of a specific-binding target molecule (e.g., antigen) can be identified, for example, by immunoassay, ELISA, biolayer interference (“BLI”), SPR (e.g., Biacore), or other techniques known to those skilled in the art. Typically, the specific response is at least twice the background signal or noise, and can exceed 10 times the background. For example, for a discussion of antibody specificity, see Paul (ed.), 1989, Fundamental Immunology Second Edition, Raven Press, New York, pp. 332-336. The binding moiety of a specific-binding target molecule can bind to that target molecule with an affinity higher than its affinity with different molecules. In some embodiments, the binding moiety of the specifically binding target molecule has an affinity for that target molecule that is at least 20, 30, 40, 50, 60, 70, 80, 90, or 100 times greater than its affinity for different molecules. In some embodiments, the affinity of the specifically binding moiety of the particular target molecule for different molecules is so low that the binding cannot be detected using the assays described herein or known in the art. In some embodiments, "specific binding" refers, for example, to a binding moiety with a K+ concentration of about 0.1 mM or lower. D Binding to a molecular target. In some embodiments, "specific binding" refers to the peptide or molecule binding at a concentration of approximately 10 µM or less, or approximately 1 µM or less. DBinding to the target. In some embodiments, "specific binding" refers to the peptide or molecule binding at a K+ level of about 0.1 µM or less, about 0.01 µM or less, or about 1 nM or less. D Target binding. Due to sequence identity between homologous proteins in different species, specific binding may include peptides or molecules that recognize proteins or targets in more than one species. Similarly, due to homology in certain regions of peptide sequences of different proteins, specific binding may include peptides or molecules that recognize more than one protein or target. It should be understood that in some embodiments, the binding portion (e.g., an antibody) that specifically binds to a first target may or may not specifically bind to a second target. Therefore, “specific binding” does not necessarily require (although it may include) exclusive binding, i.e., binding to only a single target. Thus, in some embodiments, the binding portion (e.g., an antibody) may specifically bind to more than one target. For example, in some cases, an antibody may contain two identical antigen-binding sites, each of which specifically binds to the same epitope on two or more proteins.
[0097] The term "binding affinity" as used in this article generally refers to the strength of the sum of all non-covalent interactions between the binding moiety and the target molecule (e.g., antigen). Binding between the binding moiety and the target molecule is a reversible process, and the affinity of this binding is typically expressed as a function of the equilibrium dissociation constant (K0). D () indicates. K D dissociation rate (k) off or k d ) and association rate (k on or k a The ratio of ) to. Combined with the pair K D The lower the value, the higher the affinity. Various methods for measuring binding affinity are known in the art, any of which can be used for the purposes of this disclosure. Specific exemplary embodiments include the following. In some embodiments, “K…” D "or "K D The value can be measured by methods known in the art, such as by combination determination. K D It can be measured in radiolabeled antigen binding assays (RIA) (Chen, et al., (1999) J. Mol Biol 293:865-881). K D or K D The value can also be measured using biological layer interferometry (BLI), for example using the Gator system (Probe Life) or the Octet-96 system (Sartorius AG). K D or K DThe values can also be measured using Biacore's surface plasmon resonance (SPR) measurement, for example using BIAcore™-2000 or BIAcore™-3000 (BIAcore, Inc., Piscataway, NJ).
[0098] The term "antibody-drug conjugate" or "ADC" refers to a type of molecule designed for targeted cancer therapy. An ADC consists of a monoclonal antibody that provides specific targeting of pathological cells (e.g., cancer cells); a therapeutic component that delivers a therapeutic effect (e.g., cytotoxicity) to the targeted cancer cells; and a linker that facilitates the conjugation of these two main components. Upon binding, the ADC is internalized into the cancer cells, thereby releasing the therapeutic component.
[0099] As used herein, the term "OX40 positive" in the context of cells refers to cells exhibiting detectable OX40 expression. In some embodiments, the cells exhibit detectable OX40 expression on their surface. As used herein, the term "OX40 positive" in the context of cancer or tumor refers to cancer or tumor containing cells exhibiting detectable OX40 expression. Those skilled in the art can readily determine whether a cancer or tumor expresses OX40 using any method known and available in the art, including, for example, immunohistochemistry (IHC), immunocytochemistry (ICC), enzyme-linked immunosorbent assay (ELISA), flow cytometry (FACS), etc.
[0100] As used herein, the term "vector" and its grammatical equivalents refer to a tool for carrying genetic material (e.g., a polynucleotide sequence) that can be introduced into a host cell, where it can be replicated and / or expressed. Suitable vectors include, for example, expression vectors, plasmids, phage vectors, viral vectors, episomes, and artificial chromosomes, which may include selectable sequences or marker genes operable for stable integration into the host cell chromosome. Furthermore, vectors may include one or more selectable marker genes and appropriate expression control sequences. For example, the selectable marker genes may provide resistance to antibiotics or toxins, compensate for auxotrophic deficiencies, or provide critical nutrients absent in the culture medium. Expression control sequences may include constitutive and inducible promoters, transcription enhancers, transcription terminators, etc., as well known in the art. When two or more polynucleotides are to be co-expressed, for example, the two polynucleotides may be inserted into a single expression vector or into separate expression vectors. For single-vector expression, the encoding polynucleotide may be operatively linked to a common expression control sequence or to different expression control sequences, such as an inducible promoter and a constitutive promoter. The introduction of the polynucleotide into the host cell can be confirmed using methods well known in the art. Those skilled in the art will understand that polynucleotides are expressed in an amount sufficient to produce the desired product, and will also understand that expression levels can be optimized using methods well known in the art to obtain sufficient expression.
[0101] As used herein, the term "encoding" and its syntactic equivalents refer to the inherent property of a specific nucleotide sequence in a polynucleotide or nucleic acid (e.g., gene, cDNA, or mRNA) to serve as a template in biological processes for the synthesis of other polymers and macromolecules having a defined nucleotide sequence (i.e., rRNA, tRNA, and mRNA) or a defined amino acid sequence and the resulting biological properties. Therefore, if the transcription and translation of the mRNA corresponding to a gene produces the protein, then the gene encodes that protein. Unless otherwise stated, "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence. Nucleotide sequences encoding proteins and RNA may include introns.
[0102] The term "polynucleotide encoding a polypeptide" encompasses polynucleotides that include only the coding sequence of the polypeptide, as well as polynucleotides that include additional coding and / or non-coding sequences. The polynucleotides disclosed herein may be in RNA or DNA form. The DNA may be cDNA, genomic DNA, or synthetic DNA, and may be double-stranded or single-stranded. Single-stranded DNA may be a coding strand or a non-coding (antisense) strand. The polynucleotides disclosed herein may be mRNA.
[0103] As used herein, the terms “identical,” “percentage of identity,” and their grammatical equivalents, in the context of two or more polynucleotides or polypeptides, mean that two or more sequences or subsequences are identical to each other, or have a specified percentage of identical nucleotide or amino acid residues, when compared and aligned (with gaps introduced where necessary) to obtain maximum correspondence, wherein no conserved amino acid substitutions are considered part of sequence identity. The percentage of identity can be determined using sequence comparison software or algorithms, or by visual inspection. Various algorithms and software available for obtaining amino acid or nucleotide sequence alignments are well known in the art. These include, but are not limited to, BLAST, ALIGN, Megalign, BestFit, GGWisconsin Package, and variants thereof. In some embodiments, “two polynucleotides or polypeptides are substantially identical” as provided herein means that, when compared and aligned to obtain maximum correspondence, they have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and in some embodiments at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% nucleotide or amino acid residue identity, as determined by sequence comparison algorithms or by visual inspection. In some embodiments, the identity exists in a region of an amino acid sequence, the region being at least about 10 residues, at least about 20 residues, at least about 40-60 residues, at least about 60-80 residues, or any integer value between these lengths. In some embodiments, the identity exists in a region longer than 60-80 residues, for example, at least about 80-100 residues, and in some embodiments, the sequences are substantially identical in length across the entire length of the compared sequences, such as the coding region of a target protein or antibody. In some embodiments, the identity exists in a region of a nucleotide sequence, the region being at least about 10 bases, at least about 20 bases, at least about 40-60 bases, at least about 60-80 bases, or any integer value between these lengths. In some embodiments, the identity exists in a region longer than 60-80 bases, for example, at least about 80-1000 bases or more, and in some embodiments, the sequences are substantially identical in length across the entire length of the compared sequences, such as the nucleotide sequence encoding a protein of interest.
[0104] "Isolated" polypeptides, peptides, proteins, antibodies, polynucleotides, carriers, cells, or compositions refer to polypeptides, peptides, proteins, antibodies, polynucleotides, carriers, cells, or compositions that exist in a form not found in nature. Isolated polypeptides, peptides, proteins, antibodies, polynucleotides, carriers, cells, or compositions include those that have been purified to the point that they no longer exist in their naturally occurring form. In some embodiments, the isolated polypeptides, peptides, proteins, antibodies, polynucleotides, carriers, cells, or compositions are substantially pure.
[0105] The terms "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" refer to a material suitable for administration to an individual along with an active agent without causing undesirable biological effects and without interacting with any other component of the pharmaceutical composition in a harmful manner. In some embodiments, the pharmaceutical compositions disclosed herein may comprise one or more buffer systems, preservatives, isotonic agents, chelating agents, stabilizers, and / or surfactants, as well as various combinations thereof. The use of preservatives, isotonic agents, chelating agents, stabilizers, and surfactants in pharmaceutical compositions is well known to those skilled in the art. See Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
[0106] The term “treatment” as used herein, and its grammatical equivalents, when relating to a disease or condition, or a subject suffering from a disease or condition, refers to actions, interventions, and / or measures that suppress, eliminate, reduce, and / or improve symptoms, symptom severity, and / or symptom frequency associated with the disease or disorder being treated.
[0107] As used herein, the term "administration" and its grammatical equivalents refer to the act of delivering, or facilitating the delivery of, a therapeutic agent or pharmaceutical composition to a subject by the methods described herein or otherwise known in the art. The therapeutic agent may be a compound, peptide, antibody, antibody-drug conjugate, or cell. Administering a therapeutic agent or pharmaceutical composition includes prescribing for delivery of the therapeutic agent or pharmaceutical composition to a subject. Exemplary forms of administration include oral dosage forms, such as tablets, capsules, syrups, and suspensions; injectable dosage forms, such as intravenous (IV), intramuscular (IM), or intraperitoneal (IP); transdermal dosage forms, including creams, gels, powders, or patches; buccal mucosal dosage forms; inhaled powders, sprays, suspensions, and rectal suppositories.
[0108] As used herein, the terms "effective amount," "therapeutic effective amount," and their grammatical equivalents refer to the amount of an agent administered to a subject (alone or as part of a pharmaceutical composition, and in a single dose or as part of a series of doses) that, when administered to the subject, produces any detectable positive effect on any symptom, aspect, or characteristic of a disease, disorder, or condition. The therapeutic effective amount can be determined by measuring the relevant physiological effects. The exact amount required varies from subject to subject, depending on the subject's age, weight and general condition, the severity of the condition being treated, the clinician's judgment, etc. In any individual case, the appropriate "effective amount" can be determined by a person skilled in the art through routine laboratory procedures.
[0109] As used herein, the term "subject" refers to any animal (e.g., a mammal), including but not limited to humans, non-human primates, canines, felines, rodents, etc., that will serve as a recipient of a specific treatment. Mammals include, but are not limited to, farm animals, sporting animals, pets, primates, horses, dogs, cats, mice, and rats. Human subjects requiring this treatment may be those who have, are at risk of having, or are suspected of having a disease. Subjects with a disease can be identified through routine medical examinations, such as physical examination, laboratory tests, organ function tests, CT scans, or ultrasound examinations. Subjects suspected of having any such disease may exhibit one or more symptoms of that disease. Subjects at risk of having the disease may be those who have one or more risk factors for that disease. Subjects may be human. Subjects may have a specific disease or condition.
[0110] Scope: In this disclosure, various aspects of the invention may be presented in a scope format. It should be understood that the scope format is used for convenience and brevity purposes only and should not be construed as a rigid limitation on the scope of the invention. Therefore, a description of a scope should be considered as a specific disclosure of all possible sub-scopes within that scope, as well as individual numerical values. For example, a description of a scope of 1 to 6 should be considered as a specific disclosure of sub-scopes such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., and individual numbers within that scope, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. The above principles apply regardless of the width of the scope.
[0111] The exemplary genes and peptides described herein are illustrated by reference to GenBank numbers, GI numbers, and / or SEQ ID NOS. It should be understood that those skilled in the art can readily identify homologous sequences by referring to sequence sources, including but not limited to Uniprot (https: / / www.uniprot.org / ), GenBank (ncbi.nlm.nih.gov / genbank / ), and EMBL (embl.org / ). 1.2 Antibodies
[0112] This document provides antibodies or antigen-binding fragments thereof capable of specifically binding to OX40. In some embodiments, this document provides anti-OX40 antibodies. In some embodiments, the antibody is an IgA, IgD, IgE, IgG, or IgM antibody. In some embodiments, the antibody is an IgA antibody. In some embodiments, the antibody is an IgD antibody. In some embodiments, the antibody is an IgE antibody. In some embodiments, the antibody is an IgG antibody. In some embodiments, the antibody is an IgM antibody. In some embodiments, the antibody provided herein may be an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody. In some embodiments, the antibody is an IgG1 antibody. In some embodiments, the antibody is an IgG2 antibody. In some embodiments, the antibody is an IgG3 antibody. In some embodiments, the antibody is an IgG4 antibody.
[0113] In some embodiments, this document provides an antigen-binding fragment of an anti-OX40 antibody. In some embodiments, the antigen-binding fragment provided herein may be a single-domain antibody (sdAb), a heavy-chain antibody (HCAb), Fab, Fab', F(ab')2, Fv, a single-chain variable fragment (scFv), or (scFv)2. In some embodiments, the antigen-binding fragment of the anti-OX40 antibody is a single-domain antibody (sdAb). In some embodiments, the antigen-binding fragment of the anti-OX40 antibody is a heavy-chain antibody (HCAb). In some embodiments, the antigen-binding fragment of the anti-OX40 antibody is Fab. In some embodiments, the antigen-binding fragment of the anti-OX40 antibody is Fab'. In some embodiments, the antigen-binding fragment of the anti-OX40 antibody is F(ab')2. In some embodiments, the antigen-binding fragment of the anti-OX40 antibody is Fv. In some embodiments, the antigen-binding fragment of the anti-OX40 antibody is scFv. In some embodiments, the antigen-binding fragment of the anti-OX40 antibody is a disulfide-linked scFv [(scFv)2]. In some implementations, the antigen-binding fragment of the anti-OX40 antibody is a diabody (dAb).
[0114] In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise recombinant antibodies or antigen-binding fragments. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise monoclonal antibodies or antigen-binding fragments. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise polyclonal antibodies or antigen-binding fragments. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise camelid (e.g., camel, dromedary camel, and llama) antibodies or antigen-binding fragments. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise chimeric antibodies or antigen-binding fragments. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise humanized antibodies or antigen-binding fragments. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise human antibodies or antigen-binding fragments. In some embodiments, the present invention provides anti-OX40 human scFv.
[0115] In some embodiments, the anti-OX40 antibody or antigen-binding fragment provided herein is isolated. In some embodiments, the anti-OX40 antibody or antigen-binding fragment provided herein is substantially pure.
[0116] In some embodiments, the anti-OX40 antibody or antigen-binding fragment is a monoclonal antibody or antigen-binding fragment. Monoclonal antibodies can be prepared by any method known to those skilled in the art. One exemplary method is to screen protein expression libraries, such as phage display libraries or ribosome display libraries. For example, phage display is described in, for example, U.S. Patent No. 5,223,409 to Ladner et al.; Smith (1985) Science 228:1315-1317; and WO 92 / 18619. In some embodiments, recombinant monoclonal antibodies are isolated from phage display libraries expressing the variable region or CDR of the desired species. Screening of phage libraries can be performed using various techniques known in the art.
[0117] In some embodiments, monoclonal antibodies are modified using recombinant DNA technology to generate alternative antibodies. In some embodiments, the constant domains of the light and heavy chains of mouse monoclonal antibodies are replaced with constant regions of human antibodies to generate chimeric antibodies. In some embodiments, constant regions are truncated or removed to generate desired antibody fragments of monoclonal antibodies. In some embodiments, site-directed mutagenesis or high-density mutagenesis of variable regions is employed to optimize the specificity and / or affinity of the monoclonal antibody.
[0118] In some embodiments, this document provides anti-OX40 antibodies having the sequence characteristics described below. The specific CDR sequences defined herein are generally based on Kabat or IMGT definitions. However, it should be understood that general references to the heavy chain CDR or CDR and / or light chain CDR or CDR of a particular antibody encompass all CDR definitions known to those skilled in the art. In some embodiments, this document provides anti-OX40 antibodies having the VL CDR and / or VH CDR of antibody HX011 disclosed herein, wherein the CDR is defined by Kabat, Chothia, IMGT, AbM, or Contact. In some embodiments, the CDR is defined by Kabat (as detailed in the examples below). In some embodiments, the CDR is defined by Chothia (as detailed in the examples below). In some embodiments, the CDR is defined by IMGT. In some embodiments, the CDR is defined by AbM. In some embodiments, the CDR is defined by Contact.
[0119] In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof provided herein is an antibody designated as HX011. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof provided herein has a VL (SEQ ID NO:15) from HX011. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof provided herein has a VH (SEQ ID NO:16) from HX011. The anti-OX40 antibody or antigen-binding fragment thereof provided herein may have both a VL and a VH from HX011. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof provided herein has a VL comprising VL CDR1, VL CDR2, and VL CDR3 of the VL (SEQ ID NO:15) from HX011. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof provided herein has a VH comprising VH CDR1, VH CDR2, and VH CDR3 of the VH (SEQ ID NO:16) from HX011. The anti-OX40 antibody or its antigen-binding fragment provided herein may have a VL comprising VL CDR1, VL CDR2, and VL CDR3, and a VH comprising VH CDR1, VH CDR2, and VH CDR3, wherein the VL and VH are derived from the VL and VH of HX011, respectively. The CDRs may be defined by any system known in the art. In some embodiments, the CDRs are defined by Kabat, Chothia, IMGT, AbM, or Contact. In some embodiments, the CDRs are defined by Kabat or IMGT, as detailed herein. In some embodiments, the CDRs are defined by Chothia. In some embodiments, the CDRs are defined by AbM. In some embodiments, the CDRs are defined by Contact.
[0120] In some embodiments, the anti-OX40 antibody or its antigen-binding fragment provided herein is a variant of HX011. The HX011 variant may have a VL, which is a variant of the VL of HX011 having up to about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in SEQ ID NO:15. The HX011 variant may have a VL, which is a variant of the VL of HX011 having up to about 5 amino acid substitutions, additions, and / or deletions in SEQ ID NO:15. The HX011 variant may have a VH, which is a variant of the VH of HX011 having up to about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in SEQ ID NO:16. The HX011 variant may have a VH, which is a variant of the VH of HX011 having up to about 5 amino acid substitutions, additions, and / or deletions in SEQ ID NO:16. The amino acid substitutions, additions, and / or deletions may be located in a VH CDR or a VL CDR. In some embodiments, the amino acid substitutions, additions, and / or deletions are not located in a CDR. In some embodiments, the HX011 variant has up to about 5 conserved amino acid substitutions. In some embodiments, the HX011 variant has up to 3 conserved amino acid substitutions. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof provided herein is a humanized antibody or antigen-binding fragment derived from HX011. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof provided herein is a human antibody or antigen-binding fragment derived from HX011.
[0121] In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise one, two, three, four, five, and / or six CDRs of any of the antibodies described herein. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise a light chain variable region (VL) comprising one, two, and / or three light chain CDRs (VL CDRs) from Table 3. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise a heavy chain variable region (VH) comprising one, two, and / or three heavy chain CDRs (VHCDRs) from Table 4. In some embodiments, the anti-OX40 antibody or antigen-binding fragments provided herein comprise one, two, and / or three VL CDRs from Table 3 and one, two, and / or three VH CDRs from Table 4.
[0122] Table 3. Amino acid sequence of the light chain variable region CDR (VL CDR) of HX011
[0123] Table 4. Amino acid sequence of the heavy chain variable region CDR (VH CDR) of HX011.
[0124] In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising a VL, wherein the VL comprises (1) a VL CDR1 having an amino acid sequence of SEQ ID NO: 1 or 4; (2) a VL CDR2 having an amino acid sequence of AAT or SEQ ID NO: 5; and / or (3) a VL CDR3 having an amino acid sequence of SEQ ID NO: 3 or 6; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VL CDRs; and / or comprises a VH, wherein the VH comprises (1) a VH CDR1 having an amino acid sequence of SEQ ID NO: 7 or 10; (2) a VH CDR2 having an amino acid sequence of SEQ ID NO: 8 or 11; and / or (3) a VH CDR3 having an amino acid sequence of SEQ ID NO: 9 or 12; or variants thereof, wherein the variants have at most ... CDRs have up to about 3, about 5, about 8, about 10, about 12 or about 15 amino acid substitutions, additions and / or deletions.
[0125] In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising a VL, wherein the VL comprises (1) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1 or 4; (2) a VL CDR2 having the amino acid sequence of AAT or SEQ ID NO: 5; or (3) a VL CDR3 having the amino acid sequence of SEQ ID NO: 3 or 6; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VL CDRs. In some embodiments, the variants have at most about 5 amino acid substitutions, additions, and / or deletions in the VL CDRs. In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising a VL, wherein the VL comprises (1) a VL CDR1 having the amino acid sequence of SEQ ID NO: 1 or 4; (2) a VL CDR2 having the amino acid sequence of AAT or SEQ ID NO: 5; and (3) a VLCDR3 having the amino acid sequence of SEQ ID NO: 3 or 6; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VL CDRs. In some embodiments, the variants have at most about 5 amino acid substitutions, additions, and / or deletions in the VL CDRs.
[0126] In some embodiments, this document provides antibodies having a VL that specifically bind to OX40, or antigen-binding fragments thereof, wherein the VL comprises VL CDR1, CDR2, and CDR3 (as defined by Kabat) having amino acid sequences of SEQ ID NOs:4, 5, and 6, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VL CDRs. In some embodiments, the variants have at most about 5 amino acid substitutions, additions, and / or deletions in the VL CDRs. In some embodiments, this document provides antibodies having a VL that specifically binds to OX40, or antigen-binding fragments thereof, wherein the VL comprises VL CDR1, CDR2, and CDR3 (as defined by IMGT) having amino acid sequences of SEQ ID NO:1, AAT, and SEQ ID NO:3, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VL CDRs. In some implementations, the variants have up to about 5 amino acid substitutions, additions, and / or deletions in the VL CDRs.
[0127] In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising a VH, wherein the VH comprises (1) a VH CDR1 having the amino acid sequence of SEQ ID NO: 7 or 10; (2) a VH CDR2 having the amino acid sequence of SEQ ID NO: 8 or 11; or (3) a VH CDR3 having the amino acid sequence of SEQ ID NO: 9 or 12; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VH CDRs. In some embodiments, the variants have at most about 5 amino acid substitutions, additions, and / or deletions in the VH CDRs. In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising a VH, wherein the VH comprises (1) a VH CDR1 having the amino acid sequence of SEQ ID NO: 7 or 10; (2) a VH CDR2 having the amino acid sequence of SEQ ID NO: 8 or 11; and (3) a VHCDR3 having the amino acid sequence of SEQ ID NO: 9 or 12; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VH CDRs. In some embodiments, the variants have at most about 5 amino acid substitutions, additions, and / or deletions in the VH CDRs.
[0128] In some embodiments, this document provides antibodies having a VH that specifically bind to OX40, or antigen-binding fragments thereof, wherein the VH comprises VH CDR1, CDR2, and CDR3 (as defined by Kabat) having amino acid sequences of SEQ ID NOs:10, 11, and 12, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VH CDRs. In some embodiments, the variants have at most about 5 amino acid substitutions, additions, and / or deletions in the VH CDRs. In some embodiments, this document provides antibodies having a VH that specifically binds to OX40, or antigen-binding fragments thereof, wherein the VH comprises VH CDR1, CDR2, and CDR3 (as defined by IMGT) having amino acid sequences of SEQ ID NOs:7, 8, and 9, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VH CDRs. In some implementations, the variants have up to about 5 amino acid substitutions, additions, and / or deletions in the VH CDRs.
[0129] In some embodiments, this document provides antibodies or antigen-binding fragments thereof that specifically bind to OX40, comprising (as defined by Kabat): (a) VL, wherein the VL comprises VLCDR1, VL CDR2, and VL CDR3 having amino acid sequences of SEQ ID NOs:4, 5, and 6, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VL CDRs; and / or (b) VH, wherein the VH comprises VH CDR1, VH CDR2, and VH CDR3 having amino acid sequences of SEQ ID NOs:10, 11, and 12, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VH CDRs.
[0130] In some embodiments, this document provides antibodies that specifically bind to OX40 or antigen-binding fragments thereof comprising VL CDR1, VL CDR2, VL CDR3, VH CDR1, VH CDR2, and VH CDR3, and having amino acid sequences of SEQ ID NOs:4, 5, 6, 10, 11, and 12, respectively (as defined by Kabat); or variants thereof, wherein the variants have substitutions, additions, and / or deletions of up to about 3, about 5, about 8, about 10, about 12, or about 15 amino acids in the CDRs.
[0131] In some embodiments, this document provides antibodies or antigen-binding fragments thereof that specifically bind to OX40, comprising (as defined by IMGT): (a) VL, wherein the VL comprises VL CDR1, VL CDR2, and VL CDR3 having amino acid sequences of SEQ ID NO:1, AAT, and SEQ ID NO:3, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VL CDRs; and / or (b) VH, wherein the VH comprises VH CDR1, VH CDR2, and VH CDR3 having amino acid sequences of SEQ ID NOs:7, 8, and 9, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the VH CDRs.
[0132] In some embodiments, this document provides antibodies or antigen-binding fragments thereof that specifically bind to OX40, comprising VL CDR1, VL CDR2, VL CDR3, VH CDR1, VH CDR2, and VH CDR3, and having amino acid sequences (as defined by IMGT) of SEQ ID NO:1, AAT, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively; or variants thereof, wherein the variants have at most about 3, about 5, about 8, about 10, about 12, or about 15 amino acid substitutions, additions, and / or deletions in the CDRs.
[0133] Table 5. Amino acid sequences of the light chain variable region (VL) and heavy chain variable region (VH) of humanized antibody HX011.
[0134] In some embodiments, this document provides an antibody that specifically binds to OX40 or an antigen-binding fragment thereof comprising VL, wherein said VL has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:15. In some embodiments, this document provides an antibody that specifically binds to OX40 or an antigen-binding fragment thereof comprising VH, wherein said VH has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:16.
[0135] In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising: (a) VL, wherein the VL has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:15; and (b) VH, wherein the VH has at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:16. In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising VL and VH, wherein the VL and VH have amino acid sequences of SEQ ID NOs:15 and 16, respectively.
[0136] In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising a VL, wherein the VL has at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:15. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof comprises a VL, wherein the VL has at least 85% sequence identity with SEQ ID NO:15. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof comprises a VL, wherein the VL has at least 90% sequence identity with SEQ ID NO:15. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof comprises a VL, wherein the VL has at least 95% sequence identity with SEQ ID NO:15. In some embodiments, the anti-OX40 antibody or its antigen-binding fragment has a VL, wherein the VL has at least 98% sequence identity with SEQ ID NO:15. In some embodiments, this document provides an antibody or its antigen-binding fragment that specifically binds to OX40, comprising a VL, wherein the VL has the amino acid sequence of SEQ ID NO:15.
[0137] In some embodiments, this document provides an antibody or antigen-binding fragment thereof that specifically binds to OX40, comprising a VH, wherein the VH has at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:16. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof comprises a VH, wherein the VH has at least 85% sequence identity with SEQ ID NO:16. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof comprises a VH, wherein the VH has at least 90% sequence identity with SEQ ID NO:16. In some embodiments, the anti-OX40 antibody or antigen-binding fragment thereof comprises a VH, wherein the VH has at least 95% sequence identity with SEQ ID NO:16. In some embodiments, the anti-OX40 antibody or its antigen-binding fragment has a VH, wherein the VH has at least 98% sequence identity with SEQ ID NO:16. In some embodiments, this document provides an antibody or its antigen-binding fragment that specifically binds to OX40, comprising a VH, wherein the VH has the amino acid sequence of SEQ ID NO:16.
[0138] In some embodiments, this document provides an anti-OX40 antibody or an antigen-binding fragment thereof comprising a VL CDR from the VL (SEQ ID NO:15) described herein and / or a VH CDR from the VH (SEQ ID NO:16) described herein. Methods for identifying CDRs are well known in the art. For example, software programs (e.g., abYsis) publicly available on websites are known to those skilled in the art for analyzing antibody sequences and determining CDRs.
[0139] In some embodiments, this document provides an antibody that specifically binds to OX40 or an antigen-binding fragment thereof comprising (a) a VL comprising VL CDRs 1, 2 and 3 of a VL having the amino acid sequence of SEQ ID NO:15; or (b) a VH comprising VH CDRs 1, 2 and 3 of a VH having the amino acid sequence of SEQ ID NO:16.
[0140] In some embodiments, this document provides an antibody that specifically binds to OX40 or an antigen-binding fragment thereof comprising (a) a VL comprising VL CDRs 1, 2 and 3 of a VL having the amino acid sequence of SEQ ID NO:15; and (b) a VH comprising VH CDRs 1, 2 and 3 of a VH having the amino acid sequence of SEQ ID NO:16.
[0141] The anti-OX40 antibody or its antigen-binding fragment may comprise a combination of any VL and any VH disclosed herein. In some embodiments, the VL and VH are linked by a linker peptide. The linker peptide may be a flexible linker peptide or a rigid linker peptide. In some embodiments, the linker peptide has an amino acid sequence of (GGGGS)n, where n = 1, 2, 3, 4, or 5 (SEQ ID NO: 31). In some embodiments, the linker peptide has an amino acid sequence of (EAAAK)n, where n = 1, 2, 3, 4, or 5 (SEQ ID NO: 32). In some embodiments, the linker peptide has an amino acid sequence of (PA)nPAP, where n = 0, 1, 2, 3, or 4 (SEQ ID NO: 33).
[0142] In some embodiments, the anti-OX40 antibody provided herein comprises a light chain and a heavy chain. The light chain may comprise a light chain constant domain (CL) and a light chain variable domain (VL). The heavy chain may comprise a heavy chain variable domain (VH) and a heavy chain constant domain (CH). The VL / VH can be any VL / VH disclosed herein. In some embodiments, the light chain constant domain (CL) is κ CL (Cκ; SEQ ID NO:19). In some embodiments, the light chain constant domain (CL) is λ CL (Cλ; SEQ ID NO:20). In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) derived from human IgA. In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) derived from human IgD. In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) derived from human IgE. In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) derived from human IgG. In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) from human IgM. In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) from human IgG1 (e.g., SEQ ID NO:21). In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) from human IgG2 (e.g., SEQ ID NO:22). In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) from human IgG3 (e.g., SEQ ID NO:23). In some embodiments, the heavy chain may comprise a heavy chain constant domain (CH) from human IgG4 (e.g., SEQ ID NO:24). The CH may further comprise a C-terminal lysine (K). This document explicitly covers any and all combinations of the VL / VH pairs disclosed herein that specifically bind to OX40 (e.g., human OX40) with the CL / CH disclosed herein or otherwise known in the art.
[0143] In some embodiments, the antibody provided herein has a light chain constant region (CL), wherein the CL has at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO:19. In some embodiments, the antibody provided herein has a CL, wherein the CL has the amino acid sequence of SEQ ID NO:19. In some embodiments, the antibody provided herein has a light chain constant region (CL), wherein the CL has at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO:20. In some embodiments, the antibody provided herein has a CL, wherein the CL has the amino acid sequence of SEQ ID NO:20. In some embodiments, the antibody provided herein has a heavy chain constant region (CH), wherein the CH has at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO:21. In some embodiments, the antibody provided herein has a CH, wherein the CH has the amino acid sequence of SEQ ID NO:21. In some embodiments, the antibody provided herein has CH, wherein CH has at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO:22. In some embodiments, the antibody provided herein has CH, wherein CH has the amino acid sequence of SEQ ID NO:22. In some embodiments, the antibody provided herein has CH, wherein CH has at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO:23. In some embodiments, the antibody provided herein has CH, wherein CH has the amino acid sequence of SEQ ID NO:23. In some embodiments, the antibody provided herein has CH, wherein CH has at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity with SEQ ID NO:24. In some embodiments, the antibody provided herein has CH, wherein CH has the amino acid sequence of SEQ ID NO:24.
[0144] In some embodiments, the anti-OX40 antibody provided herein comprises: (1) a light chain comprising, from the N-terminus to the C-terminus, a VL region and a light chain constant (CL) region; and / or (2) a heavy chain comprising, from the N-terminus to the C-terminus, a VH region and a heavy chain constant (CH) region. In some embodiments, the anti-OX40 antibody provided herein comprises a light chain comprising, from the N-terminus to the C-terminus, a VL region and a light chain constant (CL) region, wherein the light chain has an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to that of SEQ ID NO:27. In some embodiments, the anti-OX40 antibody provided herein comprises a heavy chain comprising, from the N-terminus to the C-terminus, a VH region and a heavy chain constant (CH) region, wherein the heavy chain has an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to that of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody provided herein comprises a heavy chain comprising a VH region and a heavy chain constant (CH) region sequentially from the N-terminus to the C-terminus, wherein the heavy chain has an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:29. In some embodiments, the anti-OX40 antibody provided herein comprises a light chain comprising a VL region and a light chain constant (CL) region sequentially from the N-terminus to the C-terminus, wherein the light chain has the amino acid sequence of SEQ ID NO:27. In some embodiments, the anti-OX40 antibody provided herein comprises a heavy chain comprising a VH region and a heavy chain constant (CH) region sequentially from the N-terminus to the C-terminus, wherein the heavy chain has the amino acid sequence of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody provided herein comprises a heavy chain comprising a VH region and a heavy chain constant (CH) region sequentially from the N-terminus to the C-terminus, wherein the heavy chain has the amino acid sequence of SEQ ID NO:29. In some embodiments, the anti-OX40 antibody provided herein comprises: (1) a light chain comprising, from the N-terminus to the C-terminus, a VL region and a light chain constant (CL) region; and (2) a heavy chain comprising, from the N-terminus to the C-terminus, a VH region and a heavy chain constant (CH) region; wherein the light chain has an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to that of SEQ ID NO:27, and the heavy chain has an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to that of SEQ ID NO:28.In some embodiments, the anti-OX40 antibody provided herein comprises: (1) a light chain comprising, from the N-terminus to the C-terminus, a VL region and a light chain constant (CL) region; and (2) a heavy chain comprising, from the N-terminus to the C-terminus, a VH region and a heavy chain constant (CH) region; wherein the light chain has the amino acid sequence of SEQ ID NO:27 and the heavy chain has the amino acid sequence of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody provided herein comprises: (1) a light chain comprising, from the N-terminus to the C-terminus, a VL region and a light chain constant (CL) region; and (2) a heavy chain comprising, from the N-terminus to the C-terminus, a VH region and a heavy chain constant (CH) region; wherein the light chain has an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to that of SEQ ID NO:27, and the heavy chain has an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% identical to that of SEQ ID NO:29. In some embodiments, the anti-OX40 antibody provided herein comprises: (1) a light chain comprising, from the N-terminus to the C-terminus, a VL region and a light chain constant (CL) region; and (2) a heavy chain comprising, from the N-terminus to the C-terminus, a VH region and a heavy chain constant (CH) region; wherein the light chain has the amino acid sequence of SEQ ID NO:27 and the heavy chain has the amino acid sequence of SEQ ID NO:29.
[0145] Table 6. Amino acid sequences of the light and heavy chains of humanized antibody HX011.
[0146] In some embodiments, this document also provides antibodies or antigen-binding fragments that compete with the antibody or antigen-binding fragments provided above (e.g., HX011) for binding to OX40 (e.g., human OX40). An antibody that “competes” with another antibody for binding to a target refers to an antibody that inhibits (partially or completely) the binding of another antibody to that target. Whether two antibodies compete for binding to a target, i.e., whether and to what extent one antibody inhibits the binding of the other antibody to the target, can be determined using known competition assays, such as BIACORE. ®Surface plasmon resonance (SPR) analysis. In some embodiments, an anti-OX40 antibody or antigen-binding fragment competes with another antibody or antigen-binding fragment and inhibits its binding to OX40 by at least 50%, 60%, 70%, 80%, 90%, or 100%. The competition assay can be performed, for example, as described in Ed Harlow and David Lane, Cold Spring HarbProtoc; 2006; doi: l0.H0l / pdb.prot4277, or as described in Chapter 11 of “Using Antibodies” by Ed Harlow and David Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA 1999.
[0147] Epitope mapping is a method for identifying binding sites, regions, or epitopes on target proteins where antibodies bind. Various methods for locating epitopes on target proteins are known in the art. These methods include mutation generation, including but not limited to shotgun mutagenesis, site-directed mutagenesis, and alanine scanning; domain or fragment scanning; peptide scanning (e.g., Pepscan technology); display methods (e.g., phage display, microbial display, and ribosome / mRNA display); methods involving proteolysis and mass spectrometry; and structural determinations (e.g., X-ray crystallography and NMR). In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein is characterized by assays including but not limited to N-terminal sequencing, amino acid analysis, HPLC, mass spectrometry, ion-exchange chromatography, and papain digestion.
[0148] The anti-OX40 antibody or antigen-binding fragment disclosed herein can be analyzed for its physical, chemical, and / or biological properties using various methods known in the art. In some embodiments, the ability of the anti-OX40 antibody to bind to OX40 (e.g., human OX40) is tested. Binding assays include, but are not limited to, BLI, SPR (e.g., Biacore), ELISA, and FACS. Furthermore, the antibody can be evaluated for solubility, stability, thermal stability, viscosity, expression level, expression quality, and / or purification efficiency.
[0149] In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein binds to human OX40 with high affinity, for example, K... D 10 -7 M or lower, 5×10 -8 M or lower, 10 -8 M or lower, 5×10 -9M or lower, 10 -9 M or lower, 5×10 -10 M or lower, or 10 -10 M or lower. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein is at K D 10 -9 M or lower binds to human OX40. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein binds to human OX40 with high affinity, for example, K. D Approximately 10 -7 M, approximately 5 × 10 -8 M, approximately 10 -8 M, approximately 5 × 10 -9 M, approximately 10 -9 M, approximately 5 × 10 -10 M, or approximately 10 -10 M. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein is in K D Approximately 10 -9 M binds to human OX40. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein is expressed at a KD of 10. -10 M to 10 -7 Within the range of M, in 10 -9 M to 10 -7 Within the range of M, in 10 -8 M to 10 -7 Within the range of M, in 10 -10 M to 5×10 -8 Within the range of M, in 10 -9 M to 5×10 -8 Within the range of M, in 10 -8 M to 5×10 -8 Within the range of M, in 10 -10 M to 10 -8 Within the range of M, in 10 -9 M to 10 -8 Within the range of M, in 10 -10 M to 5×10 -9 Within the range of M, in 10 -9 M to 5×10 -9 Within the range of M, or within 10 -10 M to 10 -9 Within the M range, it binds to human OX40. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein binds to human OX40 with high affinity, for example, K... D 10 -10 M to 10 -9M. In some implementations, K D Determined via BLI. In some implementations, K D Determined by SPR. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein binds to human OX40 with high affinity, for example, a KD of 10. -7 M or lower, 5×10 -8 M or lower, 10 -8 M or lower, 5×10 -9 M or lower, 10 -9 M or lower, 5×10 -10 M or lower, or 10 -10 M or lower; or approximately 10 -7 M, approximately 5 × 10 -8 M, approximately 10 -8 M, approximately 5 × 10 -9 M, approximately 10 -9 M, approximately 5 × 10 -10 M, or approximately 10 -10 M; or in 10 -10 M to 10 -7 Within the range of M, in 10 -9 M to 10 -7 Within the range of M, in 10 -8 M to 10 -7 Within the range of M, in 10 -10 M to 5×10 -8 Within the range of M, in 10 -9 M to 5×10 -8 Within the range of M, in 10 -8 M to 5×10 -8 Within the range of M, in 10 -10 M to 10 -8 Within the range of M, in 10 -9 M to 10 -8 Within the range of M, in 10 -10 M to 5×10 -9 Within the range of M, in 10 -9 M to 5×10 -9 Within the range of M, or within 10 -10 M to 10 -9 Within the range of M, as measured by SPR.
[0150] In some embodiments, the anti-OX40 antibodies or antigen-binding fragments described herein (e.g., HX011) do not block the binding of OX40L to OX40. Because these antibodies do not interfere with the normal function of OX40L / OX40 signaling, they are expected to have fewer side effects and a more favorable safety profile compared to blocking antibodies.
[0151] In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) is efficiently internalized by OX40-positive cells. For example, endocytosis via receptor-mediated endocytosis makes the antibody or antigen-binding fragment highly suitable for use in ADCs. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) exhibits a higher level of internalization by OX40-positive cells compared to known anti-OX40 antibodies or antigen-binding fragments (e.g., BMS-986178).
[0152] In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) is a depleting antibody, meaning it can eliminate OX40-positive cells, for example, via ADCC. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) depletes OX40-positive regulatory T cells within the TME. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) is a depleting antibody and does not block the binding of OX40L to OX40. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) exhibits significant ADCC. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) exhibits stronger ADCC compared to known anti-OX40 antibodies or antigen-binding fragments (e.g., BMS-986178). In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) enhances anti-tumor immune responses. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) reduces immunosuppression in the tumor microenvironment (TME). In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) enhances immunological activity in the TME. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) converts cold tumors into hot tumors. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011) is a humanized antibody or antigen-binding fragment.
[0153] In some implementations, the anti-OX40 antibody or antigen-binding fragment described herein induces T cell activation.
[0154] In some implementations, the anti-OX40 antibody or antigen-binding fragment described herein induces IFN-γ secretion.
[0155] In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein has antitumor activity. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein can be used to treat cancer. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein can be used to treat solid tumors or liquid tumors with OX40+ TILs. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein can be used to treat OX40+ T-cell leukemia or lymphoma. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein can be used to treat OX40+ peripheral T-cell lymphoma (PTCL, e.g., OX40+ adult T-cell leukemia (ATL) and OX40+ angioimmunoblastic T-cell lymphoma (AITL)) or OX40+ T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein can be used to treat HPV+ or EBV+ solid tumors or liquid tumors. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein can be used to treat EBV+ B-cell lymphoma, extranodal NK / T-cell lymphoma (ENKTL; e.g., nasal type), HPV16+ head and neck squamous cell carcinoma (HNSCC), EBV+ esophageal cancer, or HPV18+ cervical cancer. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein can be used to treat OX40+ solid tumors. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein can be used to treat OX40+ sarcoma, OX40+ breast cancer, OX40+ non-small cell lung cancer (NSCLC), OX40+ melanoma, or OX40+ ovarian cancer.
[0156] In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein may be used to treat autoimmune or inflammatory diseases. In some embodiments, the autoimmune or inflammatory disease is rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease (CD), graft-versus-host disease (GvHD), multiple sclerosis (MS), type 1 diabetes mellitus, atopic dermatitis, asthma, psoriasis, Sjögren's syndrome (SS), or idiopathic thrombocytopenic purpura (ITP).
[0157] This disclosure also covers other variants and equivalents substantially homologous to the recombinant, monoclonal, chimeric, and humanized antibodies or antibody fragments thereof described herein. In some embodiments, it is desirable to enhance the binding affinity of the antibody. In some embodiments, it is desirable to modulate the biological properties of the antibody, including but not limited to specificity, thermostability, expression level, effector function, glycosylation, immunogenicity, and / or solubility. Those skilled in the art will understand that amino acid alterations can modify the post-translational processes of an antibody, such as changing the number or location of glycosylation sites or altering membrane anchoring properties.
[0158] Variants can be substitutions, deletions, or insertions of one or more nucleotides encoding an antibody or peptide, resulting in an alteration of the amino acid sequence compared to the native antibody or peptide sequence. In some embodiments, amino acid substitutions are produced by replacing one amino acid with another that has similar structure and / or chemical properties, such as replacing leucine with serine, i.e., a conserved amino acid substitution. The range of insertions or deletions can be from about 1 to 5 amino acids. In some embodiments, the substitutions, deletions, or insertions relative to the parent molecule include substitutions of fewer than 25 amino acids, fewer than 20 amino acids, fewer than 15 amino acids, fewer than 10 amino acids, fewer than 5 amino acids, fewer than 4 amino acids, fewer than 3 amino acids, or fewer than 2 amino acids. In some embodiments, biologically useful and / or relevant variations in the amino acid sequence can be identified by systematically performing insertions, deletions, or substitutions in the sequence and testing the activity of the resulting variant protein relative to the parent protein.
[0159] In some embodiments, variants of the anti-OX40 antibody or antigen-binding fragment described herein are provided. In some embodiments, variants of the anti-OX40 antibody HX011 are provided. In some embodiments, the variants contain 1 to 30 amino acid substitutions, additions, and / or deletions in the parent antibody or antigen-binding fragment. In some embodiments, the variants contain 1 to 25 amino acid substitutions, additions, and / or deletions in the parent antibody or antigen-binding fragment. In some embodiments, the variants contain 1 to 20 substitutions, additions, and / or deletions in the parent antibody or antigen-binding fragment. In some embodiments, the variants contain 1 to 15 substitutions, additions, and / or deletions in the parent antibody or antigen-binding fragment. In some embodiments, the variants contain 1 to 10 substitutions, additions, and / or deletions in the parent antibody or antigen-binding fragment. In some embodiments, the variants contain 1 to 5 amino acid substitutions, additions, and / or deletions in the parent antibody or antigen-binding fragment. In some embodiments, the variants contain 1 to 3 amino acid substitutions, additions, and / or deletions in the parent antibody or antigen-binding fragment. In some embodiments, the amino acid substitution is located in the CDR of the antibody or antigen-binding fragment. In some embodiments, the amino acid substitution is not located in the CDR of the antibody or antigen-binding fragment. In some embodiments, the amino acid substitution is located in the frame region of the antibody or antigen-binding fragment. In some embodiments, the amino acid substitution, addition, and / or deletion are conserved amino acid substitutions.
[0160] It is known in the art that the constant regions of antibodies mediate several effector functions, and these effector functions can vary depending on the antibody isotype. For example, the binding of the C1 component of complement to the Fc region of an IgG or IgM antibody (which binds to an antigen) activates the complement system. Activation of complement is important in the opsonization and lysis of cellular pathogens. Activation of complement also stimulates inflammatory responses and can participate in autoimmune hypersensitivity reactions. Furthermore, the Fc region of an antibody can bind to cells expressing Fc receptors (FcRs). Several Fc receptors exist that are specific to different classes of antibodies, including IgG (γ receptor), IgE (ε receptor), IgA (α receptor), and IgM (μ receptor). Binding of antibodies to cell surface Fc receptors triggers a variety of important and diverse biological responses, including phagocytosis and destruction of antibody-coated particles, clearance of immune complexes, lysis of antibody-coated target cells by cytotoxic cells (a process known as antibody-dependent cytotoxicity or ADCC), release of inflammatory mediators, placental transport, and control of immunoglobulin production.
[0161] In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgA antibody. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgD antibody. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgE antibody. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgG antibody. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgM antibody. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgG1 antibody. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgG2 antibody. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgG3 antibody. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein contains a constant region of a human IgG4 antibody.
[0162] In some embodiments, at least one or more constant regions in the anti-OX40 antibody or antigen-binding fragment described herein have been modified or deleted. In some embodiments, the antibody comprises modification of one or more of the three heavy chain constant regions (CH1, CH2, or CH3) and / or of the light chain constant region (CL).
[0163] In some embodiments, the heavy chain constant region of the modified antibody includes at least one human constant region. In some embodiments, the heavy chain constant region of the modified antibody includes more than one human constant region. In some embodiments, modification of the constant region includes the addition, deletion, or substitution of one or more amino acids in one or more regions. In some embodiments, one or more regions are partially or completely deleted from the constant region of the modified antibody. In some embodiments, the entire CH2 domain of the antibody has been removed from the antibody (ΔCH2 construct). In some embodiments, the deleted constant region is replaced by a short amino acid spacer peptide that provides some of the molecular flexibility typically conferred by the deleted constant region. In some embodiments, the modified antibody includes a CH3 domain fused directly to the antibody hinge region. In some embodiments, the modified antibody includes a peptide spacer peptide inserted between the hinge region and the modified CH2 and / or CH3 domains.
[0164] Human constant regions exhibit both allotropic and intratype-specific variations among individuals; that is, constant regions can differ at one or more polymorphic sites in different individuals. The difference between intratype-specific and allotropic regions lies in the fact that serum identifying intratype-specific regions binds to one or more non-polymorphic regions of other isotypes.
[0165] One or more amino acids at the amino or carboxyl terminus of the light and / or heavy chains (e.g., the C-terminal lysine of the heavy chain) may be deleted or derivatized in part or all of the molecule. Substitutions may be made in the constant region to reduce or enhance effector function, such as complement-mediated cytotoxicity or ADCC (see, for example, US Patent No. 5,624,821; US Patent No. 5,834,597; and Lazar et al., Proc. Natl. Acad. Sci. USA 103:4005, 2006), or to prolong the half-life in humans (see, for example, Hinton et al., J. Biol. Chem. 279:6213, 2004).
[0166] Exemplary substitutions include the introduction of amino acid substitutions at amino acid sites 234, 235, 237, 239, 267, 298, 299, 326, 330, or 332, replacing a native amino acid with a cysteine residue, preferably the S239C mutation in the human IgG1 isotype (US 20100158909). The presence of additional cysteine residues allows for the formation of interchain disulfide bonds. The formation of such interchain disulfide bonds can lead to steric hindrance, thereby reducing the affinity of the Fc region-FcγR binding interaction. Cysteine residues introduced within or adjacent to the Fc region of the IgG constant region can also serve as sites for coupling with therapeutic groups (i.e., coupling cytotoxic drugs using thiol-specific agents (e.g., maleimide derivatives of drugs)). The presence of therapeutic groups can lead to steric hindrance, thereby further reducing the affinity of the Fc region-FcγR binding interaction. Other substitutions at any of sites 234, 235, 236, and / or 237 reduce affinity for the Fcγ receptor, particularly FcγRI (see, for example, US 6,624,821, US 5,624,821).
[0167] The in vivo half-life of an antibody can also affect its effector function. The half-life of an antibody can be increased or decreased to modify its therapeutic activity. FcRn is a receptor structurally similar to an MHC class I antigen and non-covalently associated with β2-microglobulin. FcRn regulates the catabolic metabolism of IgG and its transcellular transport across tissues (Ghetie and Ward, 2000, Annu.Rev. Immunol. 18:739-766; Ghetie and Ward, 2002, Immunol. Res. 25:97-113). IgG-FcRn interaction occurs at pH 6.0 (the pH of intracellular vesicles) but not at pH 7.4 (the pH of blood); this interaction allows IgG to be recycled back into circulation. Regions on human IgG1 involved in FcRn binding have been localized (Shields et al., 2001, J. Biol. Chem. 276:6591-604). Substitution of alanine at proline 238, threonine 256, threonine 307, glutamine 311, aspartic acid 312, glutamate 380, glutamate 382, or asparagine 434 sites in human IgG1 enhances FcRn binding. IgG1 molecules carrying these substitutions have a longer serum half-life. Therefore, these modified IgG1 molecules are able to perform their effector functions for a longer period compared to unmodified IgG1, thus exerting their therapeutic efficacy over a longer duration. Other exemplary substitutions for increasing FcRn binding include glutamine at site 250 and / or leucine at site 428. All sites in the constant region are numbered using EU.
[0168] Oligosaccharides covalently linked to conserved asparagine 297 participate in the ability of IgG to bind to FcγR in the Fc region (Lund et al., 1996, J. Immunol. 157:4963-69; Wright and Morrison, 1997, TrendsBiotechnol. 15:26-32). Engineering this glycoform on IgG can significantly improve IgG-mediated ADCC. Adding bibranched N-acetylglucosamine to this glycoform (Umana et al., 1999, Nat. Biotechnol. 17: 176-180; Davies et al., 2001, Biotech. Bioeng. 74:288-94) or removing fucose from this glycoform (Shields et al., 2002, J. Biol. Chem. 277:26733-40; Shmkawa et al., 2003, J. Biol. Chem. 278:6591-604; Niwa et al., 2004, Cancer Res. 64:2127-33) are two examples of IgG Fc engineering that improve the binding between IgG Fc and FcγR, thereby enhancing IgG-mediated ADCC activity. In some embodiments, the anti-OX40 antibody described herein or the anti-OX40 antibody of the ADC described herein has a glycan attached at a conserved asparagine 297 residue in the constant region, wherein the amino acid residues in the constant region are numbered according to the EU-index. In some embodiments, the glycan is biantennary. In some embodiments, the glycan is core-fucosylated. In some embodiments, the glycan has zero terminal galactose residues. In some embodiments, the glycan is biantennary and core-fucosylated. In some embodiments, the glycan is biantennary and has zero terminal galactose residues. In some embodiments, the glycan is core-fucosylated and has zero terminal galactose residues. In some embodiments, the glycan is biantennary, core-fucosylated, and has zero galactose residues. In some implementations, in the population of anti-OX40 antibodies of the anti-OX40 antibodies or ADCs described herein, the conserved asparagine 297 residues in the constant region (where the amino acid residues in the constant region are numbered according to the EU-index) are predominantly occupied by a dual-antenna, core fucosylated glycan with zero terminal galactose residues.
[0169] Systematic substitution of solvent-exposed amino acids in the Fc region of human IgG1 has yielded IgG variants with altered ADCC / CDC activity and / or FcγR binding affinity. For example, a subset of these variants involving substitution of alanine at T256 / S298, S298 / E333, S298 / K334, or S298 / E333 K334 showed increased affinity for both FcγR and ADCC activity compared to parental IgG1 (Shields et al., 2001, J. Biol. Chem. 276:6591-604; Okazaki et al., 2004, J. Mol. Biol. 336: 1239-49). In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprise a variant of the human IgG1 heavy chain constant region, said variant comprising one or more amino acid substitutions selected from the group consisting of L234, L235, G236, S239, F243, H268, D270, R292, S298, Y300, V305, K326, A330, I332, E333, K334, and P396. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein comprises an IgG1 heavy chain constant region comprising at least one amino acid substitution. The IgG1 heavy chain constant region may comprise an L234 substitution. The L234 substitution may, for example, be L234Y. The IgG1 heavy chain constant region may comprise an L235 substitution. The L235 substitution may, for example, be L235Q or L235V. The IgG1 heavy chain constant region may comprise a G236 substitution. The G236 substitution may be, for example, G236A or G236W. The IgG1 heavy chain constant region may contain an S239 substitution. The S239 substitution may be, for example, S239D or S239M. The IgG1 heavy chain constant region may contain an F243 substitution. The F243 substitution may be, for example, F243L. The IgG1 heavy chain constant region may contain an H268 substitution. The H268 substitution may be, for example, H268D. The IgG1 heavy chain constant region may contain a D270 substitution. The D270 substitution may be, for example, D270E. The IgG1 heavy chain constant region may contain an R292 substitution. The R292 substitution may be, for example, R292P. The IgG1 heavy chain constant region may contain an S298 substitution. The S298 substitution may be, for example, S298A. The IgG1 heavy chain constant region may contain a Y300 substitution. The Y300 substitution may be, for example, Y300L. The IgG1 heavy chain constant region may contain a V305 substitution. The V305 substitution may, for example, be V305I. The IgG1 heavy chain constant region may contain a K326 substitution. The K326 substitution may, for example, be K326D. The IgG1 heavy chain constant region may contain an A330 substitution. The A330 substitution may, for example, be A330M or A330L.The IgG1 heavy chain constant region may contain I332 substitutions. For example, the I332 substitution may be I332E. The IgG1 heavy chain constant region may contain E333 substitutions. For example, the E333 substitution may be E333A. The IgG1 heavy chain constant region may contain K334 substitutions. For example, the K334 substitution may be K334A or K334E. The IgG1 heavy chain constant region may contain P396 substitutions. For example, the P396 substitution may be P396L. All numbering is based on the EU Index.
[0170] In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprise a variant of the human IgG1 heavy chain constant region, said variant comprising one or more amino acid substitutions selected from the group consisting of L234Y, L235Q, L235V, G236A, G236W, S239D, S239M, F243L, H268D, D270E, R292P, S298A, Y300L, V305I, K326D, A330M, A330L, I332E, E333A, K334A, K334E, and P396L. In some embodiments, said IgG1 heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of K214R, L234A, L235E, G237A, A330S, P331S, D356E, and L358M. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for S298A, E333A, and K334A. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for S239D and I332E. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for S239D, A330L, and I332E. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for G236A. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for G236A, S239D, and I332E. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for G236A, A330L, and I332E. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for G236A, S239D, A330L, and I332E. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for F243L, R292P, Y300L, V305I, and P396L. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions for L235V, F243L, R292P, Y300L, and P396L.In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions of L234Y, L235Q, G236W, S239M, H268D, D270E, and S298A. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions of D270E, K326D, A330M, and K334E. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with well-known amino acid substitutions that specifically increase FcγRIIB binding affinity. In some embodiments, the anti-OX40 antibody and antigen-binding fragment described herein comprises variants of the human IgG1 heavy chain constant region modified with amino acid substitutions of S267E / L328F that specifically increase FcγRIIB binding affinity. All numbering is based on the EU Index.
[0171] References to human constant regions include constant regions having any natural allotype or occupying polymorphic positions in natural allotypes. Furthermore, up to 1, 2, 5, or 10 mutations may exist relative to the natural human constant region, such as those described above that reduce FcγR binding or increase FcRn binding.
[0172] In some embodiments, the variant may include the addition of amino acid residues to the amino and / or carboxyl termini of the antibody or peptide. The length of the added amino acid residues may range from one residue to one hundred or more residues. In some embodiments, the variant contains an N-terminal methionine residue. In some embodiments, the variant contains an additional peptide / protein (e.g., an Fc region) to form a fusion protein. In some embodiments, the variant is engineered to be detectable and may contain a detectable marker and / or protein (e.g., a fluorescent tag or enzyme).
[0173] The variant antibodies or antigen-binding fragments described herein can be generated using methods known in the art, including but not limited to site-directed mutagenesis, alanine scan mutagenesis, and PCR mutagenesis. Methods for mutagenesis and nucleotide sequence alteration are well known in the art. For example, see Walker and Gaastra, eds. (1983) Techniques in Molecular Biology (MacMillan Publishing Company, New York); Kunkel, Proc. Natl. Acad. Sci. USA 82:488-492 (1985); Kunkel et al., Methods Enzymol. 54:367-382 (1987); Sambrook et al. (1989) Molecular Cloning: A Laboratory Manual (Cold SpringHarbor, NY); US Pat. No. 4,873,192; and the references cited therein, which are incorporated herein by reference. Guidance on appropriate amino acid substitutions that do not affect the biological activity of the target peptide can be found in the model of Dayhoff et al. (1978) in Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington, DC), pp. 345-352, which is incorporated herein by reference in its entirety. Dayhoff et al.'s model uses a Point Accepted Mutation (PAM) amino acid similarity matrix (PAM 250 matrix) to determine appropriate conserved amino acid substitutions. Conserved substitutions (e.g., exchanging one amino acid for another with similar properties) can be beneficial. Examples of conserved amino acid substitutions taught by the PAM 250 matrix of Dayhoff et al.'s model include, but are not limited to, glycine → alanine, valine → isoleucine → leucine, aspartic acid → glutamic acid, lysine → arginine, asparagine → glutamine, and phenylalanine → tryptophan → tyrosine.
[0174] When constructing anti-OX40 binding molecules (e.g., antibodies or antigen-binding fragments) or variants or derivatives thereof, modifications should be made such that the variant retains the desired properties, such as high-affinity specific binding to OX40, non-interference with the binding between OX40L and OX40, induction of IFN-γ secretion, induction of T cell activation, and / or antitumor activity. Clearly, any mutations made in the DNA encoding the variant polypeptide must not cause the sequence to deviate from its reading frame. In some embodiments, mutations made in the DNA do not produce complementary regions that could form mRNA secondary structures.
[0175] In some embodiments, variants of the anti-OX40 antibody or antigen-binding fragment disclosed herein may retain an OX40 binding capacity similar to, the same as, or greater than that of the parental antibody or antigen-binding fragment. In some embodiments, the variants may be at least about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or greater identical in amino acid sequence to the parental antibody or antigen-binding fragment. In some embodiments, the variants of the anti-OX40 antibody or antigen-binding fragment comprise the amino acid sequence of the parental anti-OX40 antibody or antigen-binding fragment and have one or more conserved amino acid substitutions. Conserved amino acid substitutions are known in the art and include replacing one amino acid having certain physical and / or chemical properties with another amino acid having the same or similar chemical or physical properties.
[0176] In some embodiments, variants of the anti-OX40 antibody or antigen-binding fragment comprise the amino acid sequence of the parent antibody or antigen-binding fragment and have one or more non-conserved amino acid substitutions. In some embodiments, variants of the anti-OX40 antibody or antigen-binding fragment comprise the amino acid sequence of the parent antibody or antigen-binding fragment and have one or more non-conserved amino acid substitutions, wherein the one or more non-conserved amino acid substitutions do not interfere with or inhibit one or more biological activities (e.g., OX40 binding) of the variant. In some embodiments, the one or more conserved amino acid substitutions and / or the one or more non-conserved amino acid substitutions may enhance the biological activity of the variant, such that the functional variant exhibits increased biological activity compared to the parent antibody or antigen-binding fragment.
[0177] In some embodiments, the variant may have 1, 2, 3, 4 or 5 amino acid substitutions in the CDRs of the binding portion (e.g., VH CDR1, VH CDR2, VHCDR3, VL CDR1, VL CDR2 and VL CDR3).
[0178] In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein may be chemically modified naturally or through intervention. In some embodiments, the anti-OX40 antibody or antigen-binding fragment has been chemically modified by glycosylation, acetylation, polyethylene glycolation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, and / or linking to cellular ligands or other proteins. Any of a number of chemical modifications can be performed using known techniques. The anti-OX40 antibody or antigen-binding fragment may comprise one or more amino acid analogs (including, for example, non-natural amino acids), as well as other modifications known in the art.
[0179] In some embodiments, the anti-OX40 antibody or antigen-binding fragment disclosed herein can be linked to at least one reagent to form an antibody-drug conjugate. The conjugate may, for example, be an antibody linked to another protein, carbohydrate, lipid, steroid, immunosuppressant, or mixed-group molecule. Such antibody-drug conjugates include, but are not limited to, modifications that link the antibody to one or more polymers. For example, the antibody or antigen-binding fragment may be linked to one or more water-soluble polymers. Linking to a water-soluble polymer reduces the likelihood of precipitation of the antibody or antigen-binding fragment in an aqueous environment (e.g., a physiological environment). Those skilled in the art can select a suitable water-soluble polymer based on considerations including, but not limited to, whether the polymer / antibody conjugate will be used to treat a patient, and if so, the pharmacological characteristics of the antibody (e.g., half-life, dosage, activity, antigenicity, and / or other factors).
[0180] To enhance the potency of antibody molecules as diagnostic or therapeutic agents, at least one desired molecule or group is typically linked, covalently bound, or formed into a complex. Such molecules or groups may include, but are not limited to, at least one effector molecule or reporter molecule. Non-limiting examples of reporter molecules conjugated to antibodies include enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, photosynthetic molecules, colored particles or ligands, enzymes (e.g., enzymes catalyzing colorimetric or fluorescence assays or bioluminescent reactions), substrates, and solid matrices such as biotin. The antibody may contain one, two, or more of these labels.
[0181] Antibody conjugates are also used as diagnostic reagents. In some embodiments, the anti-OX40 antibody or antigen-binding fragment described herein is conjugated to a detectable substance or molecule, thereby making the reagent available for diagnosis and / or detection. The detectable substance may include, but is not limited to, enzymes; prosthetic groups (e.g., biotin and flavin); fluorescent materials; bioluminescent materials, such as luciferase; radioactive materials; positron-emitting metals; and magnetic metal ions.
[0182] Antibody diagnostics generally fall into two categories: those used for in vitro diagnostics (e.g., in various immunoassays) and those used in in vivo diagnostic protocols, commonly referred to as "antibody-guided imaging." Many suitable imaging reagents and methods for linking them to antibodies are known in the art (see, for example, U.S. Patents 5,021,236, 4,938,948, and 4,472,509). The imaging groups used can be paramagnetic ions, radioisotopes, fluorescent dyes, NMR-detectable substances, MR hyperpolarized molecules, targeted ultrasonic bubbles, and X-ray imaging reagents.
[0183] The anti-OX40 antibody or antigen-binding fragments described herein can be attached to a solid carrier. Such solid carriers include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride, or polypropylene. In some embodiments, the immobilized anti-OX40 antibody or antigen-binding fragment is used for immunoassay. In some embodiments, the immobilized anti-OX40 antibody or antigen-binding fragment is used for the purification of a target antigen (e.g., human OX40). 1.3 Polynucleotides, Carriers, and Cells
[0184] This document also provides polynucleotides encoding at least one variable domain of the antibodies disclosed herein. This document also provides polynucleotides encoding at least one peptide chain of the antibodies disclosed herein. In some embodiments, the polynucleotides provided herein encode one peptide. In some embodiments, the polynucleotides provided herein encode more than one peptide. In some embodiments, the polynucleotides provided herein may encode the VL, VH, or both of the antibodies provided herein. For example, this document provides polynucleotides encoding the VL, VH, or both of the antibody HX011 exemplified in Table 5. In some embodiments, this document provides polynucleotides encoding the light chain, heavy chain, or both of the provided antibody. For example, this document provides polynucleotides encoding the light chain, heavy chain, or both of the antibody HX011 exemplified in Table 6.
[0185] Cistrons can be separated, for example, by internal ribosome entry sites (IRES) or 2A elements. As understood in the art, an IRES refers to a nucleotide sequence in the expression cassette that directly recruits ribosomes upon transcription into mRNA without prior scanning of the untranslated regions of the mRNA by the ribosomes. As understood in the art, a 2A element encodes a self-cleaving short peptide (approximately 20 amino acids) that provides a mechanism for subsequent separation of the target polypeptide from equimolarly generated peptides. Exemplary 2A self-cleaving peptides include P2A, E2A, F2A, and T2A.
[0186] This disclosure also provides variants of the polynucleotide described herein, wherein said variants have a nucleotide sequence that is at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identical to the polynucleotide sequence encoding at least one peptide of the antibody described herein. As used herein, the phrase “polynucleotide having a nucleotide sequence that is at least about 95% identical to the polynucleotide sequence” means that the nucleotide sequence of said polynucleotide is identical to the reference sequence, but said polynucleotide sequence may contain up to five point mutations per 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to the reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or replaced with another nucleotide, or up to 5% of the total number of nucleotides in the reference sequence may be inserted into the reference sequence. These mutations in the reference sequence can occur at the 5' or 3' end of the reference nucleotide sequence, or at any position between these end positions, and can be scattered individually among the nucleotides in the reference sequence or located in one or more consecutive groups within the reference sequence.
[0187] The polynucleotide variant may contain alterations in coding regions, non-coding regions, or both. In some embodiments, the polynucleotide variant contains alterations that produce silent substitutions, additions, or deletions, but do not change the properties or activity of the encoded polypeptide. In some embodiments, the polynucleotide variant contains silent substitutions that result in no change to the amino acid sequence of the polypeptide (due to the degeneracy of the genetic code). The polynucleotide variant may be generated for a variety of reasons, such as optimizing codon expression for a specific host (e.g., changing codons in human mRNA to codons preferred by bacterial hosts such as E. coli). In some embodiments, the polynucleotide variant contains at least one silent mutation in a non-coding or coding region of the sequence.
[0188] In some embodiments, the polynucleotide variant is generated to regulate or alter the expression (or expression level) of the encoded polypeptide. In some embodiments, the polynucleotide variant is generated to increase the expression of the encoded polypeptide. In some embodiments, the polynucleotide variant is generated to decrease the expression of the encoded polypeptide. In some embodiments, the polynucleotide variant has increased expression of the encoded polypeptide compared to the parental polynucleotide sequence. In some embodiments, the polynucleotide variant has decreased expression of the encoded polypeptide compared to the parental polynucleotide sequence.
[0189] In some embodiments, the polynucleotide comprises a coding sequence for a polypeptide (e.g., an antibody), which is fused in the same reading frame to a polynucleotide that facilitates the expression and secretion of the polypeptide by the host cell (e.g., a guide sequence that functions as a secretion sequence to control polypeptide transport). The guide sequence of the polypeptide can be excised by the host cell to form the “mature” form of the polypeptide.
[0190] In some embodiments, the polynucleotide comprises a coding sequence for a polypeptide (e.g., an antibody), which is fused with a marker or tag sequence within the same reading frame. For example, in some embodiments, the marker sequence is a hexahistidine tag (HIS-tag), which allows for efficient purification of the polypeptide fused with this tag. In some embodiments, when using a mammalian host (e.g., COS-7 cells), the marker sequence is a hemagglutinin (HA) tag derived from influenza hemagglutinin protein. In some embodiments, the marker sequence is a FLAG™ tag. In some embodiments, the marker may be used in combination with other markers or tags.
[0191] In some embodiments, the polynucleotide is isolated. In some embodiments, the polynucleotide is substantially pure.
[0192] In some embodiments, this document also provides vectors comprising the polynucleotides disclosed herein. In some embodiments, the vectors provided herein may be expression vectors. In some embodiments, the vectors provided herein comprise polynucleotides encoding at least one peptide chain of the antibody described herein. In some embodiments, this document provides recombinant expression vectors that can be used to amplify and express polynucleotides encoding at least one peptide chain of the antibody described herein. For example, the recombinant expression vector may be a reproducible DNA construct comprising a synthetic or cDNA-derived DNA fragment encoding at least one peptide chain of the antibody described herein, and operatively linked to a suitable transcriptional and / or translational regulatory element derived from a mammalian, microbial, viral, or insect gene. When DNA regions are functionally related to each other, they are referred to as “operatively linked.” For example, if a promoter controls transcription of a coding sequence, the promoter is operatively linked to the coding sequence; or, if a ribosome binding site is positioned to allow translation, the ribosome binding site is operatively linked to the coding sequence. In some embodiments, structural elements intended for use in certain expression systems include guide sequences that enable host cells to secrete translated proteins extracellularly. In some embodiments, where the recombinant protein is expressed without a guide or transport sequence, the polypeptide may contain an N-terminal methionine residue.
[0193] Examples of vectors include plasmids, autonomously replicating sequences, and transposable elements. Useful expression vectors for bacterial hosts include known bacterial plasmids, such as those from E. coli, including pCR1, pBR322, pMB9, and their derivatives, as well as plasmids with a broader host range, such as M13 and other filamentous single-stranded DNA phages. Other exemplary vectors include, but are not limited to, plasmids, phages, granules, artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or P1-derived artificial chromosomes (PAC), phages such as λ phage or M13 phage, and animal viruses. Examples of animal virus classes useful as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and polyomaviruses (e.g., SV40). Examples of expression vectors include the pClneo vector (Promega) for expression in mammalian cells; and pLenti4 / V5-DEST™, pLenti6 / V5-DEST™, and pLenti6.2 / V5-GW / lacZ (Invitrogen) for lentivirus-mediated gene transfer and expression in mammalian cells. Useful expression vectors for eukaryotic hosts include vectors containing expression control sequences from SV40, bovine papillomavirus, adenovirus, and cytomegalovirus. Exemplary transposon systems such as SleepingBeauty and PiggyBac can be used, which can be stably integrated into the genome (e.g., Ivics et al., Cell, 91 (4): 501–510 (1997); Cadiñanos et al., (2007) Nucleic Acids Research. 35 (12): e87).
[0194] In some embodiments, the vector is an episomal vector or a vector maintained extrachromosomally. As used herein, the term "episomal" refers to a vector capable of replicating without integration into the host chromosomal DNA and without gradual loss during host cell division; this also means that the vector replicates extrachromosomally or as an episomal. The vector is engineered to carry a sequence encoding the origin of replication or "ori" of DNA from a lymphoherpesvirus or gamma herpesvirus, adenovirus, SV40, bovine papillomavirus, or yeast, specifically the origin of replication of a lymphoherpesvirus or gamma herpesvirus corresponding to oriP of EBV. In some embodiments, the lymphoherpesvirus may be Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), squirrel monkey herpesvirus (HS), or Marek's disease virus (MDV). Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are also examples of gamma herpesviruses. Typically, the host cell contains a viral replication transactivator protein that activates replication.
[0195] The “expression control sequences,” “control elements,” or “regulatory sequences” present in expression vectors are those untranslated regions of the vector—origins of replication, filter boxes, promoters, enhancers, translation initiation signals (Shine Dalgarno sequences or Kozak sequences), introns, polyadenylated sequences, and the 5' and 3' untranslated regions—that interact with host cell proteins to carry out transcription and translation. The strength and specificity of these elements can vary. Depending on the vector system and host used, any number of suitable transcriptional and translational elements, including constitutive and inducible promoters, can be used.
[0196] Exemplary constitutive expression control sequences that can be used in this disclosure include, but are not limited to: cytomegalovirus (CMV) immediate early promoter, viral simian virus 40 (SV40) promoter (e.g., early or late), Moloney mouse leukemia virus (MoMLV) LTR promoter, Rous sarcoma virus (RSV) LTR, herpes simplex virus (HSV) (thymidine kinase) promoter, vaccinia virus H5, P7.5 and P11 promoters, elongation factor 1-α (EF1a) promoter, early growth response 1 (EGR1), ferritin H (FerH), ferritin L (FerL), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), eukaryotic translation initiation factor 4A1 (EIF4A1), heat shock protein 70kDa 5 (HSPA5), heat shock protein 90kDa β subunit member 1 (HSP90B1), heat shock protein 70kDa (HSP70), β-kinin (β-KIN), and human ROSA 26 site (Irions). et al., Nature Biotechnology 25, 1477-1482 (2007)), ubiquitin C promoter (UBC), phosphoglycerate kinase-1 (PGK) promoter, cytomegalovirus enhancer / chicken β-actin (CAG) promoter and β-actin promoter.
[0197] Examples of inducible promoters / systems include, but are not limited to: steroid-inducible promoters, such as promoters of genes encoding glucocorticoids or estrogen receptors (which can be induced by treatment with the corresponding hormone), metallothionein promoters (which can be induced by treatment with various heavy metals), MX-1 promoters (which can be induced by interferon), the "GeneSwitch" mifepristone-regulated system (Sirin et al., 2003, Gene, 323:67), cumate-induced gene switches (WO2002 / 088346), tetracycline-dependent regulatory systems, etc. The antibodies described herein can be prepared by any method known in the art, including chemical synthesis and recombinant expression techniques. Unless otherwise stated, the present invention is practiced using conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridization, and related fields known to those skilled in the art. These techniques are described in the references cited herein and are fully elaborated in the literature.See, for example: Maniatis et al. (1982) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; Sambrook et al. (1989), Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press; Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons (1987 and annualupdates); Current Protocols in Immunology, John Wiley & Sons (1987 and annualupdates) Gait (eds) (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein (eds.) (1991) Oligonucleotides and Analogues: A PracticalApproach, IRL Press; Birren et al. (eds.) (1999) Genome Analysis: A Laboratory Manual, Cold Spring Harbor Laboratory Press; Borrebaeck (ed.) (1995) Antibody Engineering, 2nd ed., Oxford University Press; Lo (ed.) (2006) Antibody Engineering: Methods and Protocols (Methods in Molecular Biology); Vol. 248, Humana Press, Inc.; Each of these articles is incorporated herein by reference in its entirety.
[0198] It also covers cells comprising the vectors disclosed herein. In some embodiments, a host cell comprising a vector containing the polynucleotides disclosed herein is provided herein. In some embodiments, the host cell provided herein comprises one or more vectors that collectively contain a polynucleotide encoding a polypeptide chain encoding the antibody described herein. In some embodiments, the host cell provided herein produces the antibody described herein.
[0199] Examples of suitable mammalian host cell lines include, but are not limited to: COS-7 (derived from monkey kidney), L-929 (derived from mouse fibroblasts), C127 (derived from mouse mammary tumors), 3T3 (derived from mouse fibroblasts), CHO (derived from Chinese hamster ovaries), HeLa (derived from human cervical cancer), BHK (derived from hamster kidney fibroblasts), HEK-293 (derived from human embryonic kidney) cell lines and their variants. Mammalian expression vectors may contain non-transcriptional elements, such as origin of replication, appropriate promoters and enhancers linked to the gene to be expressed, and other 5' or 3' flanking non-transcriptional and 5' or 3' non-translational sequences, such as necessary ribosome binding sites, polyadenylation sites, splice donor sites and splice acceptor sites, and transcription termination sequences. Expression of recombinant proteins in insect cell culture systems (e.g., baculoviruses) also provides a robust method for producing correctly folded and biologically functional proteins. Baculovirus systems for producing heterologous proteins in insect cells are well known to those skilled in the art. 1.4 Antibody-Drug Conjugates (ADCs)
[0200] Anti-OX40 antibodies can be conjugated to a therapeutic fraction to form an ADC. In some embodiments, this document provides ADCs comprising an antibody or antigen-binding fragment thereof conjugated to a therapeutic fraction, wherein said antibody or antigen-binding fragment specifically binds to human OX40. ADCs provided herein may comprise any anti-OX40 antibody disclosed herein or otherwise known in the art, conjugated to any therapeutic fraction disclosed herein or otherwise known in the art.
[0201] In some embodiments, the anti-OX40 antibody is an anti-OX40 antibody or antigen-binding fragment that does not block the binding of OX40L to OX40. In some embodiments, the antibody is a depleting antibody. In some embodiments, the anti-OX40 antibody is the anti-OX40 antibody or antigen-binding fragment disclosed in Section 6.2 herein. For example, in some embodiments, the ADCs provided herein may comprise an anti-OX40 antibody, wherein VL CDR1, VL CDR2, VL CDR3, VH CDR1, VH CDR2, and VH CDR3 have amino acid sequences of SEQ ID NOs:4, 5, 6, 10, 11, and 12, respectively. In some embodiments, the ADCs provided herein may comprise an anti-OX40 antibody, wherein VL has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:15, and VH has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:16. In some embodiments, the ADCs provided herein may comprise an anti-OX40 antibody, wherein the light chain has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:27; and the heavy chain has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:28. In some embodiments, the ADCs provided herein may comprise an anti-OX40 antibody, wherein the light chain has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:27; and the heavy chain has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:29.
[0202] Table 7: Sequences of exemplary anti-OX40 antibodies
[0203] The ADCs provided herein may comprise any anti-OX40 antibody, including those disclosed herein or other antibodies known in the art. In some embodiments, the ADCs provided herein may comprise the anti-OX40 antibodies provided in Table 7.
[0204] In some embodiments, the ADC provided herein may have an anti-OX40 antibody or antigen-binding fragment comprising: (a) a VL comprising VL CDR1, VLCDR2, and VL CDR3 of a VL having an amino acid sequence of SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:50, or SEQ ID NO:52; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and / or (b) a VH comprising VH CDR1, VH CDR2, and VH CDR3 of a VH having an amino acid sequence of SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:56; or variants thereof, wherein the VH ... CDR3 of a VH having an amino acid sequence of SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:51, SEQ ID NO:53, or SEQ ID NO:56; or variants thereof, The CDR contains up to approximately 5 amino acid substitutions, additions, and / or deletions.
[0205] In some embodiments, the ADC provided herein may comprise the anti-OX40 antibody or antigen-binding fragment disclosed in WO2007 / 062245A2. In some embodiments, the anti-OX40 antibody or antigen-binding fragment comprises: (a) VL comprising VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:38; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and (b) VH comprising VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:39; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a VL having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:38, and a VH having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with SEQ ID NO:39. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a light chain having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:59, and a heavy chain having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with SEQ ID NO:61.
[0206] In some embodiments, the anti-OX40 antibody or antigen-binding fragment comprises: (a) VL comprising VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:38; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and (b) VH comprising VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:56; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a VL having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:38, and a VH having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with SEQ ID NO:56. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a light chain having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:59, and a heavy chain having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with SEQ ID NO:60.
[0207] In some embodiments, the ADC provided herein may comprise the anti-OX40 antibody or antigen-binding fragment disclosed in US2023 / 0242657A1. In some embodiments, the anti-OX40 antibody or antigen-binding fragment comprises: (a) VL comprising VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:40; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and (b) VH comprising VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:41; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a VL having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:40, and a VH having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with SEQ ID NO:41. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a light chain having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:65, and a heavy chain having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with SEQ ID NO:66. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a light chain having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:65, and having a heavy chain having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO:67.
[0208] In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or antigen-binding fragment comprising: (a) a VL comprising VL CDR1, VL CDR2, and VL CDR3 of a VL having the amino acid sequence of SEQ ID NO:42; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and (b) a VH comprising VH CDR1, VH CDR2, and VHCDR3 of a VH having the amino acid sequence of SEQ ID NO:43; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a VL having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:42, and a VH having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with SEQ ID NO:43. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a light chain having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:62, and a heavy chain having at least 85%, 90%, 95%, 98%, 99%, or 100% sequence identity with SEQ ID NO:63. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a light chain having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:62, and a heavy chain having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO:64.
[0209] In some embodiments, the ADC provided herein may comprise the anti-OX40 antibody or antigen-binding fragment disclosed in WO2013 / 008171A1. In some embodiments, the anti-OX40 antibody or antigen-binding fragment comprises: (a) VL comprising VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:44; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and (b) VH comprising VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:45; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a VL having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:44, and having a VH having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO:45.
[0210] In some embodiments, the ADC provided herein may comprise the anti-OX40 antibody or antigen-binding fragment disclosed in WO2008 / 106116A3. In some embodiments, the anti-OX40 antibody or antigen-binding fragment comprises: (a) VL comprising VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:46; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and (b) VH comprising VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:47; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a VL having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:46, and having a VH having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO:47.
[0211] In some embodiments, the ADC provided herein may comprise the anti-OX40 antibody or antigen-binding fragment disclosed in WO2017 / 096182A1. In some embodiments, the anti-OX40 antibody or antigen-binding fragment comprises: (a) VL comprising VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:50; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and (b) VH comprising VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:51; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a VL having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:50, and having a VH having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with SEQ ID NO:51.
[0212] In some embodiments, the ADC provided herein may comprise the anti-OX40 antibody or antigen-binding fragment disclosed in WO2013 / 068563A2. In some embodiments, the anti-OX40 antibody or antigen-binding fragment comprises: (a) VL comprising VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:52; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and (b) VH comprising VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:53; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions. In some embodiments, the ADC provided herein may comprise an anti-OX40 antibody or an antigen-binding fragment having a VL having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:52, and a VH having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:53.
[0213] The ADCs described herein may include any suitable therapeutic portions disclosed herein or otherwise known in the art. In some embodiments, therapeutic portions suitable for conjugation with anti-OX40 antibodies may include, for example, cytotoxic agents (e.g., chemotherapeutic agents), immunomodulators (e.g., Toll-like receptor (TLR) agonists, interferon gene stimulating factor (STING) agonists), prodrug-converting enzymes, radioisotopes or compounds, and toxins (e.g., cell inhibitors or cell killers, such as abrinogen toxin, ricin A, Pseudomonas aeruginosa exotoxin, or diphtheria toxin).
[0214] In some embodiments, the ADCs provided herein may include a cytotoxic agent as a therapeutic component. Useful classes of cytotoxic agents suitable for conjugation with anti-OX40 antibodies include, for example, antimicrotubule agents, DNA minor groove binding agents, DNA replication inhibitors, chemosensitizers, or analogues. Other exemplary classes of cytotoxic agents include anthracyclines, aurestatins, camptothecins, pyruvicides, etoposides, maytansine, and vinca alkaloids. The cytotoxic agent may be a chemotherapeutic agent, such as eribulin, doxorubicin, morpholino-doxorubicin and cyanomorolino-doxorubicin, paclitaxel, melphalan, vinca alkaloids, methotrexate, mitomycin C, or etoposide. The agent may also be a CC-1065 analogue, kazimidox, maytansine, an analogue of salicylic acid, rhizomycin, or anemone toxin.
[0215] The therapeutic component of the ADCs described in this article can be an antimicrotubule agent. Examples of antimicrotubule agents include leucocele B derivatives (e.g., eribulin), taxanes (e.g., Taxol®, Taxotere®), T67 (Tularik), vinblastine alkaloids (e.g., vincristine, vinblastine, vinorelbine, and vinorelbine), and auristatins (e.g., auristatin E, auristatin F phenylenediamine (AFP), monomethylauristatin F (MMAF), monomethylauristatin E (MMAE), auristatin EB (AEB), and auristatin EFP (AEFP)).
[0216] In some embodiments, the therapeutic portion is a derivative of leptin B. In some embodiments, the therapeutic portion is eribulin.
[0217] In some embodiments, the ADC provided herein includes auristatin as a therapeutic component. In some embodiments, the therapeutic component is monomethylauristatin. In some embodiments, the therapeutic component is auristatin T. In some embodiments, the therapeutic component is MMAF. In some embodiments, the therapeutic component is MMAE.
[0218] In some embodiments, the ADCs provided herein include a maytansinoid (another group of antimicrotubule agents, such as DM1, DM2, DM3, DM4) as the therapeutic component. For example, the maytansinoid may be maytansine or a maytansine-containing drug linker, such as DM-1 or DM-4 (ImmunoGen, Inc.; see also Chari et al., 1992, Cancer Res.).
[0219] Other suitable antimicrotubule agents include baccatin derivatives, taxane analogs (e.g., epothilone A and B), nocodazole, colchicine and colcemid / colcimid, estramustine, cryptophycin / cryptophysin, cemadotin, maytansine, compbretastatin, discormolide, eleutherobin, and tubulolysin M.
[0220] The therapeutic portion may be a topoisomerase I inhibitor. Examples of topoisomerase I inhibitors include camptothecin, DXd, SN-38, and eczemab (DX-8951). In some embodiments, the therapeutic portion may be DXd. In some embodiments, the therapeutic portion may be camptothecin. In some embodiments, the therapeutic portion may be SN-38. In some embodiments, the therapeutic portion may be eczemab.
[0221] The therapeutic portion of the ADC described herein can be a DNA minor groove binding agent. (See, for example, U.S. Patent No. 6,130,237.) For example, the minor groove binding agent can be a CBI compound, an enediyne compound (e.g., cazithromycin), or lexitropsin.
[0222] The therapeutic component of the ADC provided herein can be a DNA cross-linking agent. Exemplary DNA cross-linking agents include benzodiazepines (e.g., pyrrolo[1,4]benzodiazepine dimer (PBD dimer), indolinobenzodiazepine dimer, and oxazolidinobenzodiazepine dimer).
[0223] The therapeutic component of the ADCs described herein can be an immunomodulatory agent. Useful classes of immunomodulators include, for example, TLR agonists and STING agonists. Exemplary TLR agonists include, for example, CpG oligonucleotides, imiquimod, remiquimod, polyinosinic-polycytidylic acid (poly(I:C)), and monophospholipid A (MPLA). Exemplary STING agonists include, for example, ADU-S100 (MIW815), MK-2118, benzothiophene oxybutyrate (MSA-2), and RVU-25466.
[0224] The therapeutic component of the ADC described herein can also be a prodrug-converting enzyme. Exemplary prodrug-converting enzymes include carboxypeptidase G2, β-glucuronidase, penicillin V amidase, penicillin G amidase, β-lactamase, β-glucosidase, nitroreductase, and carboxypeptidase A.
[0225] For illustrative purposes, the ADCs provided herein may comprise an anti-OX40 antibody or antigen-binding fragment disclosed herein conjugated to a therapeutic moiety, wherein the therapeutic moiety is N-acetyl-γ-carbazin (ozogamicin), monomethylaurestatin E (MMAE), monomethylaurestatin F (MMAF), DM1, Pseudomonas aeruginosa exotoxin A (PE38), DXd, SN-38, eczemab, eribulin, SG3199 (PBD dimer), IRDye700DX, or DM4. In some embodiments, the therapeutic moiety is MMAE, MMAF, DXd, SN-38, eczemab, or eribulin. In some embodiments, the therapeutic moiety is N-acetyl-γ-carbazin. In some embodiments, the therapeutic moiety is MMAE. In some embodiments, the therapeutic moiety is MMAF. In some embodiments, the therapeutic moiety is DXd. In some embodiments, the therapeutic moiety is SN-38. In some embodiments, the therapeutic portion is eczema. In some embodiments, the therapeutic portion is eribulin. In some embodiments, the therapeutic portion is DM1. In some embodiments, the therapeutic portion is Pseudomonas aeruginosa exotoxin A. In some embodiments, the therapeutic portion is SG3199 (PBD dimer). In some embodiments, the therapeutic portion is IRDye700DX. In some embodiments, the therapeutic portion is DM4.
[0226] In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment has (1) VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:15; or a variant thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:16; or a variant thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; (2) VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:38; or a variant thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:39. (2) VL CDR2 and VH CDR3; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions and / or deletions; (3) VLCDR1, VL CDR2 and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:40; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions and / or deletions; and VH CDR1, VH CDR2 and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:41; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions and / or deletions; (4) VL CDR1, VL CDR2 and VL CDR3 of VL having the amino acid sequence of SEQ ID NO:42; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions and / or deletions; and VH CDR1, VH CDR2 and VH CDR3 of VH having the amino acid sequence of VH having SEQ ID NO:43. CDR2 and VH CDR3; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions and / or deletions; or (5) VL CDR1, VL CDR2 and VLCDR3 of VL having the amino acid sequence of SEQ ID NO:38; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions and / or deletions; and VH CDR1, VH CDR2 and VH CDR3 of VH having the amino acid sequence of SEQ ID NO:56; or variants thereof, wherein the VHCDRs have up to about 5 amino acid substitutions, additions and / or deletions;Furthermore, the therapeutic component is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin.
[0227] In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment has VL CDR1, VL CDR2, and VL CDR3 derived from VL having the amino acid sequence of SEQ ID NO:15; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions, and has VH CDR1, VHCDR2, and VH CDR3 derived from VH having the amino acid sequence of SEQ ID NO:16; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment has VL CDR1, VL CDR2, and VL CDR3 derived from VL having the amino acid sequence of SEQ ID NO:38; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions, and has VH CDR1, VH CDR2, and VH CDR3 derived from VH having the amino acid sequence of SEQ ID NO:39; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment has VL CDR1, VL CDR2, and VL CDR3 derived from VL having the amino acid sequence of SEQ ID NO:40; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions, and has VH CDR1, VH CDR2, and VH CDR3 derived from VH having the amino acid sequence of SEQ ID NO:41; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin.In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment has VL CDR1, VL CDR2, and VL CDR3 derived from VL having the amino acid sequence of SEQ ID NO:42; or a variant thereof, wherein the VL CDR has up to about 5 amino acid substitutions, additions, and / or deletions, and has VH CDR1, VH CDR2, and VH CDR3 derived from VH having the amino acid sequence of SEQ ID NO:43; or a variant thereof, wherein the VH CDR has up to about 5 amino acid substitutions, additions, and / or deletions; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment has VL CDR1, VL CDR2, and VL CDR3 derived from VL having the amino acid sequence of SEQ ID NO:38; or variations thereof, wherein the VL CDR has at most about 5 amino acid substitutions, additions, and / or deletions, and has VH CDR1, VH CDR2, and VH CDR3 derived from VH having the amino acid sequence of SEQ ID NO:56; or variations thereof, wherein the VH CDR has at most about 5 amino acid substitutions, additions, and / or deletions; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the therapeutic portion is MMAE. In some embodiments, the therapeutic portion is MMAF. In some embodiments, the therapeutic portion is Dxd. In some embodiments, the therapeutic portion is SN-38. In some embodiments, the therapeutic component is eczema. In some embodiments, the therapeutic component is eribulin.
[0228] In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the antibody or antigen-binding fragment has VL and VH, and the amino acid sequences of the VL and VH are independently identical to each other to at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% of the following sequences: (1) SEQ ID NO: 15 and 16, respectively; (2) SEQ ID NO: 38 and 39, respectively; (3) SEQ ID NO: 40 and 41, respectively; (4) SEQ ID NO: 42 and 43, respectively; or (5) SEQ ID NO: 38 and 56, respectively; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the antibody or antigen-binding fragment has VL and VH, and the amino acid sequences of the VL and VH are independently identical to each other to sequences of SEQ ID NO: 15 and 16, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the antibody or antigen-binding fragment has VL and VH, and the amino acid sequences of the VL and VH are independently identical to each other to sequences of SEQ ID NO:38 and 39, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the antibody or antigen-binding fragment has VL and VH, and the amino acid sequences of the VL and VH are independently identical to each other to the sequences of SEQ ID NO:40 and 41, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczemab, or eribulin.In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the antibody or antigen-binding fragment has VL and VH, and the amino acid sequences of the VL and VH are independently identical to each other to sequences of SEQ ID NO:42 and 43, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the antibody or antigen-binding fragment has VL and VH, and the amino acid sequences of the VL and VH are independently identical to each other to sequences of SEQ ID NO: 38 and 56, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczemab, or eribulin. In some embodiments, the therapeutic portion is MMAE. In some embodiments, the therapeutic portion is MMAF. In some embodiments, the therapeutic portion is Dxd. In some embodiments, the therapeutic portion is SN-38. In some embodiments, the therapeutic portion is eczemab. In some embodiments, the therapeutic portion is eribulin.
[0229] In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain, the light chain and the heavy chain having, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity independently with the amino acid sequences numbered in the following sequence listings: (1) SEQ ID NOs: 27 and 28, respectively; (2) SEQ ID NOs: 27 and 29, respectively; (3) SEQ ID NOs: 59 and 61, respectively; (4) SEQ ID NOs: 65 and 66, respectively; (5) SEQ ID NOs: 65 and 67, respectively; (6) SEQ ID NOs: 62 and 63, respectively; (7) SEQ ID NOs: 62 and 64, respectively; or (8) SEQ ID NOs: 65 and 66, respectively. NOs:59 and 60; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczetidine, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to the therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain having, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequences of SEQ ID NOs:27 and 28 independently; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczetidine, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain, the light chain and the heavy chain having, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequences of SEQ ID NOs:27 and 29 independently; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain, the light chain and the heavy chain having, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequences of SEQ ID NOs:59 and 61 independently; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin.In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain, the light chain and the heavy chain having, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequences of SEQ ID NOs:65 and 66 independently; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain, the light chain and the heavy chain having, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequences of SEQ ID NOs: 65 and 67 independently; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain, wherein the light chain and the heavy chain have, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequences of SEQ ID NOs:62 and 63 independently; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain, the light chain and the heavy chain having, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequences of SEQ ID NOs:62 and 64 independently; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin. In some embodiments, the ADC provided herein comprises an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion, wherein the anti-OX40 antibody or antigen-binding fragment comprises a light chain and a heavy chain, the light chain and the heavy chain having, respectively, at least 85%, at least 90%, at least 92%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% identity with the amino acid sequences of SEQ ID NOs:59 and 60 independently; and wherein the therapeutic portion is MMAE, MMAF, Dxd, SN-38, eczema, or eribulin.In some embodiments, the therapeutic component is MMAE. In some embodiments, the therapeutic component is MMAF. In some embodiments, the therapeutic component is Dxd. In some embodiments, the therapeutic component is SN-38. In some embodiments, the therapeutic component is eczema. In some embodiments, the therapeutic component is eribulin.
[0230] In some embodiments, the ADC provided herein includes a linker region located between the therapeutic portion and the anti-OX40 antibody. The linker may be, for example, a cleavable linker (e.g., a peptide linker, a carbohydrate linker) or a non-cleavable linker (e.g., a linker released by antibody degradation).
[0231] In some embodiments, the linker can be cleaved under intracellular conditions such that the cleavage releases the therapeutic portion from the antibody in an intracellular environment (e.g., within lysosomes, endosomes, or cell membrane pits). The therapeutic portion can be conjugated in a manner that reduces its activity unless it is cleaved from the antibody (e.g., by hydrolysis, antibody degradation, or by a cleaving agent). Such therapeutic portions are attached to antibodies via cleavable linkers that are sensitive to cleavage in the intracellular environment of OX40-expressing cancer cells but not substantially sensitive to the extracellular environment, thereby cleaving the conjugate from the antibody when it is endocytosed by OX40-expressing cancer cells (e.g., in endosomes, or, for example, in a lysosomal environment or in a cell membrane pit environment due to pH or protease sensitivity).
[0232] The linker can be, for example, a peptide linker cleaved by an intracellular peptidase or protease, including a lysosomal or endosomal protease. Typically, the peptide linker is at least two or at least three amino acids in length. Cleavage agents can include cathepsins B and D, as well as plasmin (see, for example, Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123). Most typically, peptide linkers can be cleaved by enzymes present in OX40-expressing cells. For example, a peptide linker cleaved by the thiol-dependent protease cathepsin B, which is highly expressed in cancerous tissues, can be used (e.g., a linker containing a phenylalanine-leucine or glycine-phenylalanine-leucine-glycine peptide). Other such linkers are described, for example, in U.S. Patent No. 6,214,345. In certain embodiments, the peptide linker that can be cleaved by intracellular proteases comprises a valine-citrulline linker or a phenylalanine-lysine dipeptide (see, for example, U.S. Patent 6,214,345, which describes the synthesis of doxorubicin with a valine-citrulline linker). One advantage of using intracellular proteolytic hydrolysis to release the therapeutic portion is that it is generally attenuated when the agent is conjugated, and the serum stability of the conjugate is generally high.
[0233] The cleavable linker can be pH-sensitive, meaning it is sensitive to hydrolysis at a specific pH value. Typically, such pH-sensitive linkers are hydrolyzable under acidic conditions. For example, acid-labile linkers that are hydrolyzable in lysosomes (e.g., hydrazones, hemicarbazones, thiohemicarbazones, cis-aconitic amides, orthoesters, acetals, ketal, or the like) can be used. (See, for example, U.S. Patents 5,122,368; 5,824,805; 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem.264: 14653-14661.) Such linkers are relatively stable under neutral pH conditions (e.g., conditions in blood) but unstable below pH 5.5 or 5.0, which is an approximate pH for lysosomes. In some embodiments, the hydrolyzable linker is a thioether linker (e.g., a thioether to which the therapeutic portion is attached via an acylhydrazone bond (see, for example, U.S. Patent No. 5,622,929)).
[0234] Other linkers can be cleaved under reducing conditions (e.g., disulfide linkers). Disulfide linkers include those that can be formed using SATA (N-succinimidyl-S-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate), and SMPT (N-succinimidyloxycarbonyl-α-methyl-α-(2-pyridyldithio)toluene). (See, for example, Thorpe et al., 1987, Cancer Res. 47:5924-5931; Wawrzynczak et al., In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer (CW Vogel ed., Oxford U. Press, 1987). See also U.S. Patent No. 4,880,935.)
[0235] The linker may also be a malonic acid linker (Johnson et al., 1995, Anticancer Res. 15:1387-93), a maleimide benzoyl linker (Lau et al., 1995, Bioorg-Med-Chem. 3(10): 1299-1304) or a 3'-N-amide analog (Lau et al., 1995, Bioorg-Med-Chem. 3(10): 1305-12). The linker may also be a malonic acid linker (Johnson et al., 1995, Anticancer Res. 15: 1387-93), a maleimide benzoyl linker (Lau et al., 1995, Bioorg-Med-Chem. 3(10): 1299-1304) or a 3'-N-amide analog (Lau et al., 1995, Bioorg-Med-Chem. 3(10): 1305-12).
[0236] The linker can also be an uncuttable linker, such as a maleimide-alkylene type linker or a maleimide-aryl type linker that is directly attached to a therapeutic part (e.g., a drug). The active drug-linker is released through antibody degradation.
[0237] Typically, the linkers are not substantially sensitive to the extracellular environment, meaning that when the ADC is present in the extracellular environment (e.g., in plasma), the linkers in the ADC sample are cleaved by no more than about 20%, usually no more than about 15%, more usually no more than about 10%, and even more usually no more than about 5%, no more than about 3%, or no more than about 1%.
[0238] Whether a linker is not substantially sensitive to the extracellular environment can be determined, for example, by incubating (a) an ADC (“ADC sample”) and (b) an equimolar amount of uncoupled antibody or therapeutic fraction (“control sample”) independently with plasma for a predetermined time period (e.g., 2, 4, 8, 16, or 24 hours), and then comparing the amount of uncoupled antibody or therapeutic fraction present in the ADC sample with the amount of uncoupled antibody or therapeutic fraction present in the control sample, for example, by high performance liquid chromatography.
[0239] Linkers can also promote endocytosis. When a linker is conjugated to a therapeutic portion (i.e., in the context of a linker-therapeutic portion of an ADC or ADC derivative described herein), the linker promotes endocytosis. Alternatively, when a linker is conjugated to both a therapeutic portion and an anti-OX40 antibody (i.e., in the context of an ADC described herein), the linker promotes endocytosis.
[0240] Anti-OX40 antibodies can be coupled to linkers via heteroatoms of the antibody. These heteroatoms may be present on the antibody in its native state or may be introduced into the antibody. In some embodiments, anti-OX40 antibodies can be coupled to linkers via the nitrogen atom of a lysine residue. In other embodiments, anti-OX40 antibodies can be coupled to linkers via the sulfur atom of a cysteine residue. The cysteine residue may be a naturally occurring residue or an engineered residue introduced into the antibody. Methods for coupling linkers and drug-linkers to antibodies via lysine and cysteine residues are known in the art.
[0241] In some implementations, the ADC provided herein has an anti-OX40 antibody or antigen-binding fragment conjugated to a therapeutic portion via a linker.
[0242] In some implementations, the connector has the following structure: .
[0243] In some implementations, the linker may have the following stereochemical form: (CAS: 159857-80-4).
[0244] In some implementations, the connector has the following structure: .
[0245] In some implementations, the linker may have the following stereochemical form: (CAS: 1599440-25-1).
[0246] In some implementations, the connector has the following structure: .
[0247] In some implementations, the linker may have the following stereochemical form: .
[0248] In some implementations, the connector has the following structure: .
[0249] In some implementations, the linker may have the following stereochemical form: .
[0250] In some implementations, the connector has the following structure: .
[0251] In some implementations, the linker may have the following stereochemical form: .
[0252] In some implementations, carbonate groups may be introduced into the linker. ) or urethane groups (e.g. or (R is a substituent), or the group may be formed between the linker and the therapeutic portion. In some embodiments, a carbonate group is introduced into the linker or a carbonate group is formed between the linker and the therapeutic portion. In some embodiments, a urethane group is introduced into the linker or a urethane group is formed between the linker and the therapeutic portion.
[0253] Therefore, in some embodiments, exemplary therapeutic moiety-linker (i.e., conjugates of the therapeutic moiety and the linker) include MMAE-linker, MMAF-linker, Dxd-linker, SN-38-linker, eribulin-linker, and eczematidine-linker. In some embodiments, the ADC provided herein has an anti-OX40 antibody conjugated to the therapeutic moiety via a linker, wherein the therapeutic moiety and the linker together have the following structure: Or, or a pharmaceutically acceptable salt thereof.
[0254] The preferred stereochemistry of this type of drug-linker is shown below: (CAS: 646502-53-6).
[0255] In some implementations, the therapeutic portion and the connector together have the following structure: Or, or a pharmaceutically acceptable salt thereof.
[0256] The preferred stereochemistry of this type of drug-linker is shown below: (CAS: 863971-17-9).
[0257] In some implementations, the therapeutic portion and the connector together have the following structure: Or, or a pharmaceutically acceptable salt thereof.
[0258] The preferred stereochemistry of this type of drug-linker is shown below: (Trastuzumab, CAS: 1599440-13-7).
[0259] In some implementations, the therapeutic portion and the connector together have the following structure: Or, or a pharmaceutically acceptable salt thereof.
[0260] The preferred stereochemistry of this type of drug-linker is shown below: (CAS: 1801838-28-7).
[0261] In some implementations, the therapeutic portion and the connector together have the following structure: Or, or a pharmaceutically acceptable salt thereof.
[0262] The preferred stereochemistry of this type of drug-linker is shown below: (CAS: 2130869-18-8).
[0263] In some implementations, the therapeutic portion and the connector together have the following structure: Or, or a pharmaceutically acceptable salt thereof.
[0264] The preferred stereochemistry of this type of drug-linker is shown below: (CAS: 1600418-29-8).
[0265] Therefore, the exemplary ADCs provided herein may have any of the following structures, or pharmaceutically acceptable salts thereof: (I) (II) (III)
[0266] (IV)
[0267] (V)
[0268] (VI).
[0269] The exemplary ADC may have the following stereochemical form, or a pharmaceutically acceptable salt thereof: (Ia) (IIa) (IIIa)
[0270] (IVa)
[0271] (Va)
[0272] (VIa)
[0273] Typically, each antibody is linked to 1 to 16 drug-linkers.
[0274] In the disclosed structures (I), (II), (III), (IV), (V), (VI), (Ia), (IIa), (IIIa), (IVa), (Va), and (VIa) above, the subscript p indicates the ratio between the therapeutic portion and the antibody (or drug-antibody ratio, DAR), and, depending on the context, may indicate the number of linker-therapeutic portion conjugate molecules attached to a single antibody molecule, and is therefore an integer value; or may indicate the average DAR, and is therefore an integer or non-integer value, but is typically a non-integer value. The average DAR represents the average number of linker-therapeutic portion conjugate molecules corresponding to each antibody in a population. In some embodiments, when referring to an antibody (e.g., a monoclonal antibody), a population of antibody molecules is used. In compositions containing a population of ADC molecules, the average DAR is an important quality property because it determines the amount of drug that can be delivered to target cells. The percentage of unconjugated antibody molecules in the composition is included in the average drug loading value.
[0275] In some embodiments, when referring to a composition comprising a group of ADC compounds, the average DAR is 1 to about 16, preferably about 1 to about 14, more preferably about 1 to about 10. In some embodiments, the average drug load is about 1, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, about 11, about 11.5, or about 12. In some embodiments, the average DAR may be about 2.8. In some embodiments, the average DAR may be about 3.6. In some embodiments, the average DAR may be about 4. In some embodiments, the average DAR may be about 4.2. In some embodiments, the average DAR may be about 4.3. In some embodiments, the average DAR may be about 4.5. In some embodiments, the average DAR may be about 4.6. In some embodiments, the average DAR may be about 5. In some implementations, the average DAR may be approximately 5.3. In some implementations, the average DAR may be approximately 8.0.
[0276] For MMAE ADCs, such as those exemplified herein, a particularly preferred average DAR is about 2.8, about 3.6, about 4, about 4.2, about 4.3, or about 5. In some embodiments, the average DAR is about 2.8. In some embodiments, the average DAR is about 3.6. In some embodiments, the average DAR is about 4. In some embodiments, the average DAR is about 4.2. In some embodiments, the average DAR is about 4.3. In some embodiments, the average DAR is about 5. In exemplary embodiments, the therapeutic moiety-linker is coupled to a cysteine residue of a reduced interchain disulfide bond. In some embodiments, within a population of ADC compounds, the actual DAR of a single antibody molecule (e.g., the number of therapeutic moiety-linker molecules attached to a single antibody molecule) is 1 to 8, 1 to 4, or 1 to 2, with a predominantly DAR of 4. In some implementations, an average DAR of about 2.8, about 3.6, about 4, or about 5 is achieved through site-specific coupling techniques (e.g., introducing engineered cysteine residues into the antibody according to the EU Index numbering system, including at site 239). For example, a higher DAR can be achieved if, in addition to interchain disulfide bonds, the drug linker is also coupled to the introduced cysteine residue (e.g., a cysteine residue introduced at site 239 according to the EU index).
[0277] For MMAF ADCs, such as those exemplified herein, the average DAR may be approximately 2.8, about 3.6, about 4, about 4.2, about 4.3, or about 5. In some embodiments, the average DAR is approximately 2.8. In some embodiments, the average DAR is approximately 3.6. In some embodiments, the average DAR is approximately 4. In some embodiments, the average DAR is approximately 4.2. In some embodiments, the average DAR is approximately 4.3. In some embodiments, the average DAR is approximately 5. In exemplary embodiments, the drug linker is coupled to a cysteine residue of a reduced interchain disulfide bond. In some embodiments, the actual DAR of a single antibody molecule (e.g., the number of drug linker molecules attached to a single antibody molecule) is 1 to 10 (or 1 to 8 or 1 to 6) in a population of ADC compounds, with a predominantly DAR of 4. In some embodiments, the average DAR of about 2.8, about 3.6, about 4, or about 5 is achieved through site-specific coupling techniques (e.g., introducing engineered cysteine residues into the antibody according to the EU Index numbering system, including at site 239). For example, a higher DAR can be achieved if, in addition to interchain disulfide bonds, the drug linker is also coupled to an introduced cysteine residue (e.g., a cysteine residue introduced at site 239 according to the EU index).
[0278] For Dxd ADCs, such as those exemplified herein, a particularly preferred average DAR is approximately 5.3 or approximately 8. In some embodiments, the average DAR is approximately 5.3. In some embodiments, the average DAR is approximately 8.
[0279] For SN-38 ADCs, such as those exemplified in this paper, a particularly preferred average DAR of approximately 4.5 is preferred.
[0280] For eczema ADCs, such as those exemplified herein, a particularly preferred average DAR is about 4.2 or about 8. In some embodiments, the average DAR is about 4.2. In some embodiments, the average DAR is about 8.
[0281] For Eppendorf ADCs, such as those illustrated in this article, a particularly preferred average DAR of approximately 4.6 is.
[0282] In exemplary embodiments, the drug linker is coupled to a cysteine residue of a reduced interchain disulfide bond. In some embodiments, the actual DAR (e.g., the number of drug linker molecules attached to a single antibody molecule) in a population of ADC compounds is 1 to 10 (or 2 to 10 or 2 to 8), with 8 being the dominant DAR. In some embodiments, an average DAR of about 5.3 or about 8 is achieved by site-specific coupling techniques (e.g., introducing engineered cysteine residues into the antibody according to the EU Index numbering system, including at position 239). For example, a higher DAR can be achieved if, in addition to the interchain disulfide bond, the drug linker is also coupled to the introduced cysteine residue (e.g., a cysteine residue introduced at position 239 according to the EU index).
[0283] PEG (polyethylene glycol) can be incorporated into drug-linkers to form PEGylated ADCs. The PEG (polyethylene glycol) portion of the drug-linker can range from 8 to 36, preferably 8 to 14, 8 to 12, 10 to 12, or 10 to 14, and particularly preferably PEG having 12 ethylene oxide units. It has been found that incorporating polyethylene glycol polymers into cleavable β-glucuronide can provide OX40-targeting antibody-drug conjugates with reduced plasma clearance and enhanced antitumor activity in xenograft models, compared to non-PEGylated controls.
[0284] Polydisperse PEG, monodisperse PEG, and discrete PEG can be used to prepare the PEGylated ADCs disclosed herein. Polydisperse PEG is a heterogeneous mixture of sizes and molecular weights, while monodisperse PEG is typically purified from heterogeneous mixtures, thus providing a single chain length and molecular weight. The preferred PEG unit is discrete PEG, which is a compound synthesized stepwise rather than by a polymerization process. Discrete PEG provides a single molecule with a defined and specified chain length.
[0285] In some embodiments, the covalent linking of the antibody to the drug linker is achieved through the interaction of the thiol functional group of the antibody with the maleimide functional group of the drug linker to form a thiosubstituted succinimidide. The thiol functional group may be present in the native state of the ligand unit, for example, in naturally occurring residues (interchain disulfide residues), or may be introduced into the ligand through chemical modification or bioengineering, or a combination of both. It should be understood that the antibody-substituted succinimidide may exist in a hydrolyzed form. For example, in a preferred embodiment, the ADC comprises a succinimidide moiety, which, when bonded to the antibody, is represented by the following structure: Or it may contain its corresponding acid-amide moiety, which is represented by the following structure when bonded to an antibody: or The wavy line indicates the connection to the rest of the drug-connector.
[0286] In some embodiments, anti-OX40 antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs:15 and 16, respectively, are coupled to MMAE via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4. In some embodiments, the average value of p in the ADC population is about 2.8, about 3.6, about 4, about 4.2, about 4.3, or about 5. In some embodiments, the average value of p in the ADC population is about 2.8. In some embodiments, the average value of p in the ADC population is about 3.6. In some embodiments, the average value of p in the ADC population is about 4. In some embodiments, the average value of p in the ADC population is about 4.2. In some embodiments, the average value of p in the ADC population is about 4.3. In some embodiments, the average value of p in the ADC population is about 5. In some embodiments, the preferred stereochemistry of such ADC is... In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:29.
[0287] In some embodiments, anti-OX40 antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs:38 and 39, respectively, are coupled to MMAE via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4. In some embodiments, the average value of p in the ADC population is about 2.8, about 3.6, about 4, about 4.2, about 4.3, or about 5. In some embodiments, the average value of p in the ADC population is about 2.8. In some embodiments, the average value of p in the ADC population is about 3.6. In some embodiments, the average value of p in the ADC population is about 4. In some embodiments, the average value of p in the ADC population is about 4.2. In some embodiments, the average value of p in the ADC population is about 4.3. In some embodiments, the average value of p in the ADC population is about 5. In some embodiments, the preferred stereochemistry of such ADC is... In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:59 and a heavy chain having the amino acid sequence of SEQ ID NO:61.
[0288] In some embodiments, anti-OX40 antibodies comprising VL and VH having the amino acid sequences of SEQ ID NOs 40 and 41, respectively, are coupled to MMAE via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4. In some embodiments, the average value of p in the ADC population is about 2.8, about 3.6, about 4, about 4.2, about 4.3, or about 5. In some embodiments, the average value of p in the ADC population is about 2.8. In some embodiments, the average value of p in the ADC population is about 3.6. In some embodiments, the average value of p in the ADC population is about 4. In some embodiments, the average value of p in the ADC population is about 4.2. In some embodiments, the average value of p in the ADC population is about 4.3. In some embodiments, the average value of p in the ADC population is about 5. In some embodiments, the preferred stereochemistry of such ADC is... In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:65 and a heavy chain having the amino acid sequence of SEQ ID NO:66. In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:65 and a heavy chain having the amino acid sequence of SEQ ID NO:67.
[0289] In some embodiments, anti-OX40 antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs:42 and 43, respectively, are coupled to MMAE via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4. In some embodiments, the average value of p in the ADC population is about 2.8, about 3.6, about 4, about 4.2, about 4.3, or about 5. In some embodiments, the average value of p in the ADC population is about 2.8. In some embodiments, the average value of p in the ADC population is about 3.6. In some embodiments, the average value of p in the ADC population is about 4. In some embodiments, the average value of p in the ADC population is about 4.2. In some embodiments, the average value of p in the ADC population is about 4.3. In some embodiments, the average value of p in the ADC population is about 5. In some embodiments, the preferred stereochemistry of such ADC is... In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:62 and a heavy chain having the amino acid sequence of SEQ ID NO:63. In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:62 and a heavy chain having the amino acid sequence of SEQ ID NO:64.
[0290] In some embodiments, anti-OX40 antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs 38 and 56, respectively, are coupled to MMAE via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4. In some embodiments, the average value of p in the ADC population is about 2.8, about 3.6, about 4, about 4.2, about 4.3, or about 5. In some embodiments, the average value of p in the ADC population is about 2.8. In some embodiments, the average value of p in the ADC population is about 3.6. In some embodiments, the average value of p in the ADC population is about 4. In some embodiments, the average value of p in the ADC population is about 4.2. In some embodiments, the average value of p in the ADC population is about 4.3. In some embodiments, the average value of p in the ADC population is about 5. In some embodiments, the preferred stereochemistry of such ADC is... In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:59 and a heavy chain having the amino acid sequence of SEQ ID NO:60.
[0291] In some embodiments, anti-OX40 antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs:15 and 16, respectively, are coupled to MMAF via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4. In some embodiments, the average value of p in the ADC population is about 2.8, about 3.6, about 4, about 4.2, about 4.3, or about 5. In some embodiments, the average value of p in the ADC population is about 2.8. In some embodiments, the average value of p in the ADC population is about 3.6. In some embodiments, the average value of p in the ADC population is about 4. In some embodiments, the average value of p in the ADC population is about 4.2. In some embodiments, the average value of p in the ADC population is about 4.3. In some embodiments, the average value of p in the ADC population is about 5. In some embodiments, the preferred stereochemistry of such ADC is... In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:29.
[0292] In some embodiments, antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs:15 and 16, respectively, are coupled to Dxd via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 8. In some embodiments, the average value of p in the population of ADCs is about 5.3 or about 8. In some embodiments, the average value of p in the population of ADCs is about 5.3. In some embodiments, the average value of p in the population of ADCs is about 8. In some embodiments, the preferred stereochemistry of such ADCs is In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:29.
[0293] In some embodiments, antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs:15 and 16, respectively, are coupled to SN-38 via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4 or 5. In some embodiments, the average value of p in this population of ADCs is approximately 4.5. In some embodiments, the preferred stereochemistry of such ADCs is... In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:29.
[0294] In some embodiments, antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs:15 and 16, respectively, are conjugated to eczema via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4 or 8. In some embodiments, the average value of p in the population of ADCs is about 4.2 or about 8. In some embodiments, the average value of p in the population of ADCs is about 4.2. In some embodiments, the average value of p in the population of ADCs is about 8. In some embodiments, the preferred stereochemistry of such ADCs is In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:29.
[0295] In some embodiments, antibodies comprising VL and VH having amino acid sequences having SEQ ID NOs:15 and 16, respectively, are conjugated with eribulin via a linker to form an ADC having the following structure: Where p represents a number from 1 to 16; preferably a number from 1 to 10; more preferably 4 or 5. In some embodiments, the average value of p in this population of ADCs is approximately 4.6. In some embodiments, the preferred stereochemistry of such ADCs is... In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:28. In some embodiments, the anti-OX40 antibody comprises a light chain having the amino acid sequence of SEQ ID NO:27 and a heavy chain having the amino acid sequence of SEQ ID NO:29.
[0296] In some embodiments, the ADC described herein (e.g., HX111) does not block the binding of OX40L to OX40. In some embodiments, the ADC described herein (e.g., HX111) is efficiently internalized by OX40-positive cells. In some embodiments, the ADC described herein (e.g., HX111) depletes OX40-positive cells (e.g., OX40-positive regulatory T cells within the TME). In some embodiments, the ADC described herein (e.g., HX111) depletes OX40-positive cells without blocking the binding of OX40L to OX40. In some embodiments, the ADC described herein (e.g., HX111) exhibits significant ADCC. In some embodiments, the ADC described herein (e.g., HX111) maintains the basic ADCC of the anti-OX40 antibody or antigen-binding fragment described herein (e.g., HX011). In some embodiments, the ADC described herein (e.g., HX111) enhances the anti-tumor immune response. In some embodiments, the ADC described herein (e.g., HX111) reduces immunosuppression in the TME. In some embodiments, the ADC described herein (e.g., HX111) enhances immunological activity in the TME. In some embodiments, the ADC described herein (e.g., HX111) converts cold tumors into hot tumors. In some embodiments, the anti-OX40 antibody or antigen-binding fragment of the ADC described herein (e.g., HX011) is a humanized antibody or antigen-binding fragment.
[0297] In some embodiments, the ADC described herein has antitumor activity. In some embodiments, the ADC described herein is capable of specifically targeting and killing cancer cells expressing OX40. In some embodiments, the ADC described herein is capable of treating cancer. The cancer may be a liquid tumor or a solid tumor. In some embodiments, the ADC described herein is capable of treating OX40+ cancer. In some embodiments, the ADC described herein is capable of treating peripheral T-cell lymphoma (PTCL, such as adult T-cell leukemia (ATL), angioimmunoblastic T-cell lymphoma (AITL)) or T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the ADC described herein is capable of treating solid tumors. In some embodiments, the ADC described herein is capable of treating sarcoma, breast cancer, non-small cell lung cancer (NSCLC), melanoma, or ovarian cancer. In some embodiments, the ADC described herein is capable of treating HPV+ cancer or EBV+ cancer. In some implementations, the ADC described herein can treat EBV+ B-cell lymphoma, extranodal NK / T-cell lymphoma (ENKTL; e.g., nasal type), HPV16+ head and neck squamous cell carcinoma (HNSCC), EBV+ esophageal cancer, or HPV18+ cervical cancer.
[0298] In some embodiments, the ADCs described herein are capable of treating autoimmune or inflammatory diseases. Without being bound by theory, the ADCs provided herein treat autoimmune or inflammatory diseases at least in part by depleting pathological T cells. Therefore, in some embodiments, the ADCs described herein are capable of treating autoimmune or inflammatory diseases with excessive T cell activation. In some embodiments, the autoimmune or inflammatory disease is rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease (CD), graft-versus-host disease (GvHD), multiple sclerosis (MS), type 1 diabetes mellitus, atopic dermatitis, asthma, psoriasis, Sjögren's syndrome (SS), or idiopathic thrombocytopenic purpura (ITP). 1.5 Production Methods
[0299] This document provides anti-OX40 antibodies and their antigen-binding fragments, including but not limited to chimeric antibodies, humanized antibodies, human antibodies, and their antigen-binding fragments. The anti-OX40 antibodies or antigen-binding fragments described herein can be prepared by any method known in the art, including chemical synthesis and recombinant expression techniques. Unless otherwise indicated, the present invention is practiced using conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridization, and related fields known to those skilled in the art.
[0300] In some embodiments, the monoclonal antibody is prepared using recombinant DNA techniques known to those skilled in the art. The polynucleotides of the antibody or antigen-binding fragments provided herein can be prepared, manipulated, and / or expressed using any well-established techniques known and available in the art. In some embodiments, the polynucleotides of the antibody or antigen-binding fragments provided herein can be prepared recombinantly. A variety of vectors can be used. Exemplary vectors include, but are not limited to, plasmids, phage particles, granules, artificial chromosomes (e.g., yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), or P1-derived artificial chromosome (PAC)), bacteriophages (e.g., λ phage or M13 phage), and animal viruses. Examples of animal virus classes useful as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and polyomaviruses (e.g., SV40). Examples of expression vectors include the pClneo vector (Promega) for expression in mammalian cells; and pLenti4 / V5-DEST™, pLenti6 / V5-DEST™, and pLenti6.2 / V5-GW / lacZ (Invitrogen) for lentivirus-mediated gene transfer and expression in mammalian cells.
[0301] In some embodiments, a recombinant expression vector is used to express a polynucleotide encoding the polypeptide described herein. For example, the recombinant expression vector may be a reproducible DNA construct comprising a synthetic or cDNA-derived DNA fragment encoding the polypeptide, said DNA fragment being operatively linked to a suitable transcriptional and / or translational regulatory element derived from a mammalian, microbial, viral, or insect gene. When DNA regions are operatively linked to each other, they are functionally related to each other. For example, if a promoter controls transcription of a sequence, the promoter is operatively linked to the coding sequence; or, if a ribosome binding site is localized to allow translation, the ribosome binding site is operatively linked to the coding sequence. In some embodiments, the coding sequence of the polypeptide disclosed herein may be ligated into such an expression vector for its expression in mammalian cells. In some embodiments, a viral vector is used. In some embodiments, the structural element intended for use in a yeast expression system includes a guide sequence that enables the host cell to secrete the translated protein extracellularly. In some embodiments, where the recombinant protein is expressed in the absence of a guide sequence or transport sequence, the polypeptide may contain an N-terminal methionine residue.
[0302] A variety of expression host / vector combinations can be used. Suitable host cells for expression include prokaryotes, yeast cells, insect cells, or higher eukaryotic cells under the control of appropriate promoters. Appropriate cloning and expression vectors for bacterial, fungal, yeast, and mammalian cell hosts, as well as protein production methods (including antibody production), are well known in the art. Useful expression vectors for bacterial hosts include known bacterial plasmids, such as those from E. coli, including pCR1, pBR322, pMB9, and their derivatives, as well as plasmids with a broader host range, such as M13 and other filamentous single-stranded DNA bacteriophages.
[0303] Useful expression vectors for eukaryotic hosts include, for example, vectors containing expression control sequences from SV40, bovine papillomavirus, adenovirus, and cytomegalovirus. Examples of suitable mammalian host cell lines include, but are not limited to, COS-7 (monkey kidney), L-929 (mouse fibroblast), C127 (mouse mammary tumor), 3T3 (mouse fibroblast), CHO (Chinese hamster ovary), HeLa (human cervical cancer), BHK (hamster kidney fibroblast), HEK-293 (human embryonic kidney), and their variants. Mammalian expression vectors may contain non-transcriptional elements, such as origin of replication, appropriate promoters and enhancers linked to the gene to be expressed, and other 5' or 3' flanking non-transcriptional and 5' or 3' non-translational sequences, such as necessary ribosome binding sites, polyadenylation sites, splicing donor and acceptor sites, and transcription termination sequences. Expression of recombinant proteins in insect cell culture systems (e.g., baculoviruses) also provides a robust method for producing correctly folded and biologically functional proteins. Baculovirus systems used to produce heterologous proteins in insect cells are well known to those skilled in the art.
[0304] Peptides can also be synthesized, wholly or partially, by chemical methods (see, for example, Caruthers (1980). Nucleic Acids Res. Symp. Ser. 215; Horn (1980); and Banga, AK, Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, PA). Peptide synthesis can be performed using a variety of solid-phase techniques (see, for example, Roberge, Science 269:202 (1995); Merrifield, Methods. Enzymol. 289:3 (1997)), and can be automated, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer) according to the manufacturer's instructions. Peptides can also be synthesized using combinatorial methods. Synthetic residues and peptides can be synthesized using a variety of procedures and methodologies known in the art (see, for example, Organic Syntheses CollectiveVolumes, Gilman, et al. (eds.), John Wiley & Sons, Inc., NY). Modified peptides can be prepared by chemical modification methods (see, for example, Belousov, Nucleic Acids Res. 25:3440 (1997); Frenkel, FreeRadic. Biol. Med. 19:373 (1995); and Blommers, Biochemistry 33:7886 (1994)). Peptide sequence variants, derivatives, substitutions, and modifications can also be achieved using methods such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR-based mutagenesis. Site-directed mutagenesis (Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res. 10:6487 (1987)), cassette mutagenesis (Wells et al., Gene 34:315 (1985)), restriction selection mutagenesis (Wells et al., Philos. Trans. R. Soc. London SerA 317:415 (1986)), and other techniques can be performed on cloned DNA to produce peptide sequences, variants, fusions, and chimeras, as well as their variants, derivatives, substitutions, and modifications.
[0305] For in vivo use of antibodies in humans, human antibodies or humanized antibodies are preferred. Human antibodies can be prepared by a variety of methods known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences, including improvements to these techniques. See also U.S. Patents 4,444,887 and 4,716,111; and PCT disclosures WO 98 / 46645, WO 98 / 50433, WO 98 / 24893, WO 98 / 16654, WO 96 / 34096, WO 96 / 33735, and WO91 / 10741; the entire contents of each of these are incorporated herein by reference. Human antibodies can also be antibodies in which the heavy and light chains are encoded by nucleotide sequences derived from human DNA from one or more sources. In some embodiments, anti-OX40 antibodies or antigen-binding fragments are human antibodies or antigen-binding fragments. Human antibodies can be prepared using a variety of techniques known in the art.
[0306] Optionally, in some embodiments, the non-human antibody is humanized, wherein specific sequences or regions of the antibody are modified to increase similarity to antibodies naturally produced in humans. In some embodiments, the antigen-binding domain is partially humanized. Various methods for generating humanized antibodies are known in the art, including but not limited to CDR transplantation (see, for example, European Patent EP 239,400; International Publication WO 91 / 09967; and U.S. Patents 5,225,539, 5,530,101 and 5,585,089, the entire contents of which are incorporated herein by reference), coating or surface remodeling (see, for example, European Patents EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al., 1994, PNAS, 91:969-973, the entire contents of which are incorporated herein by reference), chain shuffling (see, for example, U.S. Patent No. 5,565,332, the entire contents of which are incorporated herein by reference), and, for example, U.S. Patent Application Publication US2005 / 0042664, U.S. Patent Application Publication US2005 / 0048617, U.S. Patent No. 6,407,213, U.S. Patent No. 5,766,886, International Publication WO 93 / 17105, Tan et al., J. Immunol., 169:1119-25 (2002), Caldas et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods, 20(3):267-79 (2000), Baca et al., J. Biol. Chem., 272(16):10678-84 The techniques disclosed in (1997), Roguska et al., Protein Eng., 9(10):895-904 (1996), Couto et al., Cancer Res., 55 (23 Supp):5973s-5977s (1995), Couto et al., Cancer Res., 55(8):1717-22 (1995), Sandhu JS, Gene, 150(2):409-10 (1994), and Pedersen et al., J. Mol. Biol., 235(3):959-73 (1994), the entire contents of which are incorporated herein by reference. Typically, the framework residues in the framework region can be replaced with corresponding residues from the CDR donor antibody to alter and preferably improve antigen binding.These framework substitutions can be identified using methods well-known in the art, such as by modeling the interaction between the CDR and framework residues to identify framework residues important for antigen binding, and by sequence comparison to identify framework residues unusual at specific positions. (See, for example, Queen et al., U.S. Patent No. 5,585,089; and Riechmann et al., 1988, Nature, 332:323, the entire contents of which are incorporated herein by reference.)
[0307] Humanized antibodies contain one or more amino acid residues introduced from a non-human source. These non-human amino acid residues are often referred to as "introduced" residues and are typically derived from "introduced" variable domains. Therefore, humanized antibodies contain one or more CDRs from non-human immunoglobulin molecules and a framework region from humans. Humanization of antibodies is well known in the art and can be performed in a manner consistent with that of Winter et al. (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by replacing the corresponding sequence of a human antibody with a rodent CDR or CDR sequence, i.e., CDR transplantation (EP 239,400; PCT Publication WO 91 / 09967; and U.S. Patents 4,816,567, 6,331,415, 5,225,539, 5,530,101, 5,585,089, and 6,548,640, the contents of which are incorporated herein by reference in their entirety). In such humanized chimeric antibodies, the portion substituted by the corresponding sequence from a non-human species is significantly less than the intact human variable domain. In practice, humanized antibodies are typically human antibodies, with some CDR residues and possibly some FR residues substituted by residues from rodent antibody-like sites. Antibody humanization can also be achieved through coating or surface remodeling (EP 592,106; EP519,596; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., Protein Engineering, 7(6):805-814 (1994); and Roguska et al., PNAS, 91:969-973 (1994)) or chain shuffling (US Patent No. 5,565,332), the contents of which are incorporated herein by reference in their entirety.
[0308] The selection of human variable domains (light and heavy chains) used to prepare humanized antibodies aims to reduce antigenicity. Following a so-called “best-match” approach, the variable domain sequences of rodent antibodies are screened against an entire library of known human variable domain sequences. The human sequence that most closely matches the rodent sequence is then accepted as the human frame (FR) for the human antibody (Sims et al., J. Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987), the contents of which are incorporated herein by reference in their entirety). Another approach uses specific frames derived from consistent sequences of all human antibodies from specific light or heavy chain subsets. The same framework can be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993), the contents of which are incorporated herein by reference in their entirety).
[0309] Antibodies can be humanized while retaining high affinity for the target antigen and other favorable biological properties. For example, humanized antibodies can be prepared by analyzing parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional models of immunoglobulins are generally available and well known to those skilled in the art. Computer programs are available to illustrate and display the possible three-dimensional conformational structures of selected candidate immunoglobulin sequences. Examination of these displays allows analysis of the possible roles of residues in the function of the candidate immunoglobulin sequence, i.e., analysis of residues affecting the binding ability of the candidate immunoglobulin to the target antigen. In this way, FR residues can be selected and combined from the receptor sequence and the introduced sequence to achieve desired antibody properties, such as increased affinity for the target antigen. Generally, CDR residues are directly and most significantly involved in influencing antigen binding.
[0310] Humanized antibodies retain similar antigen specificity to the original antibody, such as the ability to bind to the human OX40 antigen. However, with certain humanization methods, “directed evolution” approaches can be used to enhance the binding affinity and / or specificity of antibodies to specific antigens, as described by Wu et al., J. Mol. Biol., 294:151 (1999), the contents of which are incorporated herein by reference in their entirety.
[0311] Various methods for purifying anti-OX40 antibodies are known in the art, such as affinity chromatography. The eluted IgG can be detected by gel electrophoresis and high-performance liquid chromatography to ensure purity. Buffer solutions can be replaced, and concentrations can be determined. Monoclonal antibodies can be aliquoted and stored.
[0312] Methods for analyzing the binding affinity, cross-reactivity, and binding kinetics of various anti-OX40 antibodies include standard assays known in the art, such as Western blotting, ELISA, and flow cytometry. Further methods available in the art include, for example, biolayer interferometry (BLI) using the Gator system (Probe Life) or the Octet-96 system (Sartorius AG), or BIACORE™ surface plasmon resonance (SPR) analysis using the BIACORE™ 2000 SPR instrument (Biacore AB, Uppsala, Sweden).
[0313] This document also provides a method for preparing the disclosed anti-OX40 ADC (e.g., HX111, i.e., HX011 conjugated with MC-VC-PAB-MMAE (CAS: 646502-53-6)), which includes conjugating the disclosed anti-OX40 antibody (e.g., HX011) to a therapeutic portion. Techniques for conjugating therapeutic portions to proteins, especially to antibodies, are well known. (See, for example, Arnon et al., “Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy,” in Monoclonal Antibodies And Cancer Therapy (edited by Reisfeld et al., Alan R. Liss, Inc., 1985); Hellstrom et al., “Antibodies For Drug Delivery,” in Controlled Drug Delivery (edited by Robinson et al., Marcel Dekker, Inc., 2nd ed., 1987); Thorpe, “Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review,” in Monoclonal Antibodies '84: Biological And Clinical Applications (edited by Pinchera et al., 1985); “Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody In Cancer Therapy,” in Monoclonal Antibodies For Cancer Detection And Therapy (edited by Baldwin et al., Academic Press, 1985). (1985); and Thorpe et al., 1982, Immunol. Rev. 62: 119-58. See also, for example, PCT Publication WO 89 / 12624.)
[0314] Any method disclosed herein or otherwise known in the art can be used for coupling. Generally, at least three classes of methods are available and known in the art, including chemical coupling, enzyme coupling, and click chemistry.
[0315] In some embodiments, the methods provided herein include chemical coupling. For example, the therapeutic portion can be chemically coupled to the lysine or cysteine side chain of an antibody. In some embodiments, the methods provided herein include lysine coupling. An activated ester group (e.g., NHS) can react with a solvent-accessible amino group present on the lysine residue side chain to form a stable amide bond. In some embodiments, the methods provided herein include cysteine coupling. The synthetic process is also divided into two steps: an activation (reduction) step (e.g., using tris(2-carboxyethyl)phosphine (TCEP)) and subsequent thiol-maleimide coupling.
[0316] Various methods are known in the art and can be employed to further improve the therapeutic properties of the ADCs disclosed herein. To reduce the hydrophobicity of the therapeutic portion leading to early clearance of the ADC in vivo, the hydrophobic properties of the therapeutic portion can be masked using a hydrophilic linker containing PEG (Lyon et al. (2015) Biotechnol. 33(7):733-5). The XTEN platform can be used to prolong the half-life of highly drug-loaded ADCs (Podust et al. (2016), J Control Release 240:52-66). XTEN is a peptide linker composed of alanine, glycine, glutamic acid, proline, serine, and threonine.
[0317] Furthermore, cysteine rebridging can be used to prepare site-specific ADCs with relatively low DAR. This process requires a relatively small molecular weight reducing agent (e.g., TCEP) and a drug-linker containing a hydrophilic spacer group. Dialkylating agents, such as bromomethylenepyrrolidone, dithiomaleimide, dibromopyrazinedione, aryldipropynyl nitrile, and bis(ethylenesulfonyl)piperazine, are effective in site-specific coupling reactions with antibodies.
[0318] Chemical conjugation using affinity compounds (such as Z33 peptide, Z34 peptide, and Fc III-derived peptides) (called affinity labeling) can also be used for site-specific modification of antibodies. (Starovasnik et al. (1997) Proc Natl Acad SciU S A. 94(19):10080-5; DeLano et al. (2000), Science 287(5456):1279-83; Shiraiwa et al. (2020) Cell Chem Biol. 27(8):970-985.) Photoaffinity labeling can be used for conjugation. Activated esters (such as 4-fluorophenylcarbamate lysine (FPheK) or NHS esters) can also be used.
[0319] In some embodiments, the methods provided herein include enzymatic coupling. A variety of enzymes have been used to conjugate natural or genetically engineered antibodies to various therapeutic moieties, or to introduce suitable bioorthogonal functional groups into antibodies. These enzymes modify antibodies in a site-specific manner, which typically allows for the production of single-site ADCs with well-controlled DAR. Enzymes that can be used include, for example, transpeptidase A, trypsiligase, transglutaminase, formylglycine synthase, and tyrosinase.
[0320] In some implementations, the methods presented herein include the use of click chemistry. A representative reaction of click chemistry, namely azide-yne cycloaddition (AAC), can be used. Furthermore, ADCs can be synthesized without using native amino acid residues in the mAb. Two main types of AACs are copper-catalyzed AAC (CuAAC) and strain-promoted AAC (SPAAC) (VanBrunt et al. (2015) Bioconjug Chem 26(11):2249–2260.; Chio and Bane (2020), Methods MolBiol 2078:83–97). CuAAC is synthesized by combining linear alkynes with azides under copper catalysis to form heterocycles (Li et al. (2014) Angew Chem 53(28):7179–7182). SPAAC, on the other hand, is synthesized by cyclizing cyclooctyne and can be used to obtain homogeneous ADC products (Tsuchikama and An (2018) Protein Cell, 9(1):33–46.). It has been observed that CuAAC oxidizes certain amino acids in antibodies due to the presence of copper, and the oxidized protein may be immunogenic (Van Geel et al. (2015), Bioconjug Chem 26(11):2233–2242.). 1.6 Pharmaceutical Composition
[0321] This document also provides pharmaceutical compositions comprising the antibodies disclosed herein. This document also provides pharmaceutical compositions comprising the ADCs disclosed herein. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the antibody disclosed herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the ADC disclosed herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition can be used to inhibit tumor growth in a subject (e.g., a human patient). In some embodiments, the pharmaceutical composition can be used to treat cancer in a subject (e.g., a human patient).
[0322] In some embodiments, the pharmaceutical compositions provided herein comprise the antibodies provided herein. The antibodies may be present in various concentrations. In some embodiments, the pharmaceutical compositions provided herein comprise soluble antibodies provided herein at concentrations of 1-1000 mg / ml. In some embodiments, the pharmaceutical compositions comprise soluble antibodies provided herein at concentrations of 10-500 mg / ml, 10-400 mg / ml, 10-300 mg / ml, 10-200 mg / ml, 10-100 mg / ml, 20-100 mg / ml, or 50-100 mg / ml. In some embodiments, the pharmaceutical compositions provided herein comprise antibodies provided herein at concentrations of about 10 mg / ml, about 20 mg / ml, about 30 mg / ml, about 40 mg / ml, about 50 mg / ml, about 60 mg / ml, about 70 mg / ml, about 80 mg / ml, about 90 mg / ml, about 100 mg / ml, about 120 mg / ml, about 150 mg / ml, about 180 mg / ml, about 200 mg / ml, about 300 mg / ml, about 500 mg / ml, about 800 mg / ml, or about 1000 mg / ml. Those skilled in the art can readily adjust the dosage; for example, a decrease in purity may necessitate an increase in dosage.
[0323] In some embodiments, the pharmaceutical compositions provided herein comprise the ADC provided herein. The ADC may be present in various concentrations. In some embodiments, the pharmaceutical compositions provided herein comprise a soluble ADC provided herein at a concentration of 1-1000 mg / ml. In some embodiments, the pharmaceutical compositions comprise a soluble ADC provided herein at concentrations of 10-500 mg / ml, 10-400 mg / ml, 10-300 mg / ml, 10-200 mg / ml, 10-100 mg / ml, 20-100 mg / ml, or 50-100 mg / ml. In some embodiments, the pharmaceutical compositions provided herein comprise the ADC provided herein at concentrations of about 10 mg / ml, about 20 mg / ml, about 30 mg / ml, about 40 mg / ml, about 50 mg / ml, about 60 mg / ml, about 70 mg / ml, about 80 mg / ml, about 90 mg / ml, about 100 mg / ml, about 120 mg / ml, about 150 mg / ml, about 180 mg / ml, about 200 mg / ml, about 300 mg / ml, about 500 mg / ml, about 800 mg / ml, or about 1000 mg / ml. Those skilled in the art can readily adjust the dosage; for example, a decrease in purity may necessitate an increase in dosage.
[0324] This document also provides kits for preparing pharmaceutical compositions comprising the antibodies or ADCs disclosed herein. In some embodiments, the kit contains the antibody or ADC disclosed herein and a pharmaceutically acceptable carrier in one or more containers. In some embodiments, the kit may contain the antibody or ADC disclosed herein for administration to a subject. In particular embodiments, the kit includes instructions for the preparation and / or administration of the antibody or ADC disclosed herein.
[0325] In some embodiments, this document provides a pharmaceutical composition comprising an antibody or ADC disclosed herein, wherein the composition is suitable for local administration. In some embodiments, local administration includes intratumoral injection, peritumoral injection, tumor-adjacent injection, lesion-specific injection and / or injection into tumor-draining lymph nodes, or substantially any tumor-targeting injection, wherein the antitumor agent is expected to leak into the primary lymph nodes adjacent to the targeted solid tumor.
[0326] Pharmaceutically acceptable carriers that can be used in the compositions provided herein include any and all physiologically compatible substances such as solvents, dispersion media, coatings, antimicrobial and antifungal agents, isotonic agents, and absorption delay agents. In some embodiments, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active ingredient (i.e., the antibody or ADC disclosed herein) may be encapsulated in a material to protect the active ingredient from acids and other natural conditions that may inactivate it.
[0327] This document also provides pharmaceutical compositions or formulations capable of improving the stability of the antibodies or ADCs disclosed herein to allow for long-term storage. In some embodiments, the pharmaceutical compositions or formulations disclosed herein comprise: (a) the antibody disclosed herein; (b) a buffer; (c) a stabilizer; (d) a salt; (e) an excipient; and / or (f) a surfactant. In some embodiments, the pharmaceutical compositions or formulations are stable for at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, at least 5 years, or longer. In some embodiments, the pharmaceutical compositions or formulations disclosed herein comprise: (a) the ADC disclosed herein; (b) a buffer; (c) a stabilizer; (d) a salt; (e) an excipient; and / or (f) a surfactant. In some embodiments, the pharmaceutical compositions or formulations are stable for at least 1 month, at least 2 months, at least 3 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, at least 5 years, or longer. In some embodiments, the pharmaceutical composition or formulation is stable when stored at 4°C, 25°C, or 40°C.
[0328] The buffers useful in the pharmaceutical compositions or formulations disclosed herein can be weak acids or weak bases used to maintain the acidity (pH) of the solution near a selected value after the addition of another acid or base. Suitable buffers can maximize the stability of the pharmaceutical formulation by maintaining pH control. Suitable buffers can also ensure physiological compatibility or optimize solubility. Rheological properties, viscosity, and other properties may also depend on the pH of the formulation. Common buffers include, but are not limited to, histidine, citrate, succinate, acetate, and phosphate. In some embodiments, the buffer comprises histidine (e.g., L-histidine) and an isotonic agent, and pH adjustment can be performed using acids or bases known in the art. In some embodiments, the buffer is L-histidine. In some embodiments, the pH of the formulation is maintained between about 2 and about 10, or between about 4 and about 8.
[0329] Stabilizers are added to pharmaceutical products to stabilize them. These agents can stabilize proteins in various ways. Common stabilizers include, but are not limited to, amino acids (e.g., glycine, alanine, lysine, arginine, or threonine), carbohydrates (e.g., glucose, sucrose, trehalose, raffinose, or maltose), polyols (e.g., glycerol, mannitol, sorbitol, cyclodextrins of any type and molecular weight, or dextran), or PEG. In some embodiments, the stabilizer is selected to maximize the stability of the FIX peptide in the lyophilized formulation. In some embodiments, the stabilizer is sucrose and / or arginine.
[0330] Fillers can be added to pharmaceutical compositions or formulations to increase the volume and mass of the product, thereby facilitating precise measurement and handling. Common fillers include, but are not limited to, lactose, sucrose, glucose, mannitol, sorbitol, calcium carbonate, or magnesium stearate.
[0331] Surfactants are amphiphilic substances having both hydrophilic and hydrophobic groups. Surfactants can be anionic, cationic, amphoteric, or nonionic. Examples of nonionic surfactants include, but are not limited to, alkyl ethoxylates, nonylphenol ethoxylates, amine ethoxylates, polyethylene oxide, polypropylene oxide, fatty alcohols (e.g., cetyl alcohol or oleyl alcohol), cocoamide MEA, cocoamide DEA, polysorbate, or dodecyl dimethylamine oxide. In some embodiments, the surfactant is polysorbate 20 or polysorbate 80.
[0332] The pharmaceutical compositions disclosed herein may further comprise one or more buffer systems, preservatives, isotonic agents, chelating agents, stabilizers, and / or surfactants, as well as various combinations thereof. The use of preservatives, isotonic agents, chelating agents, stabilizers, and surfactants in pharmaceutical compositions is well known to those skilled in the art. See also... Remington: The Science and Practice of Pharmacy , 19th edition, 1995.
[0333] In some embodiments, the pharmaceutical composition is an aqueous formulation. Such formulations are typically solutions or suspensions, but may also include colloids, dispersions, emulsions, and multiphase materials. The term "aqueous formulation" is defined as a formulation containing at least 50% w / w water. Similarly, the term "aqueous solution" is defined as a solution containing at least 50% w / w water, and the term "aqueous suspension" is defined as a suspension containing at least 50% w / w water.
[0334] In some embodiments, the pharmaceutical compositions disclosed herein are lyophilized preparations, which are added by a physician or patient with solvents and / or diluents prior to use.
[0335] The pharmaceutical compositions disclosed herein may also include pharmaceutically acceptable antioxidants. Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfite, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.; and (3) metal chelating agents, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.
[0336] Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions or formulations described herein include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate). For example, appropriate flowability can be maintained by using coating materials (e.g., lecithin), maintaining the desired particle size in the case of dispersions, and using surfactants.
[0337] These compositions may also contain adjuvants, such as preservatives, wetting agents, emulsifiers, and dispersants. The presence of microorganisms can be prevented by the sterilization procedures described above and by the addition of various antimicrobial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, etc.). It may also be desirable to add isotonic agents, such as sugars, sodium chloride, etc., to the compositions. Furthermore, the absorption of injectable drug formulations can be prolonged by adding absorption-retarding agents (e.g., aluminum monostearate and gelatin).
[0338] Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions, as well as sterile powders for the preparation of sterile injectable solutions or dispersions. Such media and reagents are known in the art for the use of pharmaceutically active substances. Unless any conventional media or reagent is incompatible with the active compound, it is permitted for use in the pharmaceutical compositions described herein. Pharmaceutical compositions or formulations may contain preservatives or may not contain preservatives. Additional active compounds may be incorporated into the compositions.
[0339] Pharmaceutical compositions or formulations must generally remain sterile and stable under manufacturing and storage conditions. The compositions can be prepared as solutions, microemulsions, liposomes, or other ordered structures suitable for high drug concentrations. The carrier can be a solvent or dispersion medium, such as comprising water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. For example, appropriate flowability can be maintained by using coatings such as lecithin, maintaining the desired particle size in the dispersion case, and using surfactants. In many cases, the composition may include isotonic agents such as sugars, polyols (e.g., mannitol, sorbitol), or sodium chloride. The absorption of injectable compositions can be prolonged by adding absorption-retarding agents, such as monostearate and gelatin.
[0340] A sterile injectable solution can be prepared by incorporating the desired amount of the active compound into a suitable solvent, adding one or more of the components listed above as needed, followed by sterile microfiltration. Typically, a dispersion is prepared by incorporating the active compound into a sterile carrier containing a base dispersion medium and any other desired components listed herein. For sterile powders used to prepare sterile injectable solutions, some preparation methods include vacuum drying and lyophilization (freeze-drying), which produce a powder containing the active ingredient and any other desired components from a previously sterile filtered solution.
[0341] The amount of active ingredient that can be combined with a carrier material in the pharmaceutical compositions or formulations disclosed herein can vary. In some embodiments, the amount of active ingredient that can be combined with a carrier material is the amount that produces a therapeutic effect. Generally, this amount, in percentage terms, will be about 0.01% to about 99% of the active ingredient, about 0.1% to about 70% of the active ingredient, or about 1% to about 30% of the active ingredient combined with a pharmaceutically acceptable carrier.
[0342] The pharmaceutical compositions disclosed herein can be prepared using carriers that protect the active ingredient from rapid release, such as controlled-release formulations, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable and biocompatible polymers can be used, such as ethylene-vinyl acetate, polyanhydrides, polyglycolic acid, collagen, poly(oxocyanate), and polylactic acid. Many methods for preparing such formulations are patented or are well known to those skilled in the art. See, for example... Sustained and Controlled Release Drug Delivery Systems Edited by JR Robinson, Marcel Dekker, Inc., New York, 1978. 1.7 Applications and Methods
[0343] The antibodies, compositions, and methods described herein have numerous in vitro and in vivo uses, such as those relating to enhancing immune responses, for example, by activating (or stimulating) OX40 signaling. In some embodiments, the anti-OX40 antibodies described herein can be administered to human subjects, for example, in vivo, to enhance immunity in a variety of diseases. Therefore, methods for modulating immune responses in subjects are provided herein, comprising administering the anti-OX40 antibodies described herein to the subjects, thereby modulating the immune response in the subjects. In some embodiments, the response is enhanced, stimulated, or upregulated.
[0344] In some embodiments, this document provides methods for inducing or stimulating the activation of immune cells (e.g., T cells), which include contacting the immune cells with an effective amount of anti-OX40 antibody as described herein. In some embodiments, this document provides methods for inducing or stimulating the proliferation of immune cells (e.g., T cells), which include contacting the immune cells with an effective amount of anti-OX40 antibody as described herein.
[0345] Subjects suitable for this method include human patients who wish to enhance their immune response. The method is particularly suitable for treating human patients with diseases that can be treated by enhancing an immune response, such as a T-cell-mediated immune response. In some embodiments, the method is particularly suitable for the treatment of cancer in vivo. In some embodiments, this document provides a method for enhancing an immune response in subjects in need, comprising administering to the subject an effective amount of the anti-OX40 antibody as described herein.
[0346] Given the ability of anti-OX40 antibodies or the antibodies described herein to stimulate or co-stimulate T cell responses, this document provides methods for using the anti-OX40 antibodies described herein in vitro and in vivo to stimulate, enhance, or upregulate anti-tumor T cell responses. Antigen-specific T cell responses can be measured using any appropriate antigen-specific T cell response indicator. Non-limiting examples of such appropriate indicators include increased T cell proliferation in the presence of the antibody and / or increased cytokine production in the presence of the antibody. In some embodiments, the production of interleukin-2 and / or interferon-γ by activated T cells is stimulated.
[0347] The method also includes stimulating an immune response in a subject, comprising administering the anti-OX40 antibody described herein to the subject, thereby stimulating an immune response in the subject. In some embodiments, the subject is a cancer patient, and an immune response against the cancer is stimulated. The cancer may be a solid tumor or a liquid tumor, such as a hematologic malignancy. In some embodiments, the tumor is an immunogenic tumor. In some embodiments, the tumor is non-immunogenic. In some embodiments, the tumor is PD-L1 positive. In some embodiments, the tumor is PD-L1 negative. In some embodiments, the tumor is non-immunogenic. In some embodiments, the tumor is OX40 positive. The subject may also be a virus-carrying subject, and an immune response against the virus is stimulated.
[0348] This disclosure also provides methods of using the anti-OX40 antibody disclosed herein, a polynucleotide encoding such an antibody, a vector containing such a polynucleotide, ADCs, or a pharmaceutical composition containing such an antibody or ADCs for the treatment of cancer.
[0349] Without being bound by theory, in some embodiments, anti-OX40 antibodies can enhance anti-tumor immunity by activating the OX40 signaling pathway, thereby promoting the activity of immune cells (e.g., T cells) in clearing, lysing, and / or killing cancer cells. Because the anti-OX40 antibodies described herein do not block the interaction between OX40L and OX40, they do not interfere with signal activation mediated by the natural ligand OX40L, thus allowing for maximum activation of said signal. Furthermore, anti-OX40 antibodies and ADCs can specifically target OX40-positive cancer cells in vivo, thereby delivering their therapeutic effects of clearing, lysing, and / or killing cancer cells.
[0350] In some embodiments, the antibodies, ADCs, compositions, and methods described herein can be used to target and treat tumors and cancers. In some embodiments, a method for inhibiting cancer cell growth in a subject is provided, comprising administering the anti-OX40 antibody described herein to the subject, thereby inhibiting cancer growth in the subject. A method for treating cancer in a subject of need is also provided herein, comprising administering a therapeutically effective amount of the antibody disclosed herein to the subject. Use of the antibodies disclosed herein as a medicament is also provided herein. Use of the antibodies disclosed herein for treating cancer is also provided herein. Use of the antibodies disclosed herein for preparing a medicament for treating cancer is also provided herein.
[0351] In some embodiments, a method for inhibiting cancer cell growth in a subject is provided, comprising administering the anti-OX40 ADC described herein to the subject, thereby inhibiting cancer growth in the subject. A method for treating cancer in a subject in need is also provided, comprising administering a therapeutically effective amount of the ADCs disclosed herein to the subject. Use of the ADCs disclosed herein as a medicament is also provided. Use of the ADCs disclosed herein for treating cancer is also provided. Use of the ADCs disclosed herein for preparing a medicament for treating cancer is also provided. In some embodiments, a method for treating cancer in a subject in need is provided, comprising administering a therapeutically effective amount of a pharmaceutical composition disclosed herein to the subject. In some embodiments, use of the pharmaceutical composition disclosed herein for treating cancer is provided. In some embodiments, use of the pharmaceutical composition provided herein for preparing a medicament for treating cancer is provided. In some embodiments, the tumor or cancer to be treated by the methods disclosed herein is OX40 positive.
[0352] The actual dose level of the active ingredient (i.e., anti-OX40 antibody or ADCs) described herein can be varied to obtain an amount of active ingredient that effectively achieves the desired therapeutic response for a specific patient, composition, and route of administration without causing toxicity to the patient. The selected dose level will depend on a variety of pharmacokinetic factors, including the activity of the specific composition described herein, route of administration, time of administration, excretion rate, duration of treatment, other drugs, compounds, and / or materials used in combination with the specific composition employed, the age, sex, weight, condition, general health status, and medical history of the patient being treated, as well as similar factors known in the medical field. In some embodiments, the anti-OX40 antibody and ADCs described herein may be administered at doses that provide therapeutic benefit without causing high levels of immune-related adverse reactions or hematologic toxicity (anemia and / or thrombocytopenia).
[0353] The anti-OX40 antibody and ADC described herein can be administered in extended-release formulations, in which case a lower dosing frequency is required. Dosage and frequency vary depending on the half-life of the anti-OX40 antibody and ADC in the patient. In therapeutic applications, relatively high doses may sometimes be administered at relatively short intervals until disease progression is reduced or terminated, and until the patient shows partial or complete remission of disease symptoms.
[0354] The anti-OX40 antibodies, ADCs, or pharmaceutical compositions provided herein may be administered to subjects by any method known in the art, including but not limited to pleural administration, intravenous administration, subcutaneous administration, intralymphatic administration, intratumoral administration, intramuscular administration, intradermal administration, intrathecal administration, intrapleural administration, intraperitoneal administration, intracranial administration, spinal administration, or other parenteral routes, such as by injection or infusion, or direct administration to the thymus. The term "parenteral administration" as used herein refers to a route of administration other than enteral and local administration, typically by injection, and includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, tracheal, subcutaneous, subcutaneous, intra-articular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injections and infusions. In some embodiments, subcutaneous administration is used. In some embodiments, intravenous administration is used. In some embodiments, oral administration is used. In some embodiments, the anti-OX40 antibody and ADC provided herein can be administered to a subject via intratumoral injection, peritumoral injection, tumor-adjacent injection, lesion-specific injection, and / or injection into tumor-draining lymph nodes, or via substantially any tumor-targeting injection, wherein leakage of the antitumor agent is expected to occur into the primary lymph node adjacent to the target solid tumor. In some embodiments, the antibody provided herein can be regionally delivered to the tumor using known methods, including but not limited to hepatic or aortic pumps; limb, lung, or liver perfusion; via portal vein; via venous shunt; intracavitary or intravenous delivery near the tumor, etc. In another embodiment, the antibody provided herein can be administered systemically. In a preferred embodiment, the antibody is administered regionally at the tumor site. The antibody can also be administered intratumorally, for example by direct injection of cells at the tumor site and / or into tumor vessels. For example, in the case of malignant pleural diseases, mesothelioma, or lung cancer, intrapleural administration is preferred (see Adusumilli et al., Science Translational Medicine 6(261):261ra151 (2014)). Those skilled in the art can select an appropriate route of administration based on the type of cancer to be treated and / or the location of the tumor. Antibodies can be administered via injection or catheter. In one embodiment, antibodies are administered to the recipient via the pleura, for example, using an intrapleural catheter.
[0355] Cancers or tumors that can be treated using the anti-OX40 antibodies, ADCs, or pharmaceutical compositions provided herein include those that are generally responsive to immunotherapy and those that are generally unresponsive to immunotherapy. In some embodiments, the cancer has high microsatellite instability. In some embodiments, the cancer is metastatic, refractory, or recurrent. In some embodiments, the cancer is characterized by OX40+ tumor-infiltrating cells (TILs).
[0356] In some embodiments, the cancers treatable with anti-OX40 antibodies, ADCs, or pharmaceutical compositions disclosed herein are solid tumors. In some embodiments, the cancers treatable with anti-OX40 antibodies or pharmaceutical compositions disclosed herein are liquid tumors or hematologic malignancies. In some embodiments, the cancer is an OX40+ cancer. In some embodiments, the cancer is a liquid tumor. The liquid tumor may be an OX40+ liquid tumor. In some embodiments, the cancers treatable with anti-OX40 antibodies, ADCs, or pharmaceutical compositions disclosed herein are T-cell leukemia or lymphoma. In some embodiments, the cancers treatable with anti-OX40 antibodies, ADCs, or pharmaceutical compositions disclosed herein are peripheral T-cell lymphomas (PTCL, such as adult T-cell leukemia (ATL), angioimmunoblastic T-cell lymphoma (AITL)) or T-cell acute lymphoblastic leukemia (T-ALL). In some embodiments, the cancer may be ATL. In some embodiments, the cancer may be AITL. In some embodiments, the cancer may be PTCL. In some embodiments, the cancer may be T-ALL. In some embodiments, the cancers that can be treated with the anti-OX40 antibody, ADC, or pharmaceutical composition disclosed herein are solid tumors. The solid tumor may be an OX40+ solid tumor. In some embodiments, the cancers that can be treated with the anti-OX40 antibody, ADC, or pharmaceutical composition disclosed herein are sarcomas, breast cancer, non-small cell lung cancer (NSCLC), melanoma, or melanoma. In some embodiments, the cancer may be a sarcoma. In some embodiments, the cancer may be breast cancer. In some embodiments, the cancer may be NSCLC. In some embodiments, the cancer may be melanoma. In some embodiments, the cancer may be melanoma. In some embodiments, the cancer may be melanoma. In some embodiments, the cancers that can be treated with the anti-OX40 antibody, ADC, or pharmaceutical composition disclosed herein are HPV+ cancers or EBV+ cancers. In some embodiments, the cancers that can be treated with the anti-OX40 antibody, ADC, or pharmaceutical composition disclosed herein are EBV+ B-cell lymphoma, extranodal NK / T-cell lymphoma (ENKTL; e.g., nasal type), HPV16+ head and neck squamous cell carcinoma (HNSCC), EBV+ esophageal cancer, or HPV18+ cervical cancer. In some embodiments, the cancer may be EBV+ B-cell lymphoma. In some embodiments, the cancer may be extranodal NK / T-cell lymphoma (ENKTL; e.g., nasal type). In some embodiments, the cancer may be HPV16+ HNSCC. In some embodiments, the cancer may be EBV+ esophageal cancer. In some embodiments, the cancer may be HPV18+ cervical cancer.
[0357] For illustrative purposes, in some embodiments, this document provides a method for treating ATL in a subject in need, comprising administering to the subject a therapeutically effective amount of an anti-OX40 antibody disclosed herein. In some embodiments, this document provides the use of the anti-OX40 antibody disclosed herein in the treatment of ATL. In some embodiments, this document provides the use of the anti-OX40 antibody provided herein in the preparation of a medicament for treating ATL. In some embodiments, this document provides a method for treating ATL in a subject in need, comprising administering to the subject a therapeutically effective amount of an anti-OX40 ADC disclosed herein. In some embodiments, this document provides the use of the anti-OX40 ADC disclosed herein in the treatment of ATL. In some embodiments, this document provides the use of the anti-OX40 ADC provided herein in the preparation of a medicament for treating ATL. The ATL may be OX40+.
[0358] In some implementations, anti-OX40 antibodies or ADCs are administered to patients with cancer that has not responded adequately to prior treatment or has progressed during prior treatment, such as those previously treated with immuno-oncology or immunotherapy drugs, or to patients with refractory or drug-resistant cancer, where the refractory or drug-resistant condition can be intrinsic or acquired. For example, subjects who do not respond or respond poorly to a first-line therapy, or whose disease has progressed after treatment, can be treated by administering anti-OX40 antibodies or ADCs, which can be done alone or in combination with another therapy.
[0359] Anti-OX40 antibodies or ADCs can be administered in combination with standard therapy. Anti-OX40 antibodies or ADCs can be administered as maintenance therapy, such as in treatments aimed at preventing tumor development or recurrence. Anti-OX40 antibodies or ADCs can be administered in combination with another therapy, such as radiation therapy, surgery, or chemotherapy. For example, adjuvant therapy with anti-OX40 antibodies or ADCs can be administered when there is a potential risk of micrometastases and / or to reduce the risk of recurrence.
[0360] Combination therapy using agents with different mechanisms of action can produce additive or synergistic effects. Combination therapy allows for lower doses of each agent than those used in monotherapy, thereby reducing toxic side effects and / or increasing the therapeutic index of the agents disclosed herein. Combination therapy can reduce the likelihood of drug-resistant cancer cell development. In some embodiments, the additional treatment results in an increase in the therapeutic index of the antibody or pharmaceutical composition described herein. In some embodiments, the additional treatment results in a reduction in the toxicity and / or side effects of the antibody or pharmaceutical composition described herein. In some embodiments, the anti-OX40 antibody, ADC, or pharmaceutical composition described herein may be administered in combination with the additional treatment. In some embodiments, the additional treatment may be surgical resection, radiation therapy, or chemotherapy.
[0361] In some embodiments, the adjunctive treatment may be an immune checkpoint inhibitor, such as an antagonist of proteins that inhibit T cell activation, such as CTLA-4, PD-1, PD-L1, PD-L2, GITR and LAG-3, Galectin 9, CEACAM-1, CEACAM-5, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, B7-H3, B7-H4, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4. In some embodiments, the adjunctive treatment is an anti-PD-1 antibody. In some embodiments, the adjunctive treatment is an anti-PD-L1 antibody. In some embodiments, the adjunctive treatment is an anti-OX40 antibody that blocks the binding of OX40L to OX40. In some implementations, this document provides a combination therapy of the anti-OX40 antibody or ADC (e.g., HX011 or HX111) provided herein with an anti-OX40 antibody that blocks the binding between OX40L and OX40. Such combination therapies are expected to have a synergistic effect in cancer treatment.
[0362] The adjunctive treatment may be administered before, simultaneously with, or after the administration of the anti-OX40 antibody, ADC, or pharmaceutical composition described herein. Co-administration may include co-administration, which may be in a single pharmaceutical formulation or using separate formulations, or may include sequential administration in any order, but typically within a time period so that all active agents can exert their biological activity simultaneously. Those skilled in the art can readily determine appropriate regimens for co-administering the pharmaceutical composition described herein with adjunctive treatment based on the needs of the treated subject, including the timing and dosage of the adjunctive agents used in the co-administration.
[0363] In cancer treatment, cancerous or tumor cells in a subject may be eliminated, but any clinical improvement constitutes a benefit. Antitumor effects can be manifested by a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with the cancer state. Antitumor effects can also be manifested by the ability of the antibody or pharmaceutical compositions provided herein to prevent the initial occurrence of tumors. In some embodiments, an “antitumor effect” can be manifested by a reduction in cancer-induced immunosuppression. Clinical improvement includes a reduction in the risk or rate of progression or a reduction in the pathological consequences of the cancer or tumor. It should also be understood that methods of treating cancer can include any effect that improves cancer-related signs or symptoms. Such signs or symptoms include, but are not limited to, a reduction in tumor burden, including inhibition of tumor growth, slowing of tumor growth rate, reduction of tumor size, reduction of tumor number, and elimination of tumors, all of which can be measured using conventional tumor imaging techniques known in the art. Other cancer-related signs or symptoms include, but are not limited to, fatigue, pain, weight loss, and other signs or symptoms associated with various cancers.
[0364] In some embodiments, the methods or uses provided herein can reduce tumor burden. Therefore, administration of the anti-OX40 antibody, ADC, or pharmaceutical composition disclosed herein can reduce the number of tumor cells in a subject, decrease tumor size, and / or eradicate the tumor. Methods for monitoring a patient's response to administration of the pharmaceutical composition disclosed herein are known in the art and can be employed according to the methods disclosed herein.
[0365] In some implementations, treatment of subjects with cancer using the anti-OX40 antibody or ADC described herein may result in prolonged survival, such as a long-lasting response relative to current standard of care; long-term survival of at least 3 months, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, or longer; or recurrence-free survival of at least 3 months, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years, 5 years, or 10 years, or longer. In some implementations, treatment of subjects with cancer using the anti-OX40 antibody or ADC described herein may prevent or delay cancer recurrence, such as delaying it for 3 months, 6 months, 9 months, 1 year, 2 years, 3 years, 4 years, 5 years, or 10 years, or longer. Treatment of subjects with cancer using the anti-OX40 antibody described herein may result in, for example, disease stabilization, partial remission, increased overall survival, increased disease-free survival, or improved progression-free survival.
[0366] In the methods disclosed herein, a therapeutically effective amount of the disclosed anti-OX40 antibody or pharmaceutical composition is administered to a subject requiring cancer treatment. The subject may be a mammal. In some embodiments, the subject is a human. In some embodiments, these individuals do not have clinically measurable tumors. However, they are suspected of having a risk of disease progression, which may occur near the original tumor site or through metastasis. This group may be further subdivided into high-risk and low-risk individuals. This subdivision is based on characteristics observed before or after initial treatment. These characteristics are known in the field of clinical technology and are appropriately defined for different types of cancer. A typical characteristic of the high-risk subgroup is that the tumor has invaded adjacent tissues or shows lymph node involvement.
[0367] In some embodiments, the antibodies, ADCs, compositions, and methods described herein can also be used to treat autoimmune and inflammatory diseases. Some autoimmune or inflammatory diseases are characterized by unintended or excessive T cell activation. When T cells are overactivated, they release pro-inflammatory molecules (such as cytokines), leading to inflammation and tissue damage. This excessive immune response can target a wide range of organs or tissues in the body, resulting in a broad spectrum of autoimmune or inflammatory diseases. Without being bound by theory, the anti-OX40 antibodies and ADCs disclosed herein can be used to treat autoimmune and inflammatory diseases, such as those characterized by excessive T cell activation, at least in part by depleting pathological T cells with unintended activity.
[0368] In some embodiments, a method for treating an autoimmune disease or inflammatory disease in a subject is provided, comprising administering the anti-OX40 antibody described herein to the subject, thereby reducing excessive or undesirable immune activity or inflammation. In some embodiments, a method for treating an autoimmune disease or inflammatory disease in a subject is provided, comprising administering the anti-OX40 antibody described herein to the subject. The use of the antibodies disclosed herein in the treatment of autoimmune diseases or inflammatory diseases is also provided herein. The use of the antibodies disclosed herein in the preparation of medicaments for the treatment of autoimmune diseases or inflammatory diseases is also provided herein.
[0369] In some embodiments, methods are provided for treating autoimmune or inflammatory diseases in a subject, comprising administering the anti-OX40 ADC described herein to the subject, thereby reducing excessive or unwanted immune activity or inflammation. Methods are also provided herein for treating autoimmune or inflammatory diseases in a subject requiring treatment, comprising administering a therapeutically effective amount of the ADC disclosed herein to the subject. The use of the ADC disclosed herein in the treatment of autoimmune or inflammatory diseases is also provided herein. The use of the ADC disclosed herein in the preparation of medicaments for the treatment of autoimmune or inflammatory diseases is further provided herein.
[0370] In some embodiments, this document provides a method for treating an autoimmune disease or inflammatory disease in a subject requiring treatment, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. In some embodiments, this document provides the use of the pharmaceutical composition disclosed herein in the treatment of an autoimmune disease or inflammatory disease. In some embodiments, this document provides the use of the pharmaceutical composition provided herein in the preparation of a medicament for the treatment of an autoimmune disease or inflammatory disease. In some embodiments, the autoimmune disease or inflammatory disease treated by the methods disclosed herein is characterized by excessive T-cell activation.
[0371] In some implementations, the autoimmune or inflammatory diseases that can be treated with the anti-OX40 antibody, ADC, or pharmaceutical composition disclosed herein are rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease (CD), graft-versus-host disease (GvHD), multiple sclerosis (MS), type I diabetes, atopic dermatitis, asthma, psoriasis, Sjögren's syndrome (SS), or idiopathic thrombocytopenic purpura (ITP).
[0372] Graft-versus-host disease (GvHD) is a common immunological disorder in allogeneic transplantation, in which residual T cells from the donor are activated in the recipient host upon transplantation. Without effective control and management, GvHD can be classified into two types: acute GvHD or chronic GvHD, which can be modeled in the preclinical stage using various experimental systems. In some implementations, the antibodies, ADCs, compositions, and methods described herein can also be used to treat GvHD.
[0373] In subjects with rheumatoid arthritis, abnormal activation of T cells in the joints and their invasion of the synovium (joint lining) triggers an immune response, leading to inflammation, joint pain, and stiffness. Continued T cell activation results in cartilage and bone destruction, further exacerbating joint damage. In some embodiments, the antibodies, ADCs, compositions, and methods described herein can also be used to treat rheumatoid arthritis.
[0374] In subjects with Crohn's disease and ulcerative colitis (collectively referred to as inflammatory bowel disease (IBD)), overactivation of T cells in the gastrointestinal tract leads to chronic inflammation of the digestive system, causing symptoms such as abdominal pain, diarrhea, and weight loss. In some embodiments, the antibodies, ADCs, compositions, and methods described herein can also be used to treat IBD, such as Crohn's disease or ulcerative colitis.
[0375] In subjects with multiple sclerosis (MS), activated T cells infiltrate the central nervous system and mistakenly attack the myelin sheath, triggering inflammation and leading to the formation of scar tissue (sclerosis), disrupting the transmission of electrical signals between the brain and the rest of the body. Inflammation and damage caused by T cell activation in MS can lead to a wide range of symptoms, including fatigue, muscle weakness, coordination disorders, sensory disturbances, and cognitive impairment. In some embodiments, the antibodies, ADCs, compositions, and methods described herein can also be used to treat MS.
[0376] In subjects with type 1 diabetes, T cells are activated, infiltrate the pancreas, and mistarget and destroy insulin-producing beta cells in the pancreas, thereby contributing to beta cell destruction and inflammation in the islets of Langerhans. As beta cell destruction progresses, the pancreas is unable to produce enough insulin, leading to an imbalance in blood glucose levels, a characteristic symptom of type 1 diabetes. In some embodiments, the antibodies, ADCs, compositions, and methods described herein can also be used to treat type 1 diabetes.
[0377] In subjects with psoriasis, activated T cells, particularly CD4+ and CD8+ T cells, infiltrate the skin and release cytokines that promote inflammation and excessive skin cell production. This immune response leads to rapid skin cell renewal, resulting in the characteristic plaques and associated symptoms of psoriasis. In some embodiments, the antibodies, ADCs, compositions, and methods described herein can also be used to treat psoriasis.
[0378] In subjects with SLE, abnormal T-cell activation and dysregulation lead to the production of cytokines and autoantibodies, as well as the deposition of immune complexes, thereby contributing to inflammation and tissue damage to multiple organs. In some embodiments, the antibodies, ADCs, compositions, and methods described herein can also be used to treat SLE.
[0379] In subjects with ankylosing spondylitis, T cells, particularly CD4+ T cells, infiltrate affected joints and release pro-inflammatory cytokines, promoting inflammation and leading to pain, stiffness, and joint fusion. In some embodiments, the antibodies, ADCs, compositions, and methods described herein can also be used to treat ankylosing spondylitis.
[0380] Combination therapy using agents with different mechanisms of action can produce additive or synergistic effects. Combination therapy allows for lower doses of each agent compared to monotherapy, thereby reducing toxic side effects and / or increasing the therapeutic index of the agents disclosed herein. In some embodiments, the antibodies, ADCs, compositions, and methods described herein can be combined with another therapy for the treatment of autoimmune or inflammatory diseases. In some embodiments, the adjunctive therapy may be, for example, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), other biological therapies, immunosuppressants, targeted therapies, or immunomodulators. The adjunctive therapy may be administered before, simultaneously with, or after administration of the anti-OX40 antibody, ADC, or pharmaceutical composition described herein. Combination administration may include co-administration (whether in a single drug formulation or using separate formulations) or sequential administration in any order, but generally within a time period that allows all active agents to exert their biological activity simultaneously. Those skilled in the art can readily determine appropriate regimens for the combined administration of the pharmaceutical compositions described herein with adjunctive therapies, including the timing and dosage of the adjunctive agents used for combination therapy, based on the needs of the treated subject.
[0381] In the methods disclosed herein, a therapeutically effective amount of the disclosed anti-OX40 antibody, ADC, or pharmaceutical composition is administered to a subject requiring treatment for an autoimmune or inflammatory disease. The subject may be a mammal. In some embodiments, the subject is a human.
[0382] The anti-OX40 antibodies, ADCs, or pharmaceutical compositions provided herein can be administered using medical devices known in the art. For example, in some embodiments, needle-free subcutaneous injection devices, such as those disclosed in U.S. Patent Nos. 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; or 4,596,556, can be used. Examples of known implants and modules for the purposes described herein include: U.S. Patent No. 4,487,603, which discloses an implantable microinfusion pump for dispensing drugs at a controlled rate; U.S. Patent No. 4,486,194, which discloses a therapeutic device for transdermal drug administration; U.S. Patent No. 4,447,233, which discloses a drug infusion pump for delivering drugs at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable flow implantable infusion device for continuous drug delivery; U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system having a multi-chambered compartment; and U.S. Patent No. 4,475,196, which discloses an osmotic drug delivery system. These patents are incorporated herein by reference. Many other such implants, delivery systems, and modules are also known to those skilled in the art. 1.8 Reagent Kit and Device
[0383] In some embodiments, this disclosure provides a variety of kits to facilitate and / or efficiently implement the methods of this disclosure. Typically, the kits will contain sufficient quantities and / or numbers of components to enable the user to administer multiple treatments and / or conduct multiple experiments on a subject.
[0384] Any pharmaceutical composition or carrier disclosed herein may be included in the kit. In some embodiments, the kit may also include reagents and / or instructions for preparing and / or synthesizing the compounds and / or pharmaceutical compositions disclosed herein. In some embodiments, the kit may also include one or more buffer solutions. In some embodiments, the kit of this disclosure may include components for preparing protein or nucleic acid arrays or libraries, and therefore may include, for example, solid carriers.
[0385] In some embodiments, kit components may be packaged in an aqueous medium or in lyophilized form. The kit's container device typically includes at least one vial, tube, flask, bottle, syringe, or other container device in which components can be placed and appropriately aliquoted. When multiple kit components are present (labeling reagents and labels may be packaged together), the kit may also include second, third, or other additional containers in which additional components can be placed separately. In some embodiments, the kit may also include a second container device for containing sterile, pharmaceutically acceptable buffers and / or other diluents. In some embodiments, various component combinations may be contained in one or more vials. The kits of this disclosure may also typically include a device for containing the compounds and / or pharmaceutical compositions of this disclosure, such as proteins, nucleic acids, and any other reagent containers, for close packing for commercial sale. Such containers may include injection-molded or blow-molded plastic containers in which the desired vials are held.
[0386] In some embodiments, the reagent kit components are provided in the form of one and / or more liquid solutions. In some embodiments, the liquid solution is an aqueous solution, particularly a sterile aqueous solution. In some embodiments, the reagent kit components may be provided as a dry powder. When the reagents and / or components are provided in dry powder form, the powder can be reconstituted by adding an appropriate volume of solvent. In some embodiments, it is also envisioned that the solvent may be provided in another container device.
[0387] In some implementations, the kit may include instructions for using the kit components, as well as instructions for using any other reagents not included in the kit. These instructions may include implementable variations. 1.9 Exemplary Implementation Scheme
[0388] Implementation Scheme 1. An antibody that specifically binds to human OX40 or an antigen-binding fragment thereof, comprising: (a) a light chain variable region (VL) comprising VL CDR1, VL CDR2, and VLCDR3 from the amino acid sequence of VL having SEQ ID NO:15; or a variant thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and / or (b) a heavy chain variable region (VH) comprising VH CDR1, VH CDR2, and VH CDR3 from the amino acid sequence of VH having SEQ ID NO:16; or a variant thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions.
[0389] Implementation Scheme 2. The antibody or antigen-binding fragment of Implementation Scheme 1, wherein: (a) the VL CDR1, VL CDR2, and VL CDR3 have amino acid sequences of SEQ ID NOs:4, 5, and 6, respectively; or variants thereof, wherein the VL CDRs have up to about 5 amino acid substitutions, additions, and / or deletions; and / or (b) the VH CDR1, VH CDR2, and VH CDR3 have amino acid sequences of SEQ ID NOs:10, 11, and 12, respectively; or variants thereof, wherein the VH CDRs have up to about 5 amino acid substitutions, additions, and / or deletions.
[0390] Implementation Scheme 3. The antibody or antigen-binding fragment of Implementation Scheme 1, comprising VL CDR1, VL CDR2, VLCDR3, VH CDR1, VH CDR2 and VH CDR3, and having amino acid sequences of SEQ ID NOs:4, 5, 6, 10, 11 and 12, respectively.
[0391] Implementation Scheme 4. The antibody or antigen-binding fragment of any one of Implementation Schemes 1 to 3 is humanized.
[0392] Implementation Scheme 5. The humanized antibody or antigen-binding fragment of Implementation Scheme 4, comprising: (a) VL, having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:15; and / or (b) VH, having at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:16.
[0393] Implementation Scheme 6. The humanized antibody or antigen-binding fragment of Implementation Scheme 5, comprising VL and VH having amino acid sequences of SEQ ID NOs:15 and 16, respectively.
[0394] Implementation Scheme 7. An antibody or antigen-binding fragment of any one of Implementation Schemes 1 to 6, wherein the a...
Claims
1. An antibody or antigen-binding fragment thereof that specifically binds to human OX40, comprising: (a) Light chain variable region (VL), which includes VL CDR1, VLCDR2 and VL CDR3 having the amino acid sequence of SEQ ID NO:15; Or variants thereof, wherein the VL CDRs have up to about 5 conserved amino acid substitutions; and (b) Heavy chain variable region (VH) comprising VH CDR1, VHCDR2 and VH CDR3 having the amino acid sequence of SEQ ID NO:16; or variants thereof, wherein the VH CDRs have up to about 5 conserved amino acid substitutions; The antibody or its antigen-binding fragment is humanized.
2. The antibody or antigen-binding fragment according to claim 1, wherein: (a) The VL comprises VL CDR1, VL CDR2, and VLCDR3, having amino acid sequences of SEQ ID NOs:4, 5, and 6, respectively; or variants thereof, wherein the VL CDRs have up to about 5 conserved amino acid substitutions; and (b) The VH comprises VH CDR1, VH CDR2 and VH CDR3 having amino acid sequences of SEQ ID NOs:10, 11 and 12, respectively; or variants thereof, wherein the VH CDRs have up to about 5 conserved amino acid substitutions.
3. The antibody or antigen-binding fragment according to claim 2, wherein: (a) The VL comprises VL CDR1, VL CDR2, and VLCDR3, having amino acid sequences of SEQ ID NOs:4, 5, and 6, respectively; or variants thereof, wherein the VL CDRs have up to about 3 conserved amino acid substitutions; and (b) The VH comprises VH CDR1, VH CDR2 and VH CDR3 having amino acid sequences of SEQ ID NOs:10, 11 and 12, respectively; or variants thereof, wherein the VH CDRs have up to about 3 conserved amino acid substitutions.
4. The antibody or antigen-binding fragment according to claim 3, comprising VL CDR1, VL CDR2, VL CDR3, VHCDR1, VH CDR2 and VH CDR3, each having amino acid sequences of SEQ ID NOs:4, 5, 6, 10, 11 and 12.
5. The antibody or antigen-binding fragment according to claim 4, wherein the VL has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:15; and the VH has at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:
16.
6. The antibody or antigen-binding fragment according to claim 4, wherein the VL has 1 to 10 amino acid substitutions, additions, and / or deletions compared to the amino acid sequence of SEQ ID NO:15; optionally, the VL has 1 to 5 amino acid substitutions, additions, and / or deletions compared to the amino acid sequence of SEQ ID NO:15; the VH has 1 to 10 amino acid substitutions, additions, and / or deletions compared to the amino acid sequence of SEQ ID NO:16; optionally, the VH has 1 to 5 amino acid substitutions, additions, and / or deletions compared to the amino acid sequence of SEQ ID NO:
16.
7. The antibody or antigen-binding fragment according to claim 6, wherein the amino acid substitution, addition, and / or deletion is a conserved amino acid substitution.
8. The antibody or antigen-binding fragment according to claim 7, wherein the VL has 1 to 3 conserved amino acid substitutions compared to the amino acid sequence of SEQ ID NO:15; and the VH has 1 to 3 conserved amino acid substitutions compared to the amino acid sequence of SEQ ID NO:
16.
9. The antibody or antigen-binding fragment according to claim 4, comprising VL and VH having amino acid sequences of SEQ ID NOs:15 and 16, respectively.
10. The antibody or antigen-binding fragment according to any one of claims 1 to 9, wherein it is a monoclonal antibody or antigen-binding fragment.
11. The antibody or antigen-binding fragment according to any one of claims 1 to 9, wherein it is selected from the group consisting of Fab, Fab', F(ab')2, Fv, scFv and (scFv)2.
12. The antibody or antigen-binding fragment according to any one of claims 1 to 9, wherein it is an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, or an IgG4 antibody.
13. The antibody or antigen-binding fragment according to any one of claims 1 to 9, further comprising: Light chain constant region (CL) and heavy chain constant region (CH).
14. The antibody or antigen-binding fragment according to claim 13, wherein the CL region is kappa CL (Cκ; SEQ ID NO: 19) or lambda CL (Cλ; SEQ ID NO: 20), or a variant thereof, wherein it has up to ten amino acid substitutions; wherein the CH region is IgG1 CH (SEQ ID NO: 21), IgG2 CH (SEQ ID NO: 22), IgG3 CH (SEQ ID NO: 23), or IgG4 CH (SEQ ID NO: 24), or a variant thereof, wherein it has up to ten amino acid substitutions.
15. The antibody or antigen-binding fragment according to claim 14, comprising: The light chain having an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:27; and the heavy chain having an amino acid sequence that is at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity with the amino acid sequence of SEQ ID NO:28 or SEQ ID NO:
29.
16. The antibody or antigen-binding fragment according to any one of claims 1 to 9, wherein the antibody or antigen-binding fragment: (1) does not block the binding of OX40L to OX40; (2) is effectively internalized by OX40-positive cells; (3) depletes OX40-positive cells; (4) depletes OX40-positive regulatory T cells in the TME; (5) exhibits significant ADCC; (6) enhances antitumor immune responses; (7) reduces immunosuppression in the TME; or (8) enhances immunological activity in the TME; or any combination of (1) to (8).
17. A polynucleotide encoding a polypeptide of any one of claims 1 to 16, comprising an antibody or antigen-binding fragment.
18. A carrier comprising the polynucleotide of claim 17.
19. A host cell comprising the polynucleotide of claim 17.
20. A method for producing an antibody that specifically binds to human OX40 or an antigen-binding fragment thereof, comprising culturing the cells of claim 19 under conditions suitable for expressing said antibody or antigen-binding fragment.
21. A pharmaceutical composition comprising a therapeutically effective amount of an antibody or antigen-binding fragment according to any one of claims 1 to 16, and a pharmaceutically acceptable carrier.
22. A method for inducing the activation or proliferation of immune cells in vitro, comprising contacting the immune cells with an antibody or antigen-binding fragment as described in any one of claims 1 to 16.
23. The method of claim 22, wherein the immune cell is a T cell.
24. Use of an antibody or antigen-binding fragment according to any one of claims 1 to 16 for the preparation of a cancer therapeutic agent.
25. The use according to claim 24, wherein the cancer has OX40+ tumor-infiltrating lymphocytes (TILs).
26. The use according to claim 24, wherein the cancer is OX40+ cancer.
27. The use according to claim 24, wherein the cancer is a liquid cancer.
28. The use according to claim 27, wherein the cancer is T-cell leukemia or lymphoma; optionally, the cancer is peripheral T-cell lymphoma (PTCL, such as adult T-cell leukemia (ATL), angioimmunoblastic T-cell lymphoma (AITL)) or T-cell acute lymphoblastic leukemia (T-ALL).
29. The use according to claim 24, wherein the cancer is a solid tumor.
30. The use according to claim 29, wherein the cancer is sarcoma, breast cancer, non-small cell lung cancer (NSCLC), melanoma, ovarian cancer, or colon cancer.
31. The use according to claim 24, wherein the cancer is HPV+ cancer or EBV+ cancer; optionally, the cancer is EBV+ B-cell lymphoma, extranodal NK / T-cell lymphoma (ENKTL; e.g., nasal type), HPV16+ head and neck squamous cell carcinoma (HNSCC), EBV+ esophageal cancer, or HPV18+ cervical cancer.
32. Use of an antibody or antigen-binding fragment according to any one of claims 1 to 16 for the preparation of a therapeutic agent for an autoimmune disease or inflammatory disease; optionally, the autoimmune disease or inflammatory disease is characterized by excessive T cell activation.
33. The use according to claim 32, wherein the autoimmune disease or inflammatory disease is rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease (CD), graft-versus-host disease (GvHD), multiple sclerosis (MS), type I diabetes, atopic dermatitis, asthma, psoriasis, Sjögren's syndrome (SS), or idiopathic thrombocytopenic purpura (ITP).
34. A kit comprising an antibody or antigen-binding fragment according to any one of claims 1 to 16.
Citation Information
Patent Citations
Process for preparing acetylaminobenzenes
EP0001994A1
Recombinant antibodies and methods for their production
EP0239400A2
A method for reducing the immunogenicity of antibody variable domains
EP0519596A1
Resurfacing of rodent antibodies
EP0592106A1
Humanization of antibodies
US20050042664A1
